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Summary
The differentiation'of chick embryonic skeletalmy-oblasis myoblasts results in 
the formation of myotubes which are the precursors of muscle fibres. The fusion of 
mononucleated myoblasts represents an apparent switching point in differentiation since 
it results in both the formation of multinucleated myotubes and the stimulation of 
muscle specific protein synthesis. The aim of this project has been to examine the 
biochemical events involved in this process of terminal differentiation by using primary 
cultures of chick embryonic myoblasts as a model system.
Myoblast fusion is a receptor mediated event apparently coupled to inositol 
phospholipid breakdown. This results in the generation of the second messenger 
molecule sn- 1,2-diacylglycerol. Its role(s) in the process of fusion was investigated.
Many agonist activated cell surface receptors interact with their effector enzymes 
and ion channels via intermediary G-proteins. The G-proteins present in myoblast 
membranes were characterised and the involvement of these proteins in fusion was 
investigated. The differentiation related changes in G-protein levels were also 
determined.
Chick embryo spinal cord extract is able to stimulate the fusion of chick 
embryonic myoblasts in primary culture. The nature of these fusion stimulating 
factor(s) was investigated by biochemical fractionation of this extract. A protocol for 
the partial purification of the low molecular weight fusion stimulating factor was 
determined and an alternative method for assaying fusion stimulating ability was 
investigated.
Chapter 1 
Introduction
1.1 Myoblast differentiation and skeletal muscle development.
Skeletal muscle fibres are terminally differentiated, post-mitotic, multinucleated 
cells, which are formed during embryonic development as the result of the myoblast 
differentiation. During this process, myoblasts proliferate, withdraw from the cell 
cycle, align and subsequently fuse to form multinucleated myotubes which are the 
precursors of muscle fibres (Holtzer et al., 1958; reviewed in Wakelam, 1985). To 
date, most of the information about the biochemical events involved in cell fusion 
processes has come from studies using model membrane systems, such as 
phospholipid vesicles. However, these are not truly representative of cell membranes 
in that, for example, they do not have protein components. For this reason, they do not 
therefore have the potential to yield the complete information about physiological fusion 
processes. The fusion of myoblasts represents a naturally occuring model system in 
which to study membrane fusion. The fusion of myoblasts is accompanied by the 
synthesis of muscle specific proteins which are required for mature muscle cell 
function. Such proteins include components of the contractile apparatus, for example, 
actin, myosin and troponin, and the nicotinic acetylcholine and (3-adrenergic 
neurotransmitter receptors (Buckingham, 1977). The apparent temporal correlation 
between myoblast fusion and muscle specific protein synthesis indicates that fusion 
represents a defined switching point in the myoblast differentiation and suggests that 
the initiation of these complementary aspects of terminal differentiation may be co- 
ordinately regulated during embryonic development. The differentiation of skeletal 
myoblasts thus provides a model system in which to study the events underlying the 
regulation of muscle specific protein synthesis.
1.2 Systems of study.
The differentiation of groups of myoblasts occurs asynchrously in vivo which 
hinders analysis of the events involved in this process. Most of the available 
information has therefore come from studies using primary cultures of myoblasts, 
which are prepared by mechanical or enzymic disaggregation from various embryonic
sources, most commonly chick, quail or rat.(Konigsberg, 1978). These cells undergo 
reproducible differentiation in vitro and are amenable to experimental manipulation. In 
addition, various cell lines have been established from rat and mouse embiyos, the 
most extensively studied being the L6 and L8 lines which were isolated by carcinogen 
treatment of rat muscle tissue (Yaffe, 1968; Yaffe and Saxel, 1977). Fusion-negative 
mutants derived from these cell lines have been used in an attempt to elucidate the 
events that are involved in myoblast differentiation. However, these cell lines are 
transformed, and as such, may not truly represent the situation in vivo.
Primary cultures of myoblasts have been studied using two types of culture 
system: stationary and suspension. In stationary culture, which is the standard and 
most commonly used system, myoblasts are cultured as a monolayer attached to a 
substratum of gelatin or collagen. Following proliferation and withdrawal ffom the cell 
cycle, the myoblasts migrate, align in arrays and fuse to form multinucleate myotubes.
The fusion of myoblasts is not dependent upon their attachment to a substratum 
and this has allowed myoblast differentiation to be studied using cultures of myoblasts 
in suspension. In this system, myoblasts aggregate and fuse to form spherical 
multinucleate cells termed 'myoballs1 (Lass and Fischbach., 1976; Knudsen and 
Horwitz, 1977; Hausman et al., 1986). This is proposed to more truly reflect the 
situation in vivo than the stationary culture, since the myoblasts are able to interact in 3 
dimensions, rather than the 2 dimensions available to cells cultured in a monolayer.
A modification of these culture methods allows the synchronisation of fusion, 
to facilitate the analysis of the events involved in terminal differentiation. Myoblast 
fusion is a Ca2+-dependent event and can be made synchronous by depleting the culture 
medium of Ca2+ (van der Bosch et al., 1972). In this Ca2+ depletion method, 
myoblasts are cultured in a medium containing Ca2+ at a low concentration (O.lmM) 
for 50 hours, during which time they achieve fusion-competence. They are however 
unable to fuse because the Ca2+ concentration is not permissive for fusion. Raising the 
concentration of Ca 2+ in the medium results in rapid and synchronous fusion 
(Wakelam, 1983). Studies using such a system have demonstrated that the optimum
Ca2+ concentration for fusion is 1.2mM (van der Bosch et al., 1972; Schudt and Pette, 
1975).
1.3. Stages in myoblast differentiation.
1.3.1. Myoblast interactions prior to fusion.
1.3.1.1. Myoblast-myoblast interaction
Freshly prepared myoblasts proliferate in culture and go through at least one 
round of DNA replication (Yaffe, 1971). Proliferation ceases when the culture medium 
is depleted of mitogens (Konigsberg, 1971) and the myoblasts then withdraw from the 
cell cycle. Subsequent myoblast activities are important in bringing their plasma 
membranes into contact, in order to facilitate the close appostion, which is required for 
fusion.
In stationary cultures, myoblasts become aligned in arrays prior to fusion. This 
is due to myoblast specific cell-cell interaction (Bischoff, 1978) and is termed 
'recognition'. This confers the specificity of fusion which is tissue but not species 
specific. Heterotypic fusion can occur between myoblasts from different species 
(Yaffe, 1969) but does not occur between myoblasts and other cell types (Holtzer and 
Bischoff, 1970). In suspension cultures, this recognition event results in the formation 
of myoblast aggregates in which specific myoblast-myoblast adhesion occurs with the 
exclusion of fibroblasts (Knudsen and Horwitz, 1977,1978). The recognition process 
has been studied using fusion-competent myoblasts obtained by the method of Ca2+- 
depletion. These cells were suspended in a balanced salt solution in the presence of 
either 1.5mM Ca2+ or ImM EGTA (to chelate and thus deplete the medium of Ca2+) 
and examined for aggregate formation.. Myoblast aggregates were obtained in both the 
presence and absence of extracellular Ca2+ (Knudsen and Horwitz, 1978), 
demonstrating that the adhesion of myoblasts, in common with other cell types, occurs 
via both Ca2+-dependent and Ca2+-independent mechanisms. Similar observations 
have subsequently been made by Gibralter and Turner (1985).
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Using this system, the process of recognition and adhesion have been 
demonstrated to be distinct from the fusion event itself, since differential inhibition of 
these processes is obtained using various inhibitors of myotube formation (Knudsen 
and Horwitz, 1978; Knudsen, 1985). For example, treatment of fusion-competent
- f  / n  » (JO f- I  t j  p l i s t
myoblasts with colchicine andcytocholasinB (inhibitorsof microtubuledisassembl^) 
and elaidic acid or sodium butyrate (short chain fatty acids which may perturb 
membrane structure) resulted in the inhibition of fusion with no effect on aggregation. 
Treatment with energy poisons, trypsin and inhibitors of protein synthesis however 
inhibited both aggregation and subsequent fusion (Knudsen and Horwitz, 1978).
These authors thus concluded that myoblast recognition and adhesion is mediated by a 
protein that is synthesised during the development of fusion-competent myoblasts. It 
was subsequently proposed to be mediated by a glycoprotein due to its inhibition by 
tunicamycin, an inhibitor of dolichol phosphate mediated glycosylation of proteins at 
asparagine linked sites (Knudsen, 1985). This confirmed a previous observation of 
tunicamycin inhibition of fusion (Gilfix and Sanwal, 1980). This inhibition was 
partially reversed in the presence of protease inhibitors suggesting that the carbohydrate 
portion of the molecule does not directly mediate adhesion but acts instead to stabilise it 
against proteolytic degradation (Olden etal., 1981).
The neural cell adhesion molecule (N-CAM) is a potential candidate for the 
glycoprotein involved in myoblast recognition-adhesion. It is expressed by muscle 
cells (Grumet et al, 1982; Rutishauser, 1983) and has been implicated to play a role in 
myoblast development because there are changes in its isoforms during differentiation 
(Moore et a l, 1987). It is found at the neuromuscular junction (Reiger et al, 1985) 
where it is thought to mediate the initial interaction between spinal cord neurones and 
muscle cells in culture (Rutishauser et a l, 1983).
N-CAM possesses a covalently attached glycosyl-phosphatidylinositol moiety 
which serves to anchor the polypeptide portion of the molecule in the plasma membrane 
(Hemperley et a l ., 1986; He et al, 1986). Evidence for the involvement of a 
phosphatidylinositol-glycan linked protein in recognition comes from the observation of
4
Nameroff et al., (1973) that treating myoblasts in culture with phospholipase C (PLC) 
inhibited fusion. This was suggested to be due to interference with the process of 
recognition, which is supported by the finding that the treatment of fusion-competent 
myoblasts with a specific phosphatidylinositol PLC, inhibited both Ca2+-dependent and 
Ca2+-independent aggregation in a dose-dependent manner (Knudsen et al., 1989) and 
caused the release of an N-CAM immunoreactive cell surface glycoprotein which was 
prevented in the presence of D-myo-inositol 1 monophosphate. These observations are 
consistent with the known existence of phosphatidylinositol-glycan linked N-CAM in 
mouse and human muscle cells (Moore et al., 1987; Barton et al., 1988). Further 
support for N-CAM involvement comes from the demonstration that anti-N-CAM 
antibodies inhibit myoblast aggregation. N-CAM, in human muscle cells, posseses a 
muscle specific sequence in the extracellular domain (Dickson et al., 1987). N-CAM 
molecules are homophilic and function by binding to N-CAM molecules on other cells 
(Edelman et al., 1983). The presence of similar muscle specific sequences in the 
myoblast N-CAM of each species remains to be demonstrated, but if they occur, this 
homophilic binding could potentially account for the cell type (but not species type) 
specificity of myoblast -myoblast interaction.
The inhibition of myoblast aggregation by phosphatidylinositol specific PLC is 
however incomplete (Knudsen et al., 1989) suggesting that recognition and adhesion 
may involve forms of N-CAM that are resistant to this enzyme. Such isoforms of N- 
CAM do exist but the result could also indicate that the presence of an additional 
mechanism for myoblast aggregation. Hausman et al.,. (1986) have suggested that 
myoblast aggregation is mediated by the interaction of a prostaglandin with its receptor. 
It is accompanied by changes in membrane order, as measured by changes in 
membrane conductivity and by electron paramagnetic resonance (e.p.r.) using spin- 
labelled membrane probes (Bonincontro et al., 1987; Santini et al., 1988). The 
mechanism by which these are achieved, and how cell specificity is conferred remain to 
be determined.
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1.3.1.2 Myoblast-substrate interaction.
The myoblast-myoblast cell recognition phenomenon is distinct from the 
myoblast-substratum interaction observed in stationary culture, in which myoblasts and 
myotubes adhere and elongate upon the gelatin or collagen substrates. This is mediated 
by fibronectin, and only occurs in the presence of exogenous fibronectin derived, in 
culture, from serum or fibroblasts (Chiquet et al., 1981). Myoblast-substratum 
attachment is not a prerequisite for differentiation since myoblasts in suspension culture 
fuse and synthesize muscle specific proteins in fibronectin-ffee medium (Puri et al., 
1979, 1980). In addition, this process is unaffected by the presence of either soluble 
fibronectin or anti-fibronectin antibodies (Puri et al., 1980). This conflicts with 
previous observations that a cell-free matrix containing fibronectin stimulates the fusion 
of rat L8 myoblasts (Chen et al., 1978), whilst the addition of exogenous fibronectin 
led to delayed myotube formation in rat L6 myoblast cultures (Podleski et al., 1979). 
Chiquet et al.,. (1981) concluded that these results were probably due to indirect effects 
of fibronectin, and suggested that the report of fibronectin stimulation was probably 
due to its enhancement of myoblast-substratum attachment and migration and thus 
myoblast-myoblast interaction in the monolayer culture. The fibronectin induced delay 
observed by Podleski et al., (1979) was demonstrated to occur, not by inhibition of the 
fusion event itself, but as the result of increased proliferation. This reduced the number 
of myoblasts emerging from the proliferative population and thus there were fewer 
post-mitotic fusion-competent myoblasts available for fusion.
Fibronectin has instead been postulated to be involved with the morphogenesis 
of muscle in vivo rather than fusion (Chiquet et al., 1981; Ehrismann et al., 1981).
This was based on the observation that myoblasts adhere, align and migrate along 
oriented streaks of fibronectin in vitro . In addition, the myotubes formed upon fusion 
were unbranched, as is typical in vivo but infrequent in vitro. They also 
demonstrated that fibronectin is present in developing chick muscle fibres and propose 
that it, and perhaps other matrix components, may be involved in contact guidance of 
developing muscle to direct elongation in the correct orientation.
1.3.2. Fusion of myoblasts
Fusion of post-mitotic, fusion-competent, mononucleated myoblasts results in 
the formation of multinucleated myotubes. It requires the entry of Ca2+ (David et al., 
1981) and involves transient changes in membrane structure together with 
rearrangements of cytoskeletal and membrane proteins (Kalderon and Gilula, 1979; 
Fulton etal., 1981).
1.3.2.1 Assays of fusion.
The fusion of myoblasts to form myotubes may be definitively determined 
ultrastructurally using transmission electron microscopy (T.E.M.). The criteria for 
fusion are the presence of clearly resolved U shaped membranes that are reflected at 
either edge of the site and a lack of amorphous material in the region of cytoplasmic 
continuity (Bischoff, 1978). However, this method-is time consuming and thus 
impractical for routine use.
For this reason, the cells are usually examined by light microscopy and fusion 
assayed by visual scoring of the multinucleated myotubes present in the sample. 
Plasma membranes cannot be resolved at this level of magnification, so instead, the 
fused cells are defined in terms of the cell shape, size and arrangement of nuclei that are 
characteristic of myotubes. The percentage of fused cells is defined as the number of 
nuclei in cells with 3 or more nuclei divided by the total number of nuclei present in 
myoblasts in the culture (contaminating fibroblasts, identifiable by their characteristic 
triangular morphology, are excluded), and multiplied by 100. Cells with 3 or more 
nuclei are taken to be fused. Although cells with 2 nuclei may represent the product of 
the fusion of 2 mononucleated myoblasts, they could also be replicating myoblasts. 
These binucleated cells are therefore excluded to avoid errors due to such a 
misinterpretation. Cultures of myoblasts and myotubes are fixed and dehydrated using 
ethanol or methanol, and stained with, commonly, Giemsa or acetic orcein to visualise 
the nuclei. This assay is suitable for use in both monolayer and in suspension cultures.
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The myoballs formed in suspension cultures are defined as fused when they are
b d t .  & a c i
resistant to dispersion by^trypsin EDTA. These are distinct from
aggregated but unfused cells which can be dispersed by treatment with EDTA to 
remove Ca2+ (Knudsen and Horwitz, 1977). They are also defined as fused when they 
exhibit a smooth edge morphology, which is achieved as a consequence of fusion, and 
is not observed in aggregated, unfused cells (Lass and Fischbach, 1976; Gibralter and 
Turner 1985).
I.3.2.2. Ca2+-dependence of fusion.
Myoblast fusion, in common with other fusion events such as endocytosis and 
exocytosis (Poste and Allison, 1973) is a Ca2+-dependent process. This was first 
described by Shainberg et al., (1969) who demonstrated that reducing the Ca2+ 
concentration of the culture medium, from 1.4mM to 27(^aM, prevented the fusion of 
rat myoblasts. The same result was obtained in the presence of EGTA to chelate and 
thereby effectively remove Ca2+ from the medium (Paterson and Strohman, 1972).
This requirement for Ca2+ in fusion is specific and out of other ions tested, such as 
Mg2+, Zn2+, Mn2+, Ba2+, Cu2+, Cd2+, Sr2+, La2+ and Li+, only Sr2+ can replace 
Ca2+ in vitro (Schudt et al., 1973).
The Ca2+ ionophore, A23187 induces precocious fusion of myoblasts in the 
period of 1-9 hours before fusion would normally occur in culture (David et al., 1981). 
Ca2+ entry occurs just prior to fusion and is an essential requirement for fusion since it 
is inhibited by Ca2+ channel blockers. It is sensitive to La2+ (Entwistle et al., 1988), 
D600 (David et al., 1981; Rapuano et al., 1990), nitrendipine and the Ca2+ channel 
antagonist BAY K844 (Rapuano et al., 1990) which is consistent with the entry of 
Ca2+ via a voltage dependent Ca2+ channel. The exact role of Ca2+ in fusion remains 
to be fully determined but is further discussed in section 1.3.3.5.
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1.3.2.3. Requirements for fusion.
Plasma membranes are stable non- interacting structures that form a semi- 
permeable barrier separating the aqueous contents of the cell from the surrounding 
medium. The integrity of the membrane is maintained by the bilayer structure. This 
exists as a consequence of the amphipathic nature of the component phospholipids 
which possess hydrophobic hydrocarbon chains and hydrophilic polar head groups. In 
the bilayer strucure, the polar phospholipid head groups are in contact with the cytosol 
and external medium which are present on either side of the bilayer. The hydrocarbon 
chains oppose each other inside the bilayer and are thus sequestered away from the 
aqueous phases. As a consequence of this structure, short range interaction between 
membranes results in membrane-membrane repulsion, which presents a barrier to 
fusion. Fusion of myoblasts thus represents a thermodynamically unfavourable event, 
since it requires close apposition of the plasma membranes followed by mixing of their 
components, at the point of contact, so that these originally separate membranes 
become continuous and allow cytoplasmic confluence to be established. The nature of 
the intermembrane repulsive forces and a possible fusion mechanism are discussed 
more fully in Chapter 3.
1.3.2.4. Ultrastructural analysis of fusion.
Ultrastructural examination of fusing myoblasts has provided information about 
the nature of the membrane changes that occur during the fusion event.. T.E.M. has 
been used to detemine the changes in plasma membrane morphology associated with 
myoblast-myotube fusion (Lipton and Konigsberg, 1972). Each fusion site was 
analysed in serial sections and a tilting stage was used to prevent membrane 
discontinuity due to an oblique plane of section. The earliest fusion site detected 
consisted of a cytoplasmic bridge of 120nm in diameter, present at the point of 
contact,which enlarged in the later stages of fusion. These results are consistent with 
the initiation of fusion at a single site, which enlarges to allow cytoplasmic continuity 
and permit mixing of the cytosolic contents of the fused cells.
Further information about the fusion site has been obtained by combining 
electro-physiological with ultrastructural techniques (Rash and Fambrough, 1972). In 
these experiments, the time of electrical coupling between adjacent cells was taken as 
the onset of fusion and samples were fixed at various times subsequent to this. Serial 
sections of the cultures were then prepared and examined by T.E.M. using a tilting 
stage. Areas of close membrane apposition (3-5nm), similar to gap junctions, were 
found in all cells that were electrically coupled but not fused. This electrical coupling 
was followed by cytoplasmic confluence as fusion proceeded. The authors proposed 
that these structures act either as the fusion initiation site or to mediate the transfer of 
information between cells that is necessary for fusion. They also demonstrated that 
there is no detectable ionic leakage during fusion which indicated that the permeability 
barrier remains intact during rearrangement of the membrane structure of fusing cells.
I.3.2.5. Rearrangements of membrane and cytoskeletal proteins during 
fusion.
Studies on the surface biochemistry of myoblasts during fusion have 
demonstrated that there are changes in their distribution and relative amounts. One 
experimental approach to examine this has been to try and identify surface antigens that 
are unique to fusion. This has been achieved by raising mouse monoclonal antibodies 
against either whole muscle cells or membranes prepared from different stages in their 
differentiation. Antibodies raised against other cell type surfaces, that cross-react with 
myoblasts, have also been used. For example, 40 monoclonal antibodies against the 
L8E63 rat myoblast cell line were raised and identified for use as probes for quantitative 
changes in the antigenic determinants on the myoblast surface during differentiation 
(Kaufman and Foster, 1984). The monoclonal antibodies studied fell into 5 distinct 
temporal classes which probably define different stages in differentiation. Whilst this 
and other studies demonstrate that there are changes in antigenic expression during 
differentiation, the determination of their physiological significance awaits the 
identification of these antigens.
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An examination of the variations in the iodination patterns of surface proteins 
using lactc -peroxidase-catalysed iodination (Moss et al., 1978; Pauw and David,
1979) has revealed that there changes in the relative amounts of high and low molecualr 
weight proteins during fusion. Decreased amounts of high molecular weight and 
increased amounts of low molecular weight proteins were detected. This has been 
proposed to be due to limited proteolysis during fusion (Couch and Strittmatter, 1983), 
which may be the result of metalloendoprotease activity, since inhibitors of these 
enzymes, such as, 1,10 phenanthroline, inhibit fusion. It was subsequently 
demonstrated that these inhibitors act upon a cytosolic protein of 80kDa molecular 
weight (Couch and Stritmatter, 1984). This may correspond to the Ca2+-activated 
neutral protease which appears in myoblasts at the time of fusion (Kaur and Sanwal, 
1981), in which case, the entry of Ca2+ into myoblasts prior to fusion may represent a 
signal for limited proteolysis.
Cytoskeletal rearrangements occur during fusion. These have been examined 
by detergent extracting myoblasts at different stages of fusion, to reveal the cytoskeletal 
framework (Fulton et al., 1981). Lacunae were observed during fusion and these were 
suggested to be regions of the lipid bilayer that are glycoprotein-free. The 
redistribution of glycoproteins during fusion has been demonstrated using resonance 
energy transfer (Herman and Fernandez, 1982). These 'glycoprotein-free' regions may 
correspond to the lipid-rich and particle-free fusion sites observed by Kalderon and 
Gilula (1979). Such sites could potentially be created by the proteolytic degradation of 
anchoring cytoskeletal proteins to allow the migration and thus lateral movement of 
intramembranous proteins away from the site of fusion. The complex carbohydrate 
portions of glycoproteins present steric hindrance to close membrane apposition, and 
thus their clearance from the fusion site removes a barrier to fusion. This may involve 
the Ca2+-activated protease that is present in myoblasts at the time of fusion.
Following fusion, a stable cross-linked structure that has characteristic myotube 
morphology is formed. These observations of cytoskeletal rearrangements are 
consistent with the inhibition of fusion that is obtained with the microtubule -f • v
disassembly inhibitors, cytocholasin B (Holtzer et al., 1975; Knudsen and Horwitz, 
1978), taxol (Antin et al., 1981) and colchicine (Knudsen and Horwitz, 1978). The 
calmodulin antagonist, trifluoperazine, has been suggested to mediate its inhibition of 
fusion by preventing calmodulin stimulated cytoskeletal rearrangements (Bar-Sagi and 
Prives, 1983). This inhibitor may however be affecting the activity of more than one 
enzyme.
I.3.2.6. Involvement of lipids in the fusion process.
The fusion of myoblasts requires that there are transient changes in plasma 
membrane structure. Lipids are considered to be involved because there are changes in 
the physical properties of the plasma membrane lipids at the time of fusion. There is, 
for example, an increase in membrane fluidity prior to fusion (Weidekamm et al., 1976; 
Herman and Fernandez, 1978) which probably correlates with the decrease in 
membrane microviscosity that occurs at the onset of fusion (Prives and Shinitsky, 
1977). Evidence for the requirement of increased membrane fluidity for fusion also 
comes from the demonstration that fatty acids such as stearic and elaidic acid, which are 
predicted to reduce membrane fluidity, delayed fusion whilst those expected to enhance 
fluidity, such as oleic and linoleic acids brought forward the time of fusion onset 
(Prives and Shinitsky, 1977; Horwitz et al., 1978).
Further support for lipid involvement comes from experiments where
perturbation of the membrane structure modulates fusion. For example, enzymic
modification of membrane lipids by treatment of chick myoblasts with phospholipases
A or C inhibits fusion (Schudt and Pette, 1976). Such treatment with phospholipase A
might be expected to promote fusion, since it results in the generation of lysolecithin
which is fusogenic in erythrocyte membranes (Lucy, 1974). In this regard, agents
such as retinol, some fatty acids such as myristic acid and arachidonic acid and glycerol
mono-oleate, whilst inducing fusion of other cell types, inhibit myoblast fusion
(Nakomchai et al., 1981). Fusion is therefore probably mediated by discrete
biochemical changes in membrane structure at the site of fusion, which are prevented or
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interfered with by the addition of exogenous fusogens that cause general membrane 
perturbation.
The effects of fusion stimulation on the phospholipid metabolism of fusion- 
competent myoblasts havebeen examined using the Ca2+-medium depletion system 
and. Fusion was stimulated by the addition of 1.4mM Ca2+ to fusion -competent 
myoblasts and the incorporation of P 2P] Pi into phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylinositol, phosphatidylseiine and 
sphingomyelin was determined. An increase in [32P]Pi was only obtained for 
phosphatidylinositol (Wakelam and Pette, 1982) and this probably resulted from 
increased breakdown followed by compensatory resynthesis since there is a loss of 
radiolabel from phosphatidylinositol (Ptdlns) and phosphatidylinositol 4,5 
bisphosphate (Ptdlns 4,5 P2) on fusion stimulation (Wakelam, 1983). This results in 
the generation of sn -1,2- diacylglycerol and the product of its phosphorylation, 
phosphatidic acid.
Ptdlns 4,5 P2 is located on the inner leaflet of the plasma membrane and is 
formed by a two step phosphorylation of Ptdlns. This involves phosphorylation at 
postion 4 of the inositol head group to form Ptdlns 4 P, followed by phosphorylation at 
the 5 postion to form Ptdlns 4,5 P2. There are corresponding phosphomonoesterases 
which convert Ptdlns 4,5 P2 back to Ptdlns. This constitues a futile cycle. Agonist 
occupation of certain receptor types results in the diversion of Ptdlns 4,5 P2 from this 
cycle to cleavage by phosphoinositide specific phospholipase C (PI-PLC). This results 
in the loss of the hydrophilic headgroup to generate the second messengers, inositol 
(1,4,5) trisphosphate (IP3) and sn -1,2-diacylglycerol (sn -1,2-DAG). IP3 binds to 
specific receptors on the endoplasmic reticulum to release Ca2+ from intracellular stores 
and thus elevate the levels of cytosolic Ca2+. Sn -1,2-DAG is a physiological activator 
of protein kinase C (PKC), a Ca2+/phospholipid-dependent protein kinase which exerts 
its effects by the phosphorylation of proteins on serine and threonine residues 
(Nishizuka, 1984). This enzyme is considered to be involved in the regulation of many 
cell processes including exocytosis, growth and differentiation (Nishizuka et al.,
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1989). The second messenger functions of IP3 and sn -1,2 DAG are attenuated by 
their removal via metabolic pathways which result in their salvage and consequent 
recycling to Ptdlns.
IP3 is removed by the concerted interaction of a series of phosphatases and 
kinases which result in the generation of inositol. There are 2 potential removal 
pathways. In the first, IP3 is dephosphorylated by a 5-phosphatase (Ahktar and Abdel- 
Latif, 1980) to yield Ins (1,4) P2 followed by sequential dephosphorylation steps to 
form inositol. The second pathway involves phosphorylation by a specific inositol 
1,4,5 trisphosphate kinase to form inositol 1,3,4,5 tetrakisphosphate (Hawkins et al., 
1986;Irvine et al., 1986). This can be dephosphorylated by a 5-phosphatase to form 
Ins 1,3,4 P3 which is sequentially dephosphorylated to yield inositol. Li+ blocks the 
dephosphorylation of inositol monophosphate to inositol which results in the 
accumulation of inositol monophosphate and an inhibition of resynthesis of 
phosphatidylinositol by preventing the formation of free inositol. This forms the basis 
of the Li+ assay for agonist stimulated inositol phospholipid breakdown (Berridge and 
Irvine, 1984).
Sn -1,2-DAG may be removed either by its phosphorylation by DAG kinase to 
form phosphatidic acid or cleavage by DAG lipase to generate arachidonic acid and 
monoacylglycerol. The DAG kinase pathway is, however, considered to be the 
quantitatively more important in vivo (Bishop et al., 1986). Phosphatidic acid is then 
primed by combining with CTP to form CDP-diacylglycerol which reacts with inositol 
to form Ptdlns.
Agonist stimulated inositol phospholipid breakdown has generally been linked
to the entry of Ca2+ into cells in response to occupation of certain receptors by hormone
or neurotransmitter agonists. The entry of extracellular Ca2+ is required to maintain the
elevated cytosolic Ca2+ levels which result from the action of IP3 on intracellular
stores. This may be achieved by activation of voltage operated (Lee and Tsien, 1983)
or receptor operated (Macdougall et al., 1988) Ca2+ channels, or by inhibition of a
plasma membrane Ca2+ pump (Reinhart et al, 1984). Extracellular Ca2+ entry into
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myoblasts occurs via a voltage dependent Ca2+ channel. This may result from 
phosphorylation by protein kinase C since such a mechanism has been proposed for 
D600 sensitive Ca2+ channels of myotubes (Navarro, 1987) and Aplysia neurones (De 
Reimer et al., 1985)
The increase in the levels of sn -1,2-DAG could also be important for fusion per 
se, since it is a known fusogen in model systems; it is an erythrocyte fusogen when 
added exogenously, although its activity was weak (Ahkong et al., 1973) and has been 
shown to accumulate during erthrocyte vesiculation (Allan et al., 1975). This fusogen, 
in common with phosphatidylethanolamine (Sessions and Horwitz, 1973) and the 
ganglioside GDla (Whatley et al., 1976) forms the hexagonal II (Hn) structure, a non- 
lamellar structure that is more fluid than a bilayer (Cullis et al., 1983). This is 
proposed to be the preferred state for membrane lipids during cell fusion (Verkleij et 
al., 1984). Fusion may therefore occur via formation of the Hn configuration leading 
to increased membrane fluidity and fusion. The role of sn -1,2-DAG in myoblast 
fusion, both as a potential fusogen and activator of PKC, is further investigated in 
Chapter 3.
1.4. Developmental regulation of differentiation.
Fusion represents a defined switching point in myoblast differentiation,with the 
formation of multinucleated myotubes being temporally associated with increased 
muscle specific protein synthesis . It is likely that these events are under developmental 
control. There may therefore be some form of some form of diffusible signal 
stimulating the onset of fusion, the production of which is developmentally regulated.
Prostaglandin Ei (PGEi) has been proposed as a candidate, based on the
observations that it promoted precocious fusion and that fusion was inhibited in the
presence of indomethacin or aspirin, which act on the cyclo-oxygenase enzyme to
prevent prostaglandin synthesis (Zalin and Leaver, 1975). In addition, the
prostaglandin antagonist PY1 inhibited fusion suggesting that PGEi effects on fusion
were receptor-mediated (David and Higginbotham, 1981). Zalin and Montague (1974)
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had previously detected a transient 10-fold increase in the intracellular levels of cyclic 
adenosine 5' monophosphate (cyclic AMP) and thus PGEi was proposed to stimulate 
fusion by elevating cyclic AMP levels via interaction with its plasma membrane receptor 
(Zalin and Leaver, 1975). -David and Higgenbotham (1981) subsequently proposed 
that this led to an influx of extracellular Ca2+ via activation of a Ca2+ channel, which 
occured as a consequence of its phosphorylation by a cyclic AMP-dependent protein 
kinase. This conclusion has however been challenged by Schutzle et al., (1984) who 
were unable to detect this rise in cyclic AMP levels prior to fusion. They demonstrated 
instead that its levels were elevated following fusion and therefore suggest that this 
increase is a consequence, rather than a cause of fusion. Furthermore, cyclic AMP has 
been demonstrated, in some studies, to inhibit fusion (Aui et al., 1973; Wahrmann et 
al., 1973; Moriyama and Murayama, 1977).
PGEi has also been proposed to stimulate fusion by two alternative 
mechanisms. In the first, PGEi causes an increase in chloride permeability leading to a 
depolarisation of the plasma membrane which causes the entry of extracellular Ca2+ 
through a voltage dependent Ca2+ channel. Acetylcholine has been proposed to 
stimulate fusion in a similar manner by increasing membrane permeability to Na+ and 
K+ ions (Entwistle et al., 1988). The second mechanism for PGEi stimulation of 
fusion involves receptor-mediated inositol phospholipid breakdown (Farzeneh et al., 
1989). In addition to its role in the fusion event itself, the interaction of a prostaglandin 
with its receptor has been suggested to mediate specific myoblast-myoblast adhesion 
(Hausman et al., 1986), as discussed in section 1.3.1.
A peak of pH] PGEi binding to chick embryo skeletal muscle cultures occurs 
at the time of fusion (Hausman and Velleman, 1981). Specific binding of pH] PGEi 
was demonstrated since it could be displaced by non-radiolabelled PGEi. The 
specificity of the receptor for the various prostaglandin species, the identity and source 
of the native prostaglandin are however unknown. Prostaglandins of the 1 and 2 series 
are derived from dihomo-y-linoleic acid and arachidonic acid respectively, which are 
generally obtained from phospholipids (Vogt et al., 1978). Dihomo-y-linoleic acid is
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not present in myoblasts so the prostaglandin involved in myoblast fusion is therefore 
unlikely to be PGEi. Arachidonic acid is present at the 2 position of the glycerol 
backbone of phospholipids and can be generated by e ifer phospholipase A2 cleavage.
It can also be generated by DAG lipase cleavage of DAG species that possess 
arachidonic acid as the fatty acyl chain at the carbon 2 position. Since prostaglandins 
are derived from membrane lipids, it may be argued that some form of extracellular 
signal is required to stimulate their production.
The inhibition of fusion obtained using indomethacin is not complete. It delays 
the time course of fusion onset but, under conditions where indomethacin is 
continuously present, the final extent of fusion obtained is unaffected. The same result 
is also obtained if nicotinic acetylcholine receptors are blocked using a-bungarotoxin 
(Entwistle et al., 1988). This would suggest that there is alternative pathway for fusion 
stimulation.
Myoblast fusion has been proposed to be a receptor mediated event coupled to 
inositol phospholipid breakdown, which can be initiated in vitro by a fusion 
stimulating factor(s) present in chick embryo extract (Wakelam and Pette, 1984a,b).
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Chick embryo extract has been demonstrated to be essential for the fusion of chick 
myoblasts and probably contains an agonist to stimulate fusion, since in the absence of 
embryo extract, even in the presence of extracellular Ca2+, myoblasts are unable to fuse 
and no inositol phospholipid breakdown is observed. Further support for the 
involvement of inositol phospholipid breakdown in myoblast fusion comes from the 
demonstration that Sr2+, at fusion stimulating concentrations, also stimulated the 
breakdown of these lipids. In addition, when myoblasts are prevented from fusing by 
treatment with sodium butyrate, no stimulation of inositol phospholipid breakdown was 
observed (Wakelam and Pette, 1982). Furthermore, inositol phospholipid breakdown 
was not obtained when fusion-incompetent myoblast (cultured for 25 hours in a 
medium Ca2+ depleted culture) were exposed to fusion stimulating conditions. This 
would suggest that the ability to respond to fusion stimulation is a feature of fusion- 
competent cells which is acquired during differentiation.
1.5. Aims
The aim of this project has been to try to define the biochemical events involved 
in the regulation of skeletal myoblast differentiation. This has been examined using 
primary cultures of chick embryonic myoblasts obtained from the breast muscles of 12- 
day-old chick embryos. Myoblast fusion represents a key event in this process of 
terminal differentiation, with the fusion of post-mitotic myoblasts to form 
multinucleated myotubes being temporally associated with the synthesis of muscle 
specific proteins required for mature muscle function. It is receptor mediated event 
apparently coupled to inositol phospholipid breakdown (Wakelam and Pette 1984a,b). 
PI-PLC cleavage of Ptdlns 4,5 P2 results in the generation of the second messengers, 
IP3 and sn -1,2-DAG. The generation of sn -1,2-DAG in fusion-competent myoblasts 
upon fusion stimulation was determined and its role in fusion investigated. It is 
potentially involved in the fusion process because it is a known fusogen and a 
physiological activator of PKC. The role of PKC in fusion was examined by use of 
compounds to modulate its activity.
The transfer of information from many agonist activated cell surface receptor to 
effector enzymes or ion channels is mediated by a family of guanine nucleotide binding 
proteins (G-proteins). The G-proteins present in myoblasts at various stages in 
differentiation were characterised and their possible role in fusion investigated.
Myoblast fusion is accompanied by the stimulated synthesis of neurotransmitter 
receptors e.g. the p-adrenergic and nicotinic acetylcholine receptors. Given the role of 
G-proteins in signal tranduction, it is possible that there are changes in their relative 
amounts and subtypes during differentiation. This was determined by examining 
membranes prepared from myoblasts at various stages in differentiation.
The differentiation of myoblasts is developmentally regulated and is considered 
to be under neuronal control. Extracts prepared form chick embryonic spinal cord are 
able to support the fusion of myoblasts in primary culture which suggests that it 
contains fusion stimulating factor(s). This extract was thus fractionated by gel filtration 
chromatography in order to further characterise these factor(s).
18
Chapter 2 
Methods
2.1 Primary culture of myoblasts.
2.1.1 Preparation of myoblasts.
Primary cultures of embryonic myoblasts were prepared by enzymic
disaggregation of 12 day old chick embryonic breast muscle using the method of
Wakelam (1983). The method is summarised in figure 2.1.1. All procedures were
carried out under sterile conditions using a Class II laminar flow -cabinet. The breast
muscle was obtained by dissection from 12-day-old chick embryos. It was then
examined using light microscopy and tweezers were used to gently tease away and thus
remove any connective tissue present. The muscle was digested with dispase (neutral
protease from Bacillus potymyxa). This was performed at 37°C for 30 minutes using a
sterile filtered solution of 2mg/ml dispase in Earles salts (pH 7.4). The resulting
suspension of tissue was triturated to ensure its dispersal into single cells which were
collected by centrifugation at lOOOg for 5 minutes in a MSE bench top centrifuge. The
cell pellet was washed by resuspending into 50ml 'Ca2+-free' Dulbecco modified
Eagle's medium (DMEM),containing Ca2+ at a concentration of approximately 0.5mM
and supplemented with 10%w/v dialysed horse serum which inhibits any remaining
dispase activity. The cells were collected by centrifugation at lOOOg for 5 minutes and
then resuspended in Ca2+-free DMEM and preplated for 10 minutes in 60mm tissue
culture coated plastic dishes in order to selectively remove fibroblasts. During this time
the fibroblasts attach to the plastic dish whereas the myoblasts do not so that on
removal of the medium from the dish, the myoblasts are present in suspension leaving
the fibroblasts attached to the dish. The two cell types are thus separated. The
myoblasts were then cultured for 50 hours, until fusion-competence, in 'Ca2+-ffee'
DMEM supplemented with 10% v/v dialysed heat inactivated horse serum and 2% v/v
dialysed chick embryo extract. In later experiments 20|ig/ml conalbumin replaced chick
embryo extract as described by Neff and Horwitz (1982). Cells were cultured as
monolayers using either 35mm tissue culture dishes or multiwell plates (6  or 24 wells
per plate) coated with 0.3% w/v gelatin in phosphate buffered saline (PBS) or
collagen.. Alternatively, the myoblasts were plated into 60mm tissue culture dishes
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Figure 2.1.1.
The preparation of primary cultures of myoblasts.
Skeletal myoblasts were prepared from the breast muscle of 12- 
day-old chick embryos by enzymic disaggregation and trituration to 
generate a population of single cells which was enriched for 
myoblasts by the technique of pre-plating to remove fibroblasts.
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Figure 2.1.1.
Schematic representation of the preparation of primary 
cultures of myoblasts from chick embryonic breast muscle
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coated with 1.5% w/v gelatin in PBS to which they become loosely attached and may 
be easily harvested by rinsing using repeated pipetting.
2.1.2. Preparation of-supplements.
2.1.2.1, Heat inactivation of horse serum.
The horse serum was heat inactivated in order to destroy complement. This 
was achieved by placing the serum in a water bath at 56°C for 1.5 hours. The heat 
inactivated serum was then dispensed into 50ml aliquots and stored frozen at -20°C 
until use.
2.1.2.2. Preparation of Ca2+-free supplements.
Essentially Ca2+-free horse serum was prepared by extensive dialysis against 
Earles' salts. The dialysis tubing was prepared by boiling in 20mM EDTA for 20 
minutes followed by thorough washing in distilled deionised water. The tubing was 
either used immediately or stored in 20% (v/v) ethanol at 4°C. A known volume of 
chick embryo extract or heat inactivated horse serum was aliquoted into dialysis tubing 
and dialysed against 2 changes of lOOx volume dialysis medium of 1:19 dilution of a 
20x strength Earles' salts solution in distilled deionised water adjusted to pH 7.4 with 
1M sodium hydroxide. The dialysed supplement was sterilised by filtration using a 
0.2pm filter and stored at -20°C until use.
2.1.3. Fusion assay.
2.1.3.1. Sample preparation.
(i) Determining the effect of possible inhibitors of myoblast fusion.
Myoblasts were cultured in 'Ca2+ free' DMEM/ 20pg/ml conalbumin or 2% v/v
dialysed chick embryo extract/10% v/v dialysed heat inactivated horse serum until
fusion-competence. The cells were cultured in 60mm tissue culture dishes coated with
1.5% w/v gelatin in PBS to which they become loosely attached. At fusion-
competence the medium was aspirated and the cells carefully washed twice with'Ca2+-
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free' DMEM/ 20}ig/ml conalbumin to remove non-attached dead cells. The cells were 
harvested from the dish by repeated pipetting and collected by centrifugation at lOOOg 
for 5 minutes in a MSE Centaur 2 bench top centrifuge. The resultant cell pellet was 
washed with 'Ca2+-free' DMEM/ 20pg/ml conalbu&min and centrifuged as before. 
The cells were then resuspended into 'Ca2+ free’ DMEM/ 20{ig/ml conalbumin to the 
required volume, plated into 6  well plates coated with 0.3% w/v gelatin in PBS and 
incubated at 37°C for 1 hour. The samples were then pretreated with the test 
compound prior to addition of the fusion stimulating factors (10% heat inactivated 
horse serum/ 5% chick embryo extract). Myoblasts treated with no addition, and if 
necessary, the vehicle for addition of the test compound, provided the control samples. 
Fusion was assessed 20 hours later as described below in sections 2.1.3.2. and
2.1.3.3.
(ii) Determination of fusion stimulating ability.
Myoblasts were cultured in 'Ca2+-free' DMEM/ 2% v/v dialysed chick embryo 
extract/ 10 % heat inactivated dialysed horse serum until fusion competence. At this 
time, the cells were removed from the dish by repeated pipetting and collected by 
centrifugation at lOOOg for 5 minutes in a MSE Centaur 2 bench top centrifuge. The 
resultant cell pellet was washed in' Ca2+-firee' DMEM and centrifuged as before. This 
process was repeated. The myoblasts were resuspended to the required volume and 
plated at a cell density of 15,000 cells/ well into collagen coated 24 well plates in 1ml 
DMEM. The cells were left to stand for 1 hour in a 37°C incubator. In this time they 
become attached to the collagen substrate. A 75fil aliquot of the samples to be tested 
was added to each well. Fusion was assessed 20 hours later as described below in 
sections 2.1.3.2. and 2.1.3.3.
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2.1.3.2. Acridine orange staining.
The monolayers of cells were washed four times with 1ml PBS and allowed to 
air dry. Cells were fixed and dehydrated in 1ml absolute ethanol for 10 minutes. At 
this time, the ethanol was aspirated and the cells allowed to air dry before rehydration 
with 1ml 1% (v/v) acetic acid in distilled water for 10 minutes also prevents fading of 
the fluorescence on visualisation. The samples were then rinsed three times with 
distilled water which was followed by staining with 1ml acridine orange (0 .0 1 % (w/v) 
in phosphate buffer pH 7.0) for 3 minutes, and destaining with 1ml phosphate buffer 
pH 7 for 1 minute. The stain was differentiated with 1.1% w/v calcium chloride for 
approximately 30 seconds. This results in yellow-green nuclei and red-orange 
cytoplasmic staining.
2.1.3.3. Determination of percentage fused cells.
The percentage of fused cells in each sample-was calculated by taking the 
average of
The number of nuclei in cells with 3 or more nuclei x 100 
Total number of nuclei
as determined for 5 fields of view, with 200 - 400 nuclei per field in triplicate samples
stained with acridine orange. Cells with 2 nuclei may be the result of either the fusion
of 2 mononucleated cells or in the process of mitotic cell division. They are therefore
excluded from the determination in order to avoid overestimating the extent of fusion.
Samples of non-fused and fused myoblasts are shown in figure 2.1.3.3.a) and b)
respectively. It should be noted that the percentage fusion in the 'non-fused' sample is
never zero, due to the presence of a few preformed myotubes at the time of plating.
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Figure. 2.1.3.3.
Acridine orange staining of myoblast samples.
Samples of (a) 'non-fused' and (b) 'fused' myoblast were stained 
with acridine orange. The ’non-fused’ sample is composed mainly 
of mono- and binucleated cells whilst multinucleated myotubes are 
predominant in the 'fused' sample.
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2.2. Quantitation of s/t-l,2-diacyIg!yceroI
Diacylglycerol levels in crude lipid extracts of myoblasts were measured using 
the method of Preiss et al., (1986).
2.2.1. Sample preparation.
Fusion competent myoblasts were harvested from 1.5 w/v gelatin coated 60mm 
tissue culture dishes as described in 2.1.1. The cells were resuspended in HBG to the 
required volume and dispensed in 200}il aliquots into plastic scintillation vial inserts 
and left at 37°C for 30 minutes. 300,000 cells per sample were used. Cells were 
stimulated with fusion mix (10% horse serum/ 5% chick embryo extract) and after the 
appropriate time the reaction was terminated by addition of 0.94ml 
chloroform:methanol (1:2). Samples were capped and vortex mixed and left to extract 
at room temperature for 20  minutes. 0.31ml water and 0.31ml chloroform were added 
to each sample. The tubes were capped and vortex mixed prior to centrifugation at 
2000g for 5 minutes in a MSE bench top centrifuge to separate the aqueous and organic 
phases.
2.2.2. Assay for s/i-l,2-diacy!glycerol.
A 600|il aliquot of the lower organic phase was transferred to a plastic 2ml 
Sarstedt tube and dried down under vacuum in a Univap centrifugal evaporator. Mixed 
micelles were prepared by solubilising an aliquot of the dried crude lipid in 2 0pl in 
7.5% octyl-p D glucopyranoside and 5mM cardiolipin in ImM di-ethylene-triamine- 
penta-acetic-acid (DETAPAC) by sonication in a Decon FS 100 bath sonicator. The 
following additions were then made to the solubilized lipid/octylglucoside samples:
IOjllI E.coli membranes containing sn -1,2-diacylglycerol kinase (diluted 1:4 in lOmM 
Imidazole/HCl ImM DETAPAC pH 6 .6), lOjil lOOmM freshly prepared lOOmM 
dithiothreitol and 50}il incubation buffer (lOOmM Imidazole/HCl, lOOmM NaCl,
25mM MgCl2 and 2mM EDTA, pH 6 .6). The reaction was started by addition of lOfil 
5mM ATP containing 1.25 pCi [y-32p] ATP in lOOmM Imidazole/HCl, ImM
DETAPAC pH 6 .6 . All solutions were prepared in double distilled water. Following
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vortex mixing the samples were incubated at 30°C for 30 minutes. The reaction was 
terminated by addition of 450|il chloroform:methanol (1:2) and 20}il 1% (w/v) 
perchloric acid. Samples were left to extract at room temperature for 15 minutes before 
addition of 150pl chloroform and 1ml 1% perchloric acid to split the phases.
Following capping and vortex mixing the samples were centrifuged at 12,000 rpm for 2 
minutes in a Hettisch microfuge. The upper aqueous phase was removed and a further 
lml 1% perchloric acid added to wash the lower chloroform phase. The tubes were 
capped vortex mixed and centrifuged at 12,000rpm for 2minutes as before. The upper 
aqueous phase was removed. The lower phase was dried under vacuum in a Univap 
centrifugal evaporator. The products of the reaction were separated by t.l.c using Silica 
Gel 60 F254 (Merck) 20cm x 10cm plates preactivated in acetone. Plates were air dried 
and used immediately. Samples were dissolved in 20|il chloroform:methanol (95:5) 
and lOjil were spotted over 1cm of the origin. Plates were developed with 
chloroform:methanol:acetic acid (65:15:5, v/v), air dried and subjected to 
autoradiography. The band co-migrating with sn -l-stearoyl-2-arachidonyl- 
phosphatidic acid (Rp 0.41) was scraped from the plate and its radioactivity determined 
by scintillation counting in 6ml Ecoscint.
2.2.3. Assay for total lipid phosphorus
Total lipid phosphorus was determined using the free phosphate assay method 
of Bartlett (1959). A lOOjil aliquot of the chloroform phase from cell samples was 
evaporated to dryness using a Univap centrifugal evaporator. The samples was 
digested in 600|il 72% w/v perchloric acid at 260°C for 2 hours to release free 
phosphate. After cooling, 1.6ml distilled water was added to each sample together with 
0.5ml (143mM Na2S2 0 5 ,15.9mM Na2SC>3 and 0.1% (w/v) l-amino-2-napthol-4- 
sulphonic acid). Samples were vortex mixed before addition of lml 2.5% w/v 
ammonium molybdate, followed by vortex mixing and addition of a further 1.3ml 
distilled water. Samples were heated at 90°C for 30 minutes prior to determining the
absorbance at 830nm using an LKB Ultrospec 2 spectrophotometer.
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2.3. pH] Phorbol 12,13 dibutyrate binding
Binding of pH] phorbol 12,13 dibutyrate (PDBu) was determined using 
monolayers of intact myoblasts cultured in 6  well tissue culture plates. Following 
aspiration of the culture medium, the myoblasts were washed three times with lml 
PBS. Cells were then incubated with 500}il assay buffer (lmg/ml bovine serum 
albumin (fraction V) in PBS) containing lOnM pH] PDBu in the presence or absence 
of an excess of unlabelled PDBu (10mM)in order to determine non-specific binding and 
total binding respectively. After incubation for the required length of time, the cells 
were washed three times with ice cold assay buffer and solubilised in 500}il 0.1M 
sodium hydroxide. The radioactivity of 500jil cell lysate was determined by 
scintillation counting in 4ml Ecoseint Protein was determined by the method of Lowry 
et al, (1951) as described in section 2.12.
2.4. [3H] thymidine incorporation
These experiments were performed to provide a measure of cell proliferation 
according to the method of Adams (1969). Freshly prepared myoblasts were plated 
into 24 well plates at an initial density of 25,000 cells per well. The cells were cultured 
in DMEM/ 20|ig/ml conalbumin/10% heat inactivated horse serum. l|iCi/ml pH] 
thymidine was added with the appropriate additives 24 hours after initial plating. The 
medium was aspirated 24 hours later and the cell monolayers washed three times with 
500}il phosphate buffered saline followed by three washes with 500jil 5% w/v ice cold 
trichloroacetic acid. The acid insoluble material which contained pH] thymidine 
incorporated into DNA was then solubilised in 600jil 0.3M sodium hydroxide. A 
500jil aliquot of this was added to lOOjil 1.5M hydrochloric acid in a scintillation insert 
vial and the associated radioactivity in the sample determined by scintillation counting in 
4ml Ecoscint
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2.5. Fluorescence microscopy and associated techniques.
2.5.1. Leitz Microscope and photography.
Fluorescence observations and photomicrographs were obtained with a Leitz 
Ortholux II fluorescence microscope, a standard camera attachment and Ektachrome 
800-1600 ASA professional film.
2.5.2. Fluorescence Recovery After Photobleaching.
Monolayer cultures of fusion competent-myoblasts in 0.3% (w/v) gelatin coated 
35mm tissue culture dishes were labelled using the fluorescent lipid analogue 5-N- 
(octadecanoyl) aminofluorescein (AF-C18) which becomes inserted into the plasma 
membrane. A 5jil aliquot of AF-C18 (2mg/ml in absolute ethanol) was added to lml 
culture medium and the cells were incubated at 37°C for 5 minutes before washing five 
times with lml 'Ca2+ free' DMEM/ lOmM HEPES/1% w/v lactalbumin. Samples were 
placed on a heated stage at 37°C and visualised by microscopy using a Leitz (Ortholux) 
epifluorescence microscope. A layout of the apparatus constructed by Dr. John 
Gordon and Dr John Kusel, Biochemistry Dept, Glasgow University is shown in 
figure 2.5.2.1. A highly attenuated argon ion laser beam of wavelength 490 nm was 
directed into the side of the microscope and focused down through the objective lens 
onto a small spot of 1pm radius on the surface of the specimen. The fluorescent 
molecules within this spot were excited, the fluorescence was detected by a 
photomultiplier unit which converts the number of photons hitting it into an electrical 
signal which was viewed on an oscilloscope and recorded.
Light of the excitiation wavelength was produced by the attenuated laser beam
which allowed the power of the excitation light to be varied. This facility was used to
very briefly unattenuate the laser beam for approximately 100 milliseconds which
increased the power of the laser by 104 to provide a bleach pulse which caused a
proportion of the fluorophores in the spot to be irreversibly bleached. The laser beam
returned to low power immediately which was sufficient to excite molecules in that
area to fluoresce without bleaching and allowed the fluorescence in the illuminated spot
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Figure 2.5.2.1.
Apparatus for Fluorescence Recovery After 
Photobleaching (FRAP).
Diagramatic representation of the FRAP apparatus constructed 
by Drs John Gordon and John Kusel of the Biochemistry 
department, University of Glasgow.
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Figure 2.5.2.I.
Fluorescence Recovery after Photobleaching 
Layout of apparatus Glasgow 1987
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to be monitored as a function of time. Recovery of the fluorescence intensity is due 
to lateral diffusion of unbleached molecules from the surrounding area into the spot. 
The lateral diffusion coefficient can be calculated using the value obtained for the 
half time of fluorescence recovery i.e. the time taken for the intensity fluorescence 
to reach 50% of the final intensity. The fraction of fluorescently labelled molecules 
mobile in the plane of the membrane can be determined from the percentage 
recovery relative to the initial fluorescence.
2.5.3 Fluorescence Quenching.
The depth of insertion of the lipid probe AF-C18 into the membrane was 
examined by determining the ability of a non permeant molecule - trypan blue (0.25% 
w/v) to quench the probe fluorescence as described in Chapter 3.
2.6. Determination of total [3H] inositol phosphate generation.
2.6.1. Sample preparation.
Myoblasts were labelled for 48 hours prior to fusion-competence with 5jiCi /ml 
[3H] inositol in 'Ca2+ free' DMEM/ 20|ig/ml conalbumin /10% (v/v) heat inactivated 
dialysed horse serum. The cells were cultured in 60mm tissue culture dishes coated 
with 1.5% (w/v) gelatin in PBS to which they become loosely attached. After the 
labelling period the medium was aspirated and the cells carefully washed twice with 
3ml Hanks buffered saline to remove the non-attached dead cells. The cells were 
harvested from the dish by repeated pipetting and collected by centrifugation at lOOOg 
for 5 minutes in a MSE Centaur 2 bench top centrifuge. The resultant cell pellet was 
washed with Hanks buffered saline and centrifuged as before. The cells were 
resuspended into Hanks buffered saline containing 1% (w/v) bovine serum albumin 
(fraction V) and lOmM glucose (HBG) and incubated for 10 minutes at 37°C prior to 
pelleting by centrifugation and washing in HBG
The cells were resuspended in HBG to the required volume and then left for 30 
minutes at 37°C before being aliquoted into plastic scintillation vial inserts containing
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the appropriate additions and lOjil 250mM lithium chloride to a final volume of 250 ml 
per sample. The samples were incubated at 37°C in a shaking water bath for 30 
minutes and the reactions terminated by addition of 0.94ml chloroform : methanol 
(1:2). The vials were capped, vortex mixed and left to extract either for 20 minutes at 
room temperature or overnight at 4°C.
2.6.2. Extraction of [3H] inositol phosphates and [3H] inositol 
phospholipids.
0.31ml water and 0.31ml chloroform were added to each sample. The tubes 
were capped and vortex mixed prior to centrifugation at 2000g in a MSE Centaur 2 
bench top centrifuge for 5 minutes to separate the aqueous and organic phases.
2.6.3. [3H] inositol phosphates measurement.
The accumulation of inositol phosphates, present in the upper aqueous phase, 
was determined by batch chromatography on Dowex 1x8 formate anion exchange 
resin. A 0.8ml aliquot of the aqueous phase was transferred to clean tubes and 2.2ml 
water added to lower the ionic strength. 0.25ml Dowex formate slurry was added to 
each sample. The tubes were vortex mixed and left for 10 minutes to allow the Dowex 
to settle out The water was aspirated and the Dowex washed with a further 3ml water. 
The Dowex was left to settle out as before and the water was then aspirated. The 
Dowex was then washed in a similar manner with 2x3ml 60mM ammonium formate/ 
5mM sodium tetraborate followed by 3ml water.
Inositol phosphates were eluted from the resin with 0.6ml 1M ammonium 
formate/0.1M formic acid. The tubes were vortex mixed and the Dowex left to settle. 
A 0.5ml aliquot of the supematent was removed to a scintillation vial. A further 0.6ml 
1M ammonium formate/0.1M formic acid was added to the Dowex. The tubes were 
vortex mixed, the Dowex allowed to settle and 0.6ml supematent was removed and 
added to the scintillation vial. This step was repeated once to give a final volume 1.7ml
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eluate from each sample. 12 ml Ecoscint or 8ml Optiphase scintillant was added to each 
vial and the radioactivity in each sample determined by scintillation counting.
2.6.4. [3H] Inositol phospholipid measurement.
The lower organic phase contains the pH] inositol phospholipids. A 250|il 
aliquot of this phase was dried down in scintillation vials and the radioactivity in each 
sample determined by scintillation counting in 3ml Ecoscint or 1ml Optiphase.
2.6.5. Preparation Dowex 1x8-200 formate.
Dowex 1x8-200 chloride was obtained from the Sigma Chemical Company and 
converted to the formate form for use as a resin for anion exchange chromatography of 
inositol phophates.
A known packed volume of Dowex was washed with distilled water and left to 
settle. The unsettled fines were discarded. This process was repeated twice. The 
Dowex was transferred to a scintered glass funnel and washed with 20 times its volume 
of 2M sodium hydroxide, 10 times its volume of distilled water and 5 times its volume 
of 1M formic acid respectively. Following these treatments the Dowex was washed 
with 50 times its volume of distilled water until the pH of the slurry was constant at 
approximately pH 5.5.
2.7. Preparation of membrane samples.
2.7.1. Cell harvesting.
Fusion-competent myoblasts cultured on 1.5% w/v gelatin in PBS in 60mm 
tissue culture dishes were harvested. The medium was aspirated from the dishes and 
the cells carefully washed three times with 3ml PBS to remove dead non-attached cells. 
Cells were harvested by rinsing from the dish using repeated pipetting, placed into 
13.5ml centrifuge tubes and collected by centrifugation at lOOOg for 5 minutes in a 
MSE bench top centrifuge. After aspiration of the supematent, the cells were washed
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by resuspending into PBS followed by centrifugation at lOOOg for 5 minutes. The 
supematent was again aspirated and the samples stored as cell pastes at -80°C.
2.7.2. Membrane preparation.
Cell pastes were disrupted in lOmM Tris/HCl pH 7.5/ O.lmM EDTA (buffer 1) 
using a glass-on-teflon homogeniser. The resulting homogenates were centrifuged in a 
Beckman L5-50B ultracentrifuge in a Ti 50 rotor at lOOOg for 10 minutes to remove 
cellular debris and the resulting supematent was collected and centrifuged at 40,000g 
for 10 minutes to generate a membrane pellet. This was washed by resuspending in 
buffer 1 followed by centrifugation for a further 10 minutes at 40,000g. The pellet was 
resuspended in 400}il buffer 1 and stored at -80°C until use. Protein was determined 
by the method of Lowry et al., (1951) using bovine serum albumin (fraction V) as the 
standard, see section 2 .12.
2.8. Bacterial-toxin catalysed ADP-ribosylation.
Samples for pertussis-toxin/ cholera-toxin catalysed ADP-ribosylation were 
prepared as above in section 2.4.2. but omitting the first step of centrifugation at 
lOOOg. The pertussis toxin and cholera toxin were pre-activated by incubating with 
50mM freshly prepared dithiothreitol for 1 hour prior to the experiment. At this time, 
the membrane samples in 20(0.1 Tris/HCl pH 7.5/ 0. ImM EDTA were mixed with 5jil of 
either thiol-preactivated pertussis or cholera toxin and 20mM thymidine, O.lmM GTP, 
250mM potassium phosphate buffer pH 7.0, ImM ATP, 20mM arginine hydrochloride 
and 2jiCi p 2P] NAD+ in a final incubation volume of 50pl. Samples were incubated 
for 1 hour at 37°C.
Cholera-toxin catalysed ADP-ribosylated membrane samples were collected by 
the method of sodium deoxycholate/ trichloroacetic acid precipitation. 6.25|il 2% w/v 
sodium deoxycholate 750}il distilled water and 250jil 24% w/v trichloroacetic acid were 
added sequentially to the samples followed by centrifugation at 12,000ipm for 15 
minutes in a refrigerated Hettisch bench top microfuge. The supematent was discarded
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and the pellet resuspended in 20pi 1M Tris base and 20|il Laemmli buffer. Samples 
were resolved by SDS-PAGE (10% w/v acrylamide/ 0.27% bisacrylamide) in 16cm x 
18cm slab gels run overnight at 60V and 15mA. Autoradiographs.were derived from 
the dried gels using Kodak-O-Mat-S X-Ray film.
Pertussis-toxin catalysed ADP-ribosylated membrane samples were alkylated 
prior to resolution by SDS-PAGE. The samples were collected by centrifugation at 
12,000rpm for 15 minutes in a Hettisch refrigerated bench top microfuge. The 
supematent was discarded and the membrane pellet resuspended in 20|il lOmM 
Tris/HCl pH 7.5/ O.lmM EDTA. A lOjil aliquot of 50mM freshly prepared 
dithiothreitol and 5% w/v SDS was added and the samples placed in a boiling water 
bath for 10 minutes. Following cooling on ice, 25jil lOOmM N-ethyl maleimide was 
added and the samples left to alkylate for 45 minutes. The reaction was terminated by 
addition of Laemmli buffer prior to resolution by SDS-PAGE (12.5% w/v acrylamide/ 
0.06% w/v bisacrylamide) in 20cm x 20cm slab gels run overnight at 120V and 40mA. 
Autoradiographs were derived from the dried gels using Kodak-O-Mat S X-ray film.
2.9. Western Blotting.
Western immunoblotting was performed using a panel of anti-peptide anti-G- 
protein antisera raised against synthetic peptides corresponding to amino acid sequences 
unique to the various G-proteins. Each of the antisera was raised in a New Zealand 
White Rabbit using the synthetic peptide of choice, coupled to Keyhole Limpet
" /  '  • A n  ^  She, C*yHaemocyanin, as the antigen. e ^  </< cLd v,.
2.9.1. Membrane preparation.
Membranes were prepared from myoblasts cultured as monolayers in 60mm 
tissue culture dishes in Ca2+ free DMEM/10% dialysed heat inactivated horse serum/ 
20jig/ml conalbumin for 24 hours 50 hours and 98 hours. These cells are proliferating, 
fusion-competent and non-fused respectively. The cells harvested at 98 hours are non 
fused controls to compare with myotubes formed by fusion of fusion-competent
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myoblasts cultured in medium containing 1.4mM Ca2+ for 48 hours. At the time of 
harvesting the medium was aspirated and the cells washed three times with 3ml PBS to 
remove dead, non-attached cells. Cells were then scraped into 2ml PBS and collected 
into 13.5ml plastic centrifuge tubes. The dish was rinsed with a further 1ml PBS 
which was added to the centrifuge tube. The samples were centrifuged at lOOOg in a 
MSE bench top centrifuge for 5 minutes to pellet the cells and the supematent was 
aspirated. Cells were washed by resuspending in 10 ml PBS followed by centrifugation 
at lOOOg for 5 minutes and removal of the supematent by aspiration. Harvested cells 
were stored as cell pastes at -80°C. Membrane samples were prepared as described in 
section 2.7.2.
2.9.2. Immunoblotting.
Samples for immunoblotting using the anti-peptide anti-G-protein antiserum 
CS1 were collected by the method of sodium deoxycholate/ trichloroacetic acid 
precipitation. This was achieved by sequential addition of aliquots of 2% w/v sodium 
deoxycholate (6.25jil) distilled water (750pl) and 24% w/v trichloroacetic acid (250jil) 
to the membrane sample. Samples were then centrifuged at 12,000rpm for 15 minutes 
in a Hettisch refrigerated bench top microfuge. The supematent was discarded and the 
pellet resuspended in 20pl 1M Tris base and 20pl Laemmli buffer. The samples were 
resolved by SDS-PAGE (10% (w/v) acrylamide, 0.27% w/v bisacrylamide) in 16 cm x 
18cm slab gels run overnight at 60V and 15 mA. Samples for immunoblotting using 
the anti-peptide antisera SGI I3B ONI were first alkylated as this has been shown to 
enhance the resolution of mammalian pertussis toxin substrates recognised by these 
antisera. Membrane protein was resuspended in 20pl lOmM Tris/HCl pH 7.5/ O.lmM 
EDTA. A IOjjI aliquot of 50mM dithiothreitol/ 5% (w/v) SDS was added and the 
samples placed in a boiling water bath for 10 minutes. Following cooling on ice, 25pi 
lOOmM N-ethyl maleimide was added, and the samples left to alkylate at room 
temperature for 45 minutes. The reaction was terminated by addition of 20|il Laemmli
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busier prior to resolution by SDS-PAGE (12.5% w/v acrylamide, 0.06% bisacrylamide 
w/v) in 20cm x 20cm slab gels run overnight at 120V 40mA.
Proteins were transferred from the slab gels to nitrocellulose (0.45mm) using a 
LKB 2005 Transphor electrophoretic transfer unit for 1.5 hours at 2A. The blotting 
buffer was 2M glycine 0.25M Tris and 20% v/v methanol. The nitrocellulose sheets 
were treated for 6  hours at 37°C with a blocking solution of 3% w/v skimmed milk 
(Marvel) or 3% w/v gelatin in PBS. Sheets were transferred to the primary antiserum 
(1 in 200) dilution in 1% Marvel in PBS/ 0.2% (v/v) NP40 or 1% gelatin under 
equivalent conditions, and incubated overnight at 37°C. The primary antiserum was 
removed and the blot thoroughly washed in PBS/ 0.2% NP40. The secondary 
antiserum of donkey anti-rabbit IgG coupled to horseradish peroxidase (1 in 200 
dilution) was added and left at 37°C for 4 hours. After removal of the secondary 
antiserum the blot was thoroughly washed with PBS/ 0.2% NP40 followed by PBS for 
10 minutes each. The antibody complex was detected using orthodiansidine 
hydrochloride (0.025mg/ml in PBS) as the substrate for horseradish peroxidase.
2.10. Assay of GTPase activity.
Samples of membrane protein (lOjig in 20|il lOmM Tris/HCl pH 7.5/ O.lmM 
EDTA) were added to a ice cold reaction mix of lOmM creatine phosphate, ImM ATP, 
O.lmM App(NH)p, ImM ouabain, lOOmM NaCl, 5mM MgCl2, 2mM freshly prepared 
dithiothreitol, O.lmM EDTA, 20mM Tris pH 7.5, 0.5mM GTP with 5 units creatine 
kinase and approximately 50,000 cpm [y—^P] GTP per assay tube, in a final 
incubation volume of lOOpl. The samples were incubated in the absence and presence 
of agonist to determine the basal and agonist stimulated GTPase activity respectively. 
Non-specific GTPase activity was determined in the presence of ImM GTP. Sample 
incubation was carried out at 37°C for 20 minutes. At this time, the reaction was 
terminated by placing the samples on ice. An aliquot of 0.9ml activated charcoal (5% 
w/v in 20mM orthophosphoric acid) was added to each sample to remove non­
hydrolysed [y-32p] GTP. The tubes were then capped and vortex mixed prior to
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centrifugation in a microfuge for 5 minutes. A 0.5ml aliquot of the supematent was 
removed into a scintillation insert vial and the associated radioactivity determined by 
Cerenkov counting.
2.11. Electroporation.
Myoblasts were labelled for 48 hours prior to fusion competence with 5jiCi/ml 
pH] inositol in 'Ca2+ free' DMEM/ 10% w/v heat inactivated dialysed horse serum/ 
20fig/ml conalbumin. Susequent harvesting and washing of the cells was performed as 
described in section 2.7.1.with the modification of permeabilisation buffer (120mM 
KC1, O.lmM EGTA, 6mMMgCl2, 20mM Na Hepes, 2mM KH2PO4 lmg/ml bovine 
serum albumin (fraction V) and 2.5mM ATP) replacing Hanks buffered saline. Cells 
were resuspended in 1.6ml permeabilisation buffer and electropermeabilised using 
discharge pulses of 1600V/cm. The cells were then diluted to the required volume with 
permeabilisation buffer and dispensed into plastic scintillation insert vials containing the 
appropriate additions andlOjil 250mM LiCl to a final volume of 250jil. The samples 
were incubated in a shaking water bath at 37°C for 30 minutes and the reactions 
terminated by addition of 0.94ml chloroform: methanol (1:2). The vials were capped, 
vortex mixed and left to extract for 20 minutes at room temperature or overnight at 4°C. 
Samples were subsequently processed as described in sections 2.6.2. to 2.6.4.
2.12. Protein determination
The method is essentially that of Lowry et al., (1951). A standard curve for the
assay was constructed using 0, 3pg, 5pg, 7.5pg, 10pg, 15pg 20|ig and 30|ig bovine
serum albumin (fraction V). Aliquots of the unknown sample were assayed in
triplicate. 2% w/v sodium carbonate in 0.1 M sodium hydroxide, 1% w/v copper (II)
sulphate and 2 % w/v sodium potassium tartrate (100:1:1) were freshly mixed together
and 1ml added to each sample. Samples were vortex mixed and left at room
temperature for 10 minutes. A 100|il aliquot of Folin-Ciocalteau reagent (1:2 dilution
in distilled water) was added to each sample. Samples were left at room temperature
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for 30 minutes to allow the coloured complex to fully develop. The absorbance of the 
samples at 750nm was determined spectrophotometrically using a LKB Ultrospec 2.
2.13. Sephadex G100 'gel filtration chromatography.
2.13.1. Column packing.
A column of 90cm in height and 1.6cm in diameter was poured using a 75% v/v 
settled gel that was a fairly thick slurry. Sephadex was supplied as a dry powder with a 
bed volume of 15 - 20ml/g dry powder. 15g dry powder were swollen in excess 
(500ml) lOOmM acetic acid - the eluting buffer - to give an approximate bed volume of 
225 - 300ml. The gel was swollen using a boiling water bath overnight which also 
served to deaerate the buffer. Adaptors which are adjustable column end pieces were 
used to support the bed surface and protect the bed from any insoluble particles in the 
sample. The column was run at 4°C with a downward arrangement of flow. After 
pouring and settling of the column, three column volumes of lOOmM acetic acid were 
passed through the column, in order to stabilise the bed and equilibrate it with the eluent 
buffer.
2.13.2. Checking column homogeneity.
The homogeneity of the column was checked by running through a sample of a 
coloured substrate. 0.5ml Blue Dextran at a concentration of 2mg/ml in lOOmM acetic 
acid was used. The quality of the packing was checked by watching the progress of the 
band of this substance through the column bed. Skewing of the band represents a fault 
in the column but this was not seen thus indicating that there was homogeneity of 
packing. The elution of Blue Dextran from the column was followed by measuring the 
absorbance at 280nm. The flow rate was 0.3 ml/min and 1.5ml fractions were 
collected.
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2.13.3. Determination of the void volume.
Sephadex G100 has a fractionation range of 4 - 150kDa. Molecules with 
molecular weights above the upper limit of this range, which is the exclusion limit, are 
totally excluded from the gel matrix and elute at the void volume. The elution volume 
Ve was determined for Blue Dextran (2000 kDa molecular weight) and represents the 
void volume Vo of the column.
2.13.4. Determination of total column volume.
The total column volume was determined by running the potassium dichromate 
of molecular weight 294 through the column. Its molecular weight is less than 4kDa, 
the lower limit of the molecular weight fractionation range, and it therefore eluted at the 
bed volume or total volume of the column. 0.5ml 0.05M potassium dichromate was 
loaded onto the column and its elution monitored by visual inspection since it has a 
bright orange colour. The centre of the eluent peak was determined and the total 
column volume calculated.
2.13.5. Molecular weight calibration.
Sephadex G100 has a molecular weight fractionation range between 4-150kDa. 
The column was calibrated by determining the elution volumes, Ve, for a series of 
protein standards. The calibration curve was obtained by plotting log 10 molecular 
weight against Ve/Vo and is shown in fig. 2.13.5.1. The standard proteins used were 
horse heart cytochrome C, bovine carbonic anhydrase, bovine serum albumin, yeast 
alcohol dehydrogenase and sweet potato p amylase with molecular weights 12.4,29, 
66,150 and 200kDa respectively. The standards bovine carbonic anhydrase and yeast 
alcohol dehydrogenase were mixed together and run down the column as were horse 
heart cytochrome C and sweet potato p amylase. 0.5ml each sample was loaded onto 
the column and 1.5ml fractions collected. Elution profiles were obtained by monitoring 
absorbance at 280nm of the eluent and the elution volumes determined.
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2.13.6. Gel filtration chromatography of extracts.
Extracts of chick embryonic brain and spinal cord were prepared from 12 day 
old chick embryos. Following dissection from the embryo, the tissues were 
homogenised in 50% w/v PBS followed by centrifugation at 100,000gfor 2 hours.
The supematent containing the soluble fraction of the brain and spinal cord 
homogenates was collected and frozen. Samples were prepared for gel filtration 
chromatography by lyophilisation of 2ml sample followed by dissolving in 1ml eluent 
buffer 100 mM acetic acid. The sample was run through the column at a flow rate 
0.3ml/minute and 1.5ml fractions collected. The elution of the sample from the column 
was determined by monitoring the absorbance at 280nm. Each fraction to be tested for 
fusion stimulating ability was lyophilised. The factor(s) present were dissolved in 
0.5ml ImM acetic acid.
2.14. Reverse phase HPLC analysis. - -
A Waters p bondapack C l8 reverse phase column (4.6mm x 250mm 10pm 
particle size) was used with the buffers 0 .1% trifluoroacetic acid in distilled deionised 
water (buffer A) and 0.1% trifluoroacetic acid in Propan-2-ol (buffer B). A linear 
gradient of buffer Arbuffer Bfrom (90:10) to (10:90) over 80 minutes was used with a 
flow rate of lml/min. Samples were loaded using a Rheodyne injector (lOOpl sample 
loop). The HPLC apparatus consisted of a LKB 2152 controller, 2 LKB 2150 pumps 
a LKB Uvicord SD UV monitor and a LKB Superrac collection rack. Elution of 
peptides was determined by monitoring the absorbance of the eluent at 215nm.
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Figure 2.13.5.1.
Calibration curve for Sephadex G100 column.
The elution volume for blue dextran (Vo) and those (Ve) for 
the standard proteins horse heart cytochrome C, bovine carbonic 
anhydrase, bovine serum albumin, yeast alcohol dehydrogenase 
and sweet potato (3 amylase were determined using lOmM 
ammonium acetate (pH 4.0 with acetic acid)as the eluent.
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Figure 2.13.5.1.
Sephadex G100 calibration curve
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Chapter 3
The role of 5«-l,2-diacylglycerol in myoblast fusion
Introduction
The fusion of myoblasts requires that there are transient changes in membrane 
structure together with cytoskeletal rearrangements (Kalderon and.Gilula, 1979; Fulton 
et al., 1981). It is Ca2+-dependent receptor-mediated event that is apparently coupled 
to inositol phospholipid breakdown (Wakelam and Pette, 1984a,b). The cleavage of 
phosphatidylinositol 4,5 bisphosphate (Ptdlns 4,5 P2) by phospholipase C results in 
the generation of the second messengers, inositol trisphosphate (IP3) and sn -1,2 
diacylglycerol (sn -1,2-DAG) (Berridge et al., 1984). The generation of sn -1,2-DAG 
in the membranes of fusion-competent myoblasts may be a key event in the fusion 
process because (i) sn -1,2-DAG and phosphatidic acid, which is the product of its 
phosphorylation by sn -1,2-DAG kinase act as fusogens in model membrane systems 
(Ahkong et al., 1973; Sundler and Papajadopoulos, 1981) and (ii) it is a physiological 
activator of protein kinase C (PKC), a Ca2+/phospholipid dependent serine threonine 
protein kinase whose activation is considered to play a key role in many cell processes, 
including growth and differentiation (Nishizuka, 1984, 1986). The changes in its 
levels upon fusion stimulation of fusion-competent myoblasts were thus determined 
using an assay specific for sn -1,2-DAG.
PKC is an allosteric enzyme possessing a regulatory domain which, in the
resting state, keeps the catalytic domain inactive. Activation occurs when Ca2+,
phospholipid and sn -1,2-DAG bind to the regulatory domain and cause a
conformational change in the enzyme which exposes its active site in the catalytic
domain. The role of PKC in myoblast fusion was examined using compounds which
modulate its activity. Phorbol esters, of which 12-0-tetradecanoyl-13-acetate (TPA) is
an example, activate the enzyme directly by substituting for sn -1,2-DAG (Castagna et
al., 1982). Long term treatment of cells with TPA has been demonstrated to result in
the down-regulation of PKC (Rodriguez-Pena and Rozengurt, 1984) by increasing its
rate of degradation (Young et al., 1987). Myoblasts were treated with lOOnM TPA,
from 24 hours in culture to fusion-competence, in order to determine the effect of PKC
down-regulation on fusion. The changes in PKC levels, resulting from this treatment,
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Figure 3.1."
Structural formulae of TPA, staurosporine and polymyxin B
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were examined by determining specific binding of the radiolabelled phorbol ester, [3H] 
phorbol 12, 13 dibutyrate (PDBu).
Polymyxin B and staurosporine are putative inhibitors of PKC (Kuo et al.,
1983; Tamaoki et at., 1986). They exert their effects on PKC by different mechanisms: 
polymyxin B inhibits PKC by binding to the regulatory domain (Kuo et al., 1983) 
whereas staurosporine interacts with the catalytic domain (Huang, 1989). Their effects 
on myoblast fusion were determined. The structural formulae of these putative PKC 
inhibitors, together with that of TPA, are shown in fig. 3.1.
Experiments were then performed to further investigate the effects of these PKC 
modulators on fusion. A possible model of myoblast fusion is discussed to explain the 
data presented.
R esults
3.1. Generation of s/i-l,2-diacylglycerol
The levels of sn -1,2-DAG in crude neutral lipid extracts prepared from fusion- 
competent myoblasts were were measured using an assay based on the enzymatic 
conversion of sn -1,2-DAG to phosphatidic acid by sn -1,2-DAG kinase. Lipid extracts 
were dispersed into mixed detergent micelles and incubated in the presence of [y-32p]
ATP, together with membranes from an overproducing strain of E.coli, which contain sn -
1,2-DAG kinase, as approximately 15% of the membrane protein. The products of the 
reaction were separated by t.l.c. and the radioactivity associated with the band co-migrating 
with l-stearoyl-2-arachidonyl-sw -glycerophosphate determined. This species of sn -1,2- 
DAG was used since most Ptdlns 4,5 P2, which is assumed to be the major precursor of sn 
-1,2-DAG, has this fatty acid composition. Figs. 3.1.1.a) and b) show representative time 
courses of sn -1,2-DAG production in fusion-competent myoblasts stimulated with 'fusion 
mix' (1.4mM Ca2+, 10% (v/v) heat inactivated horse serum and 5% (v/v) chick embryo 
extract). An increase in sn -1,2-DAG, in response to the agonist was apparent by 5 
seconds, which was the earliest time point measured.
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Figure 3.1.1.a) and b)
Time course of sn- 1,2-DAG production in fusion mix 
stimulated myoblasts a) 0 - 600 seconds b) 0 - 30 
minutes.
Fusion-competent myoblasts were washed and resuspended 
in HBG prior to incubation for the times indicated, with fusion mix 
(1.4mM Ca2+, 10% (v/v) heat-inactivated horse serum, and 5% 
(v/v) chick embryo extract) (open circles) or HBG (closed circles). 
The results are mean ± S.D. from single experiments (n=3) typical 
of 3.
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Levels of sn -1,2-DAG levels remained elevated at subsequent time points and returned 
to control i.e. basal unstimulated levels by 20  minutes.
Assuming 100% conversion of DAG to phosphatidic acid, the basal level of sn -
1,2-DAG in fusion-competent myoblasts is 0 09 ± 0 017 nmol DAG/ lOOnmole 
phospholipid i.e. mol% (mean ± S.E.M. of 3 separate experiments). This rises by 2- 
fold on stimulation with fusion mix to 0*175 ± 0*028 mol % (mean of 3 separate 
experiments ± S.E.M.). Phospholipid phosphorus was determined using the method 
of Bartlett (1957).
3.2 Examination of the effect of long term treatment of myoblasts with 
the phorbol ester TPA.
Long term treatment of cells with TPA has been demonstrated to result in down- 
regulation of PKC in many cell types (Nishizuka, 1989). The possible involvement of 
PKC in myoblast fusion was therefore examined, by determining the effect of long 
term treatment of myoblasts with TPA from 24 hours after initial plating to fusion- 
competence. TPA was kept as a stock solution of 5mg/ml in DMSO and diluted into 
absolute ethanol as the vehicle for addition to cells. The vehicle concentration did not 
exceed 5p.l/ml.
3.2.1. Effect of long term treatment with TPA on myoblast fusion.
The effect of long term treatment of myoblasts with TPA was examined by
treating myoblasts with TPA from 24 hours after initial plating in 'Ca2+-ffee' medium
to fusion-competence. At this time, myoblasts were harvested and fusion initiated by
plating into fresh medium containing 'fusion mix' (1.4mM Ca2+ together with 10%
(v/v) heat inactivated horse serum and 5% (v/v) chick embryo extract). Fusion was
assessed 20 hours later. The results obtained are shown in fig. 3.2.1.1. and the data
are expressed in terms of fusion index. The percentage fusion in the 'fusion mix'
sample was arbitrarily assigned a fusion index of 1. These cells were cultured in the
presence of fusion mix at fusion-competence and no addition was made at 24 hours
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after initial plating. This sample represents the amount of fusion obtained in the 
absence of test additons. Control, non-fused cells were cultured in parallel in 'Ca2+- 
free' medium for the duration of the experiment. Their fusion index was 0 09 ± 0 01 
(mean of 3 separate experiments ± S.E.M.) due to the presence of pre-formed 
myotubes at the time of plating.
The effect of long term treatment of myoblasts with TPA was examined by 
incubation of the cells in the presence of lOOnM TPA from 24 hours after initial plating 
in 'Ca2+-free' medium to fusion-competence. Fusion was initiated by harvesting and 
plating these cells into fresh medium containing fusion mix. Fusion was determined 20 
hours later and expressed relative to that of cells not pretreated with TPA (fusion index 
= 1, see above).
Long term TPA treatment resulted in an inhibition of fusion. The extent of 
fusion in TPA pretreated cells was not significandy different from that of 'non-fused' 
control cells. The vehicle for addition of TPA to myoblasts or the PKC-inactive 
structural analogue of TPA, (3-phorbol, were without effect on fusion. This suggests 
that TPA-induced inhibition of myoblast fusion is due to PKC activation or PKC 
down-regulation.
The dose-dependence of this inhibition by TPA was determined using a range 
of concentrations of TPA (5 x 10_7M - lO’^M). The results are shown in fig. 3.2.1.2. 
and the data are expressed in terms of fusion index. TPA inhibited fusion in a dose- 
dependent manner with an IC 50 value of 8*3 ± l-3nM (mean of 3 separate 
experiments± S.E.M.). Maximal inhibition of fusion occurred with lOOnM TPA, 
which inhibited fusion to levels obtained for myoblasts cultured in 'Ca2+-free' medium 
for the duration of the experiment The IC50 value for the inhibition of fusion by TPA, 
is of the same order of magnitude, as the half maximal concentration of TPA required 
for activation of PKC from rat brain (Castagna et al., 1982). These results are thus 
consistent with the activation of PKC.
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Figure 3.2.1.1.
The effect of long term TPA treatment on myoblast 
fusion .
Myoblasts were plated into 'Ca2+-ffee' medium and various 
addition were made 24 hours later. Fusion was initiated, after 50 
hours in culture, by plating the cells into medium containing fusion 
mix. Control, 'non-fused cells' were cultured in ’Ca2+-free’ 
medium for the duration of the experiment. The results are mean ± 
S.D. (n=3) from a single experiment typical of 3. - .
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Figure 3.2.1.2.
The dose-dependence of TPA inhibition of myoblast 
fusion.
Myoblasts were cultured in 'Ca2+-free' medium and 
increasing concentrations of TPA were added 24 hours later. 
Fusion was initiated, after 50 hours in culture, by plating the cells 
into medium containing fusion mix. Control, non-fused cells were 
cultured in'Ca2+-free' medium for the duration of the experiment. 
The results are mean ± S.D. (n=3) from a single experiment typical 
of 3.
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Figure 3.2.1.3.
The effect of p-phorbol on myoblast fusion.
Myoblasts were cultured in 'Ca2+-free' medium and 
increasing concentrations of p-phorbol were added 24 hours later. 
Fusion was initiated, after 50 hours in culture, by plating the cells 
into medium containing fusion mix. Control, non-fused cells were 
cultured in’Ca2+-free' medium for the duration of the experiment. 
The results are mean ± S.D. (n=3) from a single experiment typical 
of 3.
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In order to confirm this, the effects of TPA were compared to those obtained using 
the PKC inactive p-phorbol. The results are shown in fig. 3.2.1.3. and the data are 
expressed in terms of fusion index. It may be seen that p-phorbol was without effect on 
myoblast fusion at concentrations up to 500nM. The vehicle control was also non- 
inhibitory for myoblast fusion. The inhibition of fusion by TPA was therefore specific to 
TPA.
3.2.2 [3Hj PDBu binding.
In order to investigate whether long term treatment of myoblasts with TPA 
resulted in the down-regulation of PKC, PKC levels were assessed by determining 
specific binding of the radiolabelled phorbol ester, pH] phorbol 12,13-dibutyrate (pH] 
PDBu). Samples were incubated in PBS containing lmg/ml BS A and lOnM pH 
PDBu] in the presence and absence of an excess (10|iM) of unlabelled PDBu, to 
determine non-specific and total binding respectively. Specific binding was determined 
by subtracting the amount of non-specific binding from the amount of total binding.
The non-specific binding was 40-8 * 2-1% of the total binding. Fig. 3.2.2.1 shows the 
time course of change in pH PDBu] binding to fusion-competent myoblasts at 37°C.
The data are expressed as d.p.m.bound per sample. Specific binding occured rapidly 
and reached equilibrium by 5 minutes. Subsequent experiments were performed using 
a 10 minute incubation with pH] PDBu.
i
Fig. 3.2.2.^. shows the effect of long term treatment of myoblasts with TPA on 
specific pH PDBu] binding. Myoblasts were treated from 24 hours after initial plating 
in 'Ca2+ free' DMEM until fusion-competence with TPA, p-phorbol, the vehicle
t
(DMSO/ ethanol) or no addition. The results are shown in fig. 3.2.2. !^. and the data 
are expressed as percentage of specific pH PDBu] binding obtained relative to the 
control sample to which no addition was made. TPA treatment resulted in a 45-7 ± 4% 
(mean of 3 separate experiments ± S.E.M.) reduction in binding relative to the control.
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Figure 3.2.2.1.
Time course of specific binding of [3H] PDBu to fusion- 
competent myoblasts.
Myoblasts were cultured until fusion-competence in 'Ca2+- 
free' medium. At this time, samples were washed with PBS 
containing lmg/ml BSA and incubated with lOnM [3H] PDBu, in 
the presence and absence of IOjiM PDBu, for the times indicated. 
Results are mean ± S.D. (n=3) from a single experiment typical of 
3.
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Figure 3.2.2.2.
Effect of long term treatment of myoblasts with TPA on 
specific binding of [3H] PDBu.
Myoblasts were plated into 'Ca2+-free' medium and various 
additions were made 24 hours later. After 50 hours in culture, the 
myoblasts were washed and the specific binding of [^H] PDBu 
determined. The results are mean ± S.D. (n=3) from a single 
experiment typical of 3.
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Treatment with lOOnM p-phorbol or the vehicle was without effect on the specific 
binding of [3H]PDBu, a result which is consistent with TPA exerting its effect by 
binding to PKC.
The results from section 3.2 indicate that TPA inhibition of fusion H resulted in 
the inhibition of myoblast fusion to levels obtained for the myoblasts cultured in 'Ca2+- 
free' medium for the duration of the experiment. In addition, this treatment resulted in 
a reduction in the amount of PKC present, as demonstrated by a 45-7% decrease in the 
specific binding of [3H] PDBu. This suggests that PKC activation is involved in the 
process of myoblast fusion.
The possible role of PKC in myoblast fusion was further investigated by 
determining the effects of treatment with the putative PKC inhibitors, polymyxin B and 
staurosporine.
3.3 Effect of treatment with PKC inhibitors on myoblast fusion.
3.3.1 Effect of polymyxin B treatment on myoblast fusion.
Polymyxin B is an amphipathic peptide antibiotic which interacts with Ca2+ and 
acidic phospholipids and inhibits PKC by binding to its regulatory domain (Kuo et al., 
1983). The effect of long term polymyxin B treatment on myoblast fusion was 
determined using myoblasts cultured medium containing 1.4mM Ca2+. Polymyxin B, 
at concentrations of 2 to 50jiM was added to myoblasts 24 hours after initial plating. 
This method of culture is commonly used to determine the effect of various compounds 
on myoblast fusion (see Bischoff, 1978). The percentage of fused cells present in each 
sample was assessed 46 hours later. The results are shown in Fig. 3.3.1.1. and the 
data expressed as % inhibition relative to the 'fused' control sample, to which no 
addition of polymyxin B was made. Polymyxin B treatment resulted in a dose- 
dependent inhibition of myoblast fusion, with maximal inhibition resulting in a 
reduction of fusion, to the level observed for 'non-fused' myoblasts, which were 
cultured in 'Ca2+-free' medium for the duration of the experiment.
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Figure 3.3.1.1.
Dose-dependence of the effect of treatment with 
polymyxin B on myoblast fusion.
Myoblasts were cultured in medium containing 1.4mM Ca2+. 
Increasing concentrations of polymyxin B were added 24 hours after 
initial plating. Results are mean ± S.D. (n=3) from a single experiment 
typical of 3.
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The IC50 value for polymyxin B inhibition of fusion was 7-2M ± 3-2jiM (mean of 3 
separate experiments ± S.E.M.).
3.3.2 Effect of staurosporine treatment on myoblast fusion.
Stauiosporine is an inhibitor of PKC (Tamaoki et al., 1986) which prevents the 
interaction of ATP and the protein substrate with the catalytic domain. It possesses a 
rigid aromatic indole carbazole system, which suggests, that it may act at the site where 
the adenine of ATP binds. However, the potency of staurosporine in cells appears to 
be incompatible with competitive inhibition at the ATP site (Nakamishi et al., 1988). 
Staurosporine, therefore, appears to exert its effects by interacting directly with the 
catalytic domain of PKC (Huang, 1989).
The effect of long term staurosporine treatment on myoblast fusion was 
determined for a range of concentrations from 3 xlO-7 to 10-10M. Myoblasts were 
cultured in medium containing 1.4mM Ca2+ and staurosporine was added from 24 
hours after initial plating. Fusion was assessed 46 hours later and the results are 
shown in fig. 3.3.2.1. The data are expressed as the % inhibition of fusion obtained 
relative to the control, 'fused' sample, grown in the absence of staurosporine. The 
addition of staurosporine to cultures at 24 hours after initial plating resulted in a dose- 
dependent inhibition of myoblast fusion. Maximal inhibition was obtained using 
lOOnM staurosporine which reduced fusion to the level observed for 'non-fused' 
myoblasts, which were cultured in 'Ca2+-free' medium for the duration of the 
experiment The IC50 of this fusion inhibition was 7-1 * l-4nM (mean of 3 separate 
experiments ± S.E.M.).
Long term treatment of myoblasts in culture with the putative PKC inhibitors, 
staurosporine and polymyxin B, resulted in the inhibition of fusion (section 3.3). In 
these experiments, monolayers of myoblasts were cultured in medium containing 
1.4mM Ca2+ and the additions of staurosporine and polymyxin B were made 24 hours 
after initial plating.
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Figure 3.3.2.1.
Dose-dependence of the effect of treatment with 
staurosporine on myoblast fusion.
Myoblasts were cultured in medium containing 1.4mM Ca2+.
Increasing concentrations of staurosporine were added 24 hours after initial 
plating. Results are mean ± S.D. (n=3) from a single experiment typical of 3.
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At this time, there is extensive alignment of the myoblasts, a process which 
precedes fusion. The inhibition of fusion observed with staurosporine and polymyxin 
B is therefore probably due to inhibition of the fusion event itself. In this culture 
system, fusion proceeds asynchronously (Wakelam and Pette, 1982), which hinders 
the mechanistic analysis of the events underlying the process of fusion.
Fusion may be made synchronous using the low Ca2+ culture system (section 
2.2.), in which myoblasts cultured in a medium containing a low concentration of Ca2+ 
become fusion-competent by 50 hours after initial plating. They are however prevented 
from fusing because the Ca2+ concentration is not permissive for fusion. Addition of 
Ca2+ to these cells results in rapid synchronous fusion. This culture system has the 
potential to yield information on the mechanism(s) of the event of myoblast fusion.
The effects of short term (10 or 15 minute) pre-incubation of fusion-competent 
myoblasts with PKC modulators were therefore determined using this culture method, 
in order to further investigate the role of PKC activation in myoblast fusion.
3.4 Investigation of the effects of short term pre-incubation with PKC
modulators on myoblast fusion.
Myoblasts were cultured in 'Ca2+-free' medium until fiision-competence. 
Following harvesting, cells were plated into 'Ca2+-ffee' DMEM supplemented with 
20fig/ml conalbumin to maintain cell viability. After 1 hour at 37°C, cells were pre­
incubated for 10 or 15 minutes, in the presence and absence of the PKC modulators. 
Fusion was then initiated by the addition of fusion mix. A range of concentrations of 
polymyxin B (2 - 50jiM), staurosporine (3 x 10'7M - 10~10M) and TPA (5 x 10'7M - 
10-IOm) were used. Fusion was assessed 20 hours later and the results obtained are 
shown in figs 3.4.1., 3.4.2. and 3.4.3. for polymyxin B, staurosporine and TPA 
respectively. The data are expressed as % inhibition relative to the control 'fused' 
sample to which no addition was made prior to the addition of fusion mix.
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Figure 3.4.1.
Dose-dependence of the effect of short term treatment 
with polymyxin B on myoblast fusion.
Myoblasts were plated into 'Ca2+-free' medium and cultured 
until fusion-competence. The cells were pretreated for 15 minutes 
with increasing concentrations of polymyxin B prior to the initiation 
of fusion by the addition of fusion mix. Results are mean ± S.D. 
(n=3) from a single experiment typical of 3.
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Figure 3.4.2.
Dose-dependence of the effect of short term treatment 
with staurosporine on myoblast fusion.
Myoblasts were cultured until fusion-competence in 'Ca2+- 
free' medium. The cells were pretreated for 10 minutes with 
increasing concentrations of staurosporine prior to the addition of 
fusion mix. Results are mean ± S.D. (n=3) from a single 
experiment typical of 3.
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Figure 3.4.3.
Dose-dependence of the effect of short term treatment 
with TPA on myoblast fusion.
Myoblasts were cultured until fusion-competence in 'Ca2+- 
free' medium. The cells were pretreated for 10 minutes with 
increasing concentrations of TPA prior to the initiation of fusion by 
the addition of fusion mix. Results are mean ± S.D. (n=3) from a 
single experiment typical of 3.
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Figure 3.4.4.
Dose-dependence of the effect of short term treatment 
with p-phorbol on myoblast fusion.
Myoblasts were cultured until fusion-competence in 'Ca2+- 
free' medium. The cells were pretreated for 10 minutes with 
increasing concentrations of (3-phorbol prior to initiation of fusion 
by the addition of fusion mix. Results are mean ± S.D. (n=3) from 
a single experiment typical of 3.
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Pre-incubation of fusion-competent myoblasts with polymyxin B resulted in a 
dose-dependent inhibition of fusion. Maximal inhibition caused a reduction in fusion to 
levels obtained for the 'non-fused' samples which were cultured in Ca2+-ffee medium. 
Polymyxin B inhibited myoblast fusion with an IC50 value of 9-3 ± l-7fiM (mean of 3 
separate experiments ± S.E.M.). This was the same order of magnitude in the previous 
experiments using polymyxin B (fig. 3.3.1.2.).
Pre-incubation of fusion-competent myoblasts with staurosporine resulted in a 
dose-dependent inhibition of myoblast fusion. Maximal inhibition was obtained with 
lOOnM staurosporine which resulted in an inhibition of fusion obtained for 'non- 
fused'samples. The IC50 value for inhibtion was 13-5 ± 2*8nM (mean of 3 separate 
experiments ± S.E.M.). This was of the same order of magnitude as that observed in 
the previous experiments using staurosporine (fig. 3.3.2.2.)
The pre-incubation of fusion-competent myoblasts with TPA resulted in an 
inhibition of fusion (Fig. 3.4.3.). This inhibition was dose-dependent, with maximal 
inhibition being obtained with lOOnM TPA, which reduced fusion to that of 'non- 
fused' samples. The vehicle for TPA addition was without effect on fusion (data not 
shown). The IC50 value for TPA inhibition was 10 ± l-2nM (mean of 3 separate 
experiments ± S.E.M.). This is consistent with activation of PKC (Castagna et al., 
1982).
In order to confirm that TPA was exerting its effect via activation of PKC, P- 
phorbol, a structural analogue of TPA that cannot activate PKC, was tested for its 
ability to inhibit fusion. The results obtained are shown in fig. 3.4.4. and the data are 
expressed in terms of fusion index, which was calculated relative to the control fused 
sample to which no addition of P-phorbol was made, p-phorbol was without effect on 
fusion at concentrations of up to 500nM. This was in contrast to TPA which caused 
maximal inhibition of fusion at a concentration of lOOnM.
The results presented thus far demonstrate that treatment of myoblasts with
TPA, polymyxin B and staurosporine resulted in fusion inhibition. These compounds
have different effects on PKC activity; polymyxin B and staurosporine are putative
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PKC inhibitors whilst TPA activates the enzyme. It thus appears that, under the 
experimental condition used, inhibition and activation of PKC both prevent myoblast 
fusion.
These results present a paradox and, in an attempt to resolve this, experiments 
were performed to try to establish the mechanism of fusion inhibition by these 
compounds. These included studies on the effect of TPA on (i) membrane fluidity; (ii) 
myoblast proliferation and (iii) fusion mix stimulated total [3H] inositol phosphate 
generation, and are described in the following section
3 .5 .  Investigation of the mechanism of fusion inhibition by PKC
modulators.
3.5.1. Investigation of the effect of TPA on membrane fluidity.
TPA is a hydrophobic molecule, which a high concentrations (>200nM), may 
act in a non-specific manner to perturb the membrane bilayer (Castagna et al., 1979; 
Weinstein et al., 1980). Such perturbation of the plasma membrane could result in the 
inhibition of fusion by interfering with the controlled transient changes in membrane 
structure which are required for fusion. The lipids of the bilayer are constantly in 
lateral motion and non-specific membrane perturbation by TPA could affect their lateral 
mobility. The effect of TPA on the lateral mobility of membrane molecules in fusion- 
competent myoblasts was therefore examined by the technique of Fluorescence 
Recovery After Photobleaching (FRAP) using the fluorescent lipid probe 5-N- 
(octadecanoyl) aminofluorescein (AF C-18), the structural formula of which is shown 
in fig. 3.5.1.1.. Fusion-competent myoblasts were labelled with AF C-18 which 
became plasma membrane inserted. An argon ion laser beam set at the excitation 
wavelength, 490nm, was focused onto a small area (approx 1pm radius) of the cell 
surface. The fluorescent molecules in this region were then destroyed or 'bleached' by 
an intense pulse of light from the laser. The subsequent recovery of fluorescence 
intensity in this area of the cell surface was monitored, as a function of time, using a 
light level that was low enough to prevent further bleaching.
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Figure 3.5.1.1.
The structural formula of aminofluorescein C-18 (AF C-18).
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Figure 3 . 5 . 1 . 1 .
Structural formula of 5-N-(octadecanoyl) aminofluorescein (AF C -18)
HO
COOH
This recovery in fluorescence occured due to the exit of bleached molecules from 
the region and the entry of unbleached molecules from the surrounding area. The rate 
and extent of recovery depend on the rate of lateral movement of AF C-18 and the 
fraction of these fluorescent molecules that are mobile in the plane of the membrane. 
The lateral mobility of AF C-18 may be expressed in terms of a lateral diffusion 
coefficient (Dl). The average distance s (in centimetres) traversed in 2 dimensions of 
time t (in seconds) depends on D l (cm2/second) according to the equation:
s = (4DLt ) ^
D l may be calculated using the value obtained for the half time of fluorescence 
recovery i.e. the time taken for the intensity of fluorescence to reach 50% of the final 
intensity. A typical trace obtained is shown in fig. 3.5.1.2. The effect of 10 minute 
TP A treatment on the D l value and % recovery of fluorescence of AF C-18 were 
determined and the results obtained are summarised in Table 3.5.1.I* below. \
Table 3.5.1.
Effect of TPA on the lateral diffusion coefficient (Dl) and % recovery 
of fluorescence of the fluorescent lipid probe AF C-18 in the plasma 
membranes of fusion competent myoblasts.
Fusion-competent myoblasts were labelled with the fluorescent lipid probe, AF 
C-18. The lateral diffusion coefficient (Dl) and % recovery of fluorescence were 
measured in myoblasts prior to and following a 10 minute preincubation with lOOnM 
TPA. Results are mean ± S.D. (n=10) from a single experiment typical of 3.
Treatment Dl % recovery
x 10*10 cm2/sec fluorescence
Control 8-3 ±3-4 58-1 ±7
lOOnM TPA 10-4 ± 2.5 58-7 ± 5-9
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Figure 3.5.1.2.
Typical FRAP curve obtained from fusion-competent 
myoblasts labelled with the fluorescent lipid probe 
AF C-18.
Fusion-competent my blasts were labelled with AF C-18. 
An argon ion laser beam, of wavelength 490nm, was focused onto 
an area of the myoblast plasma membrane. The laser was briefly 
unattenuated to provide the bleach pulse. The recovery of 
fluorescence was monitored as a function of time. -
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TPA treatment of fusion-competent myoblasts did not affect these parameters, 
relative to those obtained for the control non-TPA treated samples. It did not therefore 
perturb the myoblast membrane as assessed by FRAP using AF C-18.
Use of AF C-18 labelling as a monitor of the plasma membrane bilayer clearly 
implies that the probe itself locates within one of the two leaflets of the bilayer. Its 
location in the plasma membrane was confirmed by the technique of fluorescence 
quenching using trypan blue. Trypan blue quenches the fluorescence of AF C-18 due 
to the phenomenon of Resonance Energy Transfer (RET). AF C-18 labelled fusion- 
competent myoblasts were examined before and after the addition of 0.25% (v/v) 
trypan blue using a fluorescence microscope equipped with a camera attachment The 
results obtained are shown photographically in fig. 3.5.1.3. Addition of trypan blue to 
AF C-18 labelled myoblasts resulted in a quenching of the fluorescence which confirms 
the membrane location of the fluorescent probe (Gordon, 1989).
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Figure 3.5.I.3. a) and b)
Effect of trypan blue treatment on myoblasts labelled 
with AF C-18.
Fusion competent myoblasts were labelled with 10|ig/ml AF 
C-18 for 5 minutes and examined by fluorescence microscopy 
before (a) and after (b) the addition of 0.25% (w/v) trypan blue.
3.5.2. Effect of TPA on [methyl-3H] thymidine incorporation.
Fusion-competent myoblasts are post-mitotic cells and withdrawal from the cell 
cycle is a prerequisite for fusion. A possible mechanism for TPA inhibition of fusion 
thus exists, where TPA stimulates myoblasts to proliferate, thus maintaining them in 
the cell cycle and consequently preventing their fusion. The incorporation of [methyl- 
3H] thymidine incorporation into acid insoluble material was used to determine DNA 
synthesis (Adams, 1969), to provide a measure of cell proliferation. The effect of TPA 
on [methyl-3H] thymidine incorporation was examined by adding TPA and ljiCi/ml 
[methyl-3H] thymidine, to cultures of myoblasts, 24 hours after plating into medium 
containing 1.4mM Ca2+. At this time in culture the myoblasts are predominantly 
proliferative (Wakelam, 1985). The results are shown in fig. 3.5.2.1. with the data 
expressed as d.p.m. [methyl-3H] thymidine incorporated per sample. TPA inhibited 
[methyl-3H] thymidine incorporation into myoblasts in a dose-dependent manner. The 
vehicle for TPA addition was without effect and therefore the observed inhibition was 
not due to a component of the vehicle. Maximal inhibition of 31.1 ± 2.5% was 
obtained using lOOnM TPA. The IC50 value for inhibition was 66  ± 2-9nM (mean of 3 
separate experiments ± S.E.M.). PKC activation was observed to inhibit [methyl-3H] 
thymidine incorporation and, thus, myoblast proliferation. The proposed mechanism 
of TPA inducing myoblast proliferation and, thereby, inhibiting their fusion is, 
therefore, unlikely to occur.
In order to confirm this, the experiment was repeated using p-phorbol, a PKC 
inactive phorbol ester. The results are shown in fig. 3.5.2.2. and the data are 
expressed as d.p.m. [methyl-3H] thymidine incorporated per sample, p-phorbol was 
ineffective at concentrations up to 500nM which suggests that the effects of TPA are 
PKC specific.
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Figure 3.5.2.1.
Dose-dependence of the effect of TPA on [methyI-3H] 
thymidine incorporation.
Myoblasts were cultured in medium containing 1.4mM 
Ca2+. A range of concentrations of TPA were added, together with 
ljiCi/sample [methyl-3H] thymidine at 24 hours after initial plating. 
The radioactivity associated with acid-insoluble material was 
determined 24 hours later. Results are mean .± S.D. (n=3) of a 
single experiment typical of 3.
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Figure 3.5.2.1.
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Figure 3.5.2.2.
Effect of p-phorbol on [methyl-3H] thymidine incorporation.
Myoblasts were cultured in medium containing 1.4mM Ca2+. A range of 
concentrations of P-phorbol were added, together with 1 jiCi/sample [methyl-3H] 
thymidine at 24 hours after initial plating. The radioactivity associated with acid- 
insoluble material was determined 24 hours later. Results are mean .± S.D. (n=3) of a 
single experiment typical of 3.
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3.5.3. Effect TPA treatment on total pH] inositol phosphate generation.
PKC activation has been proposed to be involved in the negative feedback 
regulation of inositol phospholipid hydrolysis (Watson and Lapetina, 1985). For 
example, it has been demonstrated that short term pretreatment of cells with TPA, to 
activate PKC, results in the attenuation of agonist-stimulated inositol phospholipid 
breakdown in a number of systems (Leeb-Lundberg et al., 1985;. Rittenhouse and 
Sasson, 1985; Watson and Lapetina, 1985 and Brown et al., 1987). The effect of TPA 
on total pH] inositol phosphate generation was therefore examined as a possible 
mechanism for its inhibition of myoblast fusion.
Fusion-competent myoblasts, labelled to a constant specific activity with pH] 
inositol, were treated with TPA for 10 minutes prior to addition of fusion mix. Total 
pH] inositol phosphate generation was determined using the Li+ assay as previously 
described (section 2.6). 500nM p-phorbol and the vehicle for the addition of TPA/p- 
phorbol to myoblasts were also tested. Fig. 3.5.3.1-shows a dose-response curve of 
TPA effects on total pH] inositol phosphate generation and the data are expressed as 
fold stimulation over the control.
Maximal inhibition was obtained with lOOnM TPA, which inhibited total pH] 
inositol phosphate generation by 38-9 ± 4-4% (mean from 3 separate experiments ± 
S.E.M.). This inhibition was dose-dependent with an IC50 of 4-1 ± 0*7nM (mean from 
3 separate experiments ± S.E.M.), which is consistent with activation of PKC 
(Castagna et al., 1982). This observation was supported by the lack of inhibition 
obtained using the non-PKC-activating TPA analogue, P-phorbol, and the vehicle for 
TPA/p-phorbol addition to myoblasts.
Earlier experiments (section 3.2), showed that long term treatment of myoblasts 
with TPA resulted in the inhibiton of myoblast fusion. In order to determine whether 
this was due to the inhibition of inositol phospholipid breakdown in response to the 
fusion stimulator, fusion mix, the effect of long term treatment on fusion mix- 
stimulated total pH] inositol phosphate generation was examined. Myoblasts were 
treated with either no addition, lOOnM TPA, lOOnM p-phorbol or the vehicle for
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TPA/p-phorbol addition, from 24 hours after initial plating to fusion-competence.
Total [3H] inositol phosphate generation in response to fusion mix was determined 
using the Li+ assay as before. The results are shown in fig. 3.532. and the data are 
expressed as fold stimulation of total pH] inositol phosphate generation over the 
control (no addition at 24 hours after initial plating). Long term treatment of myoblasts 
with lOOnM TPA resulted in a 22-5 ± 2-5% inhibition of total pH] inositol phosphate 
generation in response to fusion mix (mean of 3 separate experiments ± S.E.M.). This 
effect was specific to TPA since P-phorbol and the vehicle for addition were without 
effect.
Long term treatment of myoblasts with TPA also results in down-regulation of 
PKC (sections 3.2.1. and 3.2.2). Under these conditions it might be expected that 
fusion-mix stimulated pH] inositol phosphate accumulation might be enhanced, as is 
observed in some other systems e.g. Swiss 3T3 fibroblasts (Brown et al., 1987). 
However, Swiss 3T3 cells are unique in that prolonged TPA pretreatment results in the 
complete down-regulation of PKC (Rodriguez-Pena and Rozengurt, 1984). In 
contrast, myoblast PKC was only partially down-regulated by 45-7 ± 4% (see section 
5.2.2). Thus, under these conditions, the remaining PKC will be activated by TPA 
and, thereby, result in the inhibition of fiision-mix stimulated pH] inositol phosphate 
accumulation in myoblasts.
The pre-incubation of fusion-competent myoblasts with lOOnM TPA resulted in 
the reduction in total pH] inositol phosphate generation in response to fusion mix and 
in the inhibition of myoblast fusion to control, 'non-fused' levels. PKC-induced 
negative regulation of agonist stimulated inositol phospholipid hydrolysis may thus 
underlie the mechanism of fusion inhibition by TPA.
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Figure 3.5.3.I.
The effect of short term TPA or p-phorbol pre­
incubation on agonist-stimulated total [3H] inositol 
phosphate generation.
Fusion-competent myoblasts that were labelled with [3H] 
inositol were collected by centrifugation and washed. The cells were 
resuspended in HBG containing lOmM LiCl and pretreated with 
lOOnM TPA or lOOnM P-phorbol for 10 minutes prior to incubation 
in the presence and absence of fusion mix for 30 minutes. Total 
[3H] inositol phoshates were batch eluted from Dowex-formate 
anion exchange resin. Results are mean ± S.D. (n=3) from a single 
experiment typical of 3.
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Figure 3.5.3.1.
F u s i o n  mix
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+ 500nM TPA
Fusion mix
Control
fold stimulation of total inositol phosphate generation
Figure 3.5.3.2.
Effect of long term TPA or p-phorbol treatment on 
agonist-stimulated total [3H] inositol phosphate 
generation.
Myoblasts were plated into 'Ca2+-free’ medium and labelled 
with [3H] inositol. lOOnM TPA or lOOnM p-phorbol were added 24 
hours after initial plating. After 50 hours in culture, fusion- 
competent myoblasts were washed and resuspended into HBG 
containing lOmM LiCl and incubated in the presence and absence of 
fusion mix for 30 minutes. Total [3H] inositol phosphates were 
batch eluted from Dowex-formate anion exchange resin. Results are 
mean ± S.D. (n=3) from a single experiment typicalof 3.
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Figure 3.5.3.2.
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3 .6 . Effect of short term  pre-incubation with PKC inhibitors on total 
[3H] inositol phosphate generation.
Polymyxin B and staurosporine were also inhibitory to fusion (sections 3.3 and 
3.4). Their effects on upon fusion mix stimulated of total pH] inositol phosphate 
generation were therefore investigated, as a possible mechanism for their inhibition of 
fusion.
Fusion-competent myoblasts were pre-incubated for 10 or 15 minutes in the 
presence and absence of polymyxin B (50}iM) and staurosporine (lOOnM), at maximal 
concentrations for fusion inhibition, prior to the addition of fusion mix. Total pH] inositol 
phosphate generation was determined using the Li+ assay as previously described (section 
2.6). The results obtained are shown in Tables 3.6.1. and 3.6.2. below.
Table 3.6.1.
Effect of short term  pre-incubation with polymyxin B on agonist-stimulated
total [3H] inositol phosphate generation in fusion-competent myoblasts.
Fusion-competent myoblasts that were labelled with pH] inositol were washed and 
resuspended into HBG containing lOmM LiCl and pretreated with polymyxin B (50jig/ml) 
for 15 minutes. The cells were then incubated in the presence and absence of fusion mix 
for 30 minutes. Total pH] inositol phosphates were batch eluted from Dowex-formate 
anion exchange resin. Results are means ± S.D. (n=3) from a single experiment typical of 
2 .
Treatment Total pH ] inositol phosphates (d.p.m.)
Control 1401± 168
fusion mix 2697 ±211
fusion mix + 50jig/ml 2518 ±30
polymyxin B
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Table 3.6.2.
Effect of short term  pre-incubation with staurosporine on agonist- 
stimulated total [3H] inositol phosphate generation in fusion-competent 
m yoblasts.
Fusion-competent myoblasts that were labelled with pH] inositol were washed and 
resuspended into HBG containing lOmM LiCl and pretreated with staurosporine (lOOnM) 
for 10 minutes. The cells were then incubated in the presence and absence of fusion mix 
for 30 minutes. Total pH] inositol phosphates were batch eluted from Dowex-formate 
anion exchange resin. Results are means ± S.D. (n=3) from a single experiment typical of 
2 .
Treatment Total [3H] inositol phosphates (d.p.m.)
Control 2426 ±71
fusion mix 3490 ±111
fusion mix
+ vehicle for addition 3453 ±519
of staurosporine -
fusion mix + lOOnM 
staurosporine
3324 ±165
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Discussion.
3.7. Possible roles for sn-1,2-DAG in myoblast fusion.
Myotube formation occurs when the plasma membranes of two or more
myoblasts fuse to become continuous and allow intermixing of their membrane
cf
components and cytosolic contents. This requires the close apposition^embranes 
followed by a local merging of the bilayers at the point of contact. The fusion of 
myoblasts apparently occurs via receptor-mediated inositol phospholipid breakdown 
(Wakelam and Pette, 1984a,b). The hydrolysis of Ptdlns 4,5 P2 results in the loss of 
the hydrophilic headgroup and the consequent generation of sn -1,2-DAG in the plasma 
membrane. As discussed in the introduction, this lipid may be involved in the events 
that underlie the fusion process since it has fusogenic properties and is a physiological 
activator of PKC. The generation of DAG in fusion-competent myoblasts upon fusion 
stimulation has previously been demonstrated using [U-14C] glycerol labelled cells.
The lipids of these cells were extracted and separated by tl.c. after fusion stimulation 
for 8 minutes. [U-14C] glycerol labelled DAG was found to be increased relative to the 
control untreated cells. The tl.c. method used in this experiment was however unable 
to resolve the sn -1,2-DAG from the sn -2,3-enantiomer. The activation of PKC by 
sn -1,2-DAG is stereospecific for this isomer, the sn -2,3-DAG and sn -1,3-DAG are 
PKC inactive (Boni and Rando,1985). Thus an assay specific for sn -1,2-DAG was 
used to determine the changes in its levels upon fusion stimulation. This method is 
based on the phosphorylation of sn -1,2-DAG by E.coli sn -1,2-DAG kinase in the 
presence of [y-32P] ATP (Preiss et al., 1986). It also has the advantage over [U-14C] 
glycerol labelling in that it precludes the assumption that [U-14C] glycerol is distributed 
equally throughout the membrane phospholipid pools. From fig. 3.1.1a) and b), there 
was approximately a 2-fold increase in sn -1,2-DAG upon fusion stimulation with 
fusion mix. This increase was apparent at five seconds following stimulation, which 
was the earliest time point measured. Its levels remained elevated at subsequent time 
points and returned to control, i.e. basal unstimulated levels by 20  minutes.
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DAG is a neutral hydrophobic molecule which tends to destabilise membrane 
bilayers by causing increased spreading of phospholipid headgroups (Das and Rand,
1986). This leads, potentially, to the formation of a non-bilayer, inverted hexagonal II 
(Hn) structure and has been demonstrated to occur in model membrane systems 
(Epand, 1985). Such structures have been proposed as possible fusion intermediates 
(Cullis and de Kruijff, 1979).
In addition to its fusogenic properties, sn -1,2-DAG is a physiological activator 
of PKC, an enzyme which is considered to be involved in the regulation many cell 
processes, for example, exocytosis, growth and differentiation (Nishizuka, 1986). It is 
a Ca2+/phospholipid dependent serine threonine protein kinase that is active when 
inserted into the membrane, which provides the correct lipid environment for activation. 
The membrane destabilising effect of sn -1,2-DAG has been suggested to allow PKC to 
penetrate the plasma membrane (Epand and Lester, 1990). The hydrophobic domain of 
sn -1,2-DAG ensures that the PKC molecule is inserted into the membrane with the 
correct orientation to allow binding of phosphatidylserine, Ca2+ and sn -1,2-DAG at 
the regulatory domain (Hannun et al., 1986). As a result, the PKC complex adopts a 
specific conformation which 'unmasks' the active site in the catalytic domain (Brumfeld 
and Lester, 1990).
These two roles for sn -1,2-DAG are further discussed in the following 
sections.
3 .8  s/i-1,2-DAG as a fusogen.
The fusion of myoblasts involves transient changes in the plasma membrane 
structure. The lipids of the apposed bilayers mix during fusion, which implies that 
there is a temporary loss of the bilayer configuration at the fusion site. This loss of the 
lipid bilayer conformation at the point of contact would destabilise the bilayer, to allow 
mixing of the apposed individual membrane lipids and thus the establishment of 
membrane continuity. Non-bilayer structures have been proposed to play a role in the 
fusion of membranes (Cullis and de Kruijff, 1979) based on the observation that
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phospholipids in the membranes of these ghost cells undergo a conformational change 
from the lamellar bilayer (La) to non-bilayer hexagonal II (Hn) structure in the presence 
of the fusogenic lipid, oleic acid, as determined using 31p Nuclear .Magnetic 
Resonance spectroscopy.'The lamellar and Hp phases possess characteristic 31P 
NMR spectra which result from the degree of diffusional freedom of the phospholipid 
molecule in the lipid aggregate (Cullis and de Kruijff 1976). In the Hn phase, lipids are 
organised in hexagonally arranged cylinders, in which the polar head groups of the 
lipid molecules surround a narrow aqueous channel. Evidence to support the 
hypothesis that lipids in the Hp phase play a critical role in membrane fusion comes 
from experiments using model membrane systems. For example, vesicles composed of 
equimolar amounts of bovine heart cardiolipin and egg phosphatidylcholine, lipids 
which prefentially adopt the Hn configuration, fuse on addition of Ca2+ (Wilschut et 
al., 1982).
Physico-chemical forces exist between membranes which result in their short 
range repulsion. These present a barrier to close membrane contact and fusion and 
therefore must be overcome for fusion to occur. They consist mainly of electrostatic 
and hydration forces (Parsegian et al., 1984) with electrostatic repulsion being 
predominant at distances of greater than 2-3nm. This is due to the negatively charged 
polar headgroups of the phospholipids which stabilise the membrane. At less than 2- 
3nm, the hydration force is dominant and it results from the water solvation of the 
phospholipid headgroups (Parsegian eta l, 1979). Dehydration, i.e. the removal of 
water from the membrane surfaces is thus considered to be the primary requirement for 
intermembrane apposition and fusion (Parsegian et al., 1984). Myoblasts fuse at 
discrete areas of the plasma membrane, so the need to remove water from the outer 
membrane surface is localised to the fusion site. The Hn structure is externally 
dehydrated and thus fusion via an inverted Hn lipid orientation would be compatible 
with this requirement to remove water from the membrane surfaces at the fusion site. 
Such a non-bilayer structure is also consistent with local point fusion, in that it allows
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intermixing of the membrane lipids in their region of contact In addition, it permits 
fusion that is non-leaky i.e. the permeability of the cell would be maintained.
The formation of the Hn phase is an inter-lamellar event, occuring only between 
closely opposed bilayers (Siegel, 1982). The concept of an intrinsic radius of curvature 
(Ro), has been adopted to describe the radius of the channel formed by the close 
packing of the lipid groups in the hexagonal phase. Lipids that form stable lamellar 
phases possess near-infinite values of Rq, while lipids that form the Hn phase possess 
small values of Rq. A small value of Rq thus favours the formation of the Hn phase. 
Conditions which favour the La to Hn phase transition result in a reduction in the phase 
transition temperature (Th). A decrease in Th and consequent stabilisation of the Hn 
phase may be achieved by factors which decrease Rq. DAG reduces Th by this 
mechanism. Siegel et al., (1989) demonstrated, by the use of X ray diffraction that 2 
mol% l-oleoyl-2-arachidonyl glycerol, dipalmitoylglycerol and dioleoylglycerol were 
each sufficient to reduce the Th of phospholipid lattices of monomethylated dioleoyl- 
phosphatidylethanolamine (DOPE-Me) by 20°C. The proximity to Lo/Hn transitions 
has been shown to affect fusion rates (Ellens et al., 1986,1989) and many 
biomembrane systems are close to this phase boundary under physiological conditions 
(Siegel, 1986b). The transient production of diacylglycerol may be sufficient to bring 
these lipids to the temperature interval for phase transition. In support of this, the La to 
Hn transition has been demonstrated to occur upon the incorporation of DAG into 
phosphatidylcholine or phosphatidylethanolamine vesicles (Das and Rand, 1984). The 
DAG content of the membrane will thus regulate the stability of the lipid bilayer. 
Transient, controlled alteration in the levels of DAG present in the plasma membrane 
therefore provides a potential mechanism for the metabolic regulation of membrane 
stability.
The orientation of diacylglycerol in the La and Hn phase in phospholipid 
systems has been investigated by Siegel et al., (1989) using acyl chain-perdeuterated 
1,2 dipalmitoylglycerol (DPG) in lattices of dioleoylphosphatidylcholine (DOPC) and 
DOPE-Me. 2H and 31p NMR spectroscopy were used to determine the orientation of
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DPG. DPG behaves like a phospholipid in both phases with the acyl chains roughly 
parallel to those of DOPE-Me and the glycerol moiety oriented at the lipid/water 
interface. These observations support the model for myoblast fusion (Wakelam, 1987) 
which is outlined in fig. 3.7.1. The production of sn -1,2-DAG in the inner leaflet of 
the plasma membrane upon agonist stimulation of fusion-competent myoblasts, results 
in the La to Hn phase transition. This occurs because the loss of the hydrophilic 
headgroup of Ptdlns 4,5 P2 causes compensatory phospholipid spreading. Membrane 
curvature is generated due to stretching of the outer leaflets of the two apposed bilayers. 
When the phospholipid headgroups become spread so far from each other that they are 
no longer able to protect the hydrophobic interior from contact with water, the bilayer 
destabilises and the lipids repack to form an Hn phase, which generates an inverted 
micellar fusion intermediate. As a result, the lipids of the membranes of the two cells 
are free to mix at the point of contact. This structure is inherently unstable andwill 
break down, leading either to fusion or reformation of two independent cells. There are 
approximately 50 molecules from each monolayer present in this intermediate (Siegel 
1984). A single molecule of DAG is thus equivalent to 2 mol%, the value required for 
the La to Hn formation in egg PE (Das and Rand, 1986).
The stimulation of fusion-competent myoblasts with fusion mix results in a 2- 
fold increase in the levels of sn -1,2-DAG to 0*175 ± 0*028 mol% in the membrane (see 
section 3.2.1). Fusion between myoblasts only occurs at discrete sites of the 
membrane, thus, if sn -1,2-DAG production is confined to these sites, the effective 
local concentration of sn -1,2-DAG generated, may approach that required to effect the 
La to Hji phase transition.
Evidence for localised changes in membrane structure on fusion comes from 
studies on the changes in membrane fluidity when myoblasts fuse. For example, 
Weidekamm et al., (1976) demonstrated that addition of Ca2+ to fusion -competent 
myoblasts resulted in an increase in membrane fluidity as measured by changes in the 
fluorescence polarisation of a membrane probe, A23 187.
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Figure 3.7.1. A possible model for the fusion of myoblasts.
A. The plasma membranes of fusion-competent myoblasts are closely 
apposed but unable to fuse due to intermembrane repulsive forces.
B. Agonist stimulated Ptd Ins 4,5 P2 breakdown results in the loss of its
hydrophilic head group and consequent generation of sn -1,2-DAG in 
the plasma membrane.
C. The phospholipid head groups separate and spread to compensate for the 
loss of the hydrophilic head group of Ptd Ins 4,5 P2. Membrane curvature
is generated due to stretching of the outer leaflets of the bilayers.
D. Eventually the spreading polar head groups are insufficient to protect the 
hydrophobic interior from contact with water. This leads to destabilisation
of the bilayer which results in the formation of the Hn structure and generation
of an inverted micellar fusion intermediate.
E. The Hjj phase is inherently unstable and breaks down, resulting in either 
fusion or the reformation of separate cells.
Studies using the technique of resonance energy transfer have shown that when cells 
fuse, the greatest changes in fluidity occur in areas of contact between fusing cells 
(Herman and Fernandez, 1982). Localised transient membrane destabilisation may 
occur by the production of sn -1,2-DAG in the plasma membrane at the sites of fusion. 
In this way, the susceptibility of these specific membrane regions to form the inverted 
micellar fusion intermediate may be controlled by sn -1,2-DAG. The levels of sn -1,2- 
DAG return to basal by 20 minutes after stimulation thus providing a mechanism for 
restabilisation of the membrane following fusion which is essential for cell viability.
Myoblast fusion does not occur instantaneously. Using the criterion of 
membrane continuity between of living cells using phase contrast microscopy, it has 
been demonstrated to require at least 10-30 minutes (Holtzer et al., 1958; Bischoff, 
1978). The kinetics of fusion have also been studied by using two complementary 
assays to measure myoblast fusion in suspension culture (Neff et al., 1984). The first 
is the assay of Knudsen and Horwitz (1977). This defines fusion as the formation of 
cell aggregates that are resistant to dispersion by trypsin and EDTA. The second assay 
measured membrane continuity which occurs on fusion, by determining the transfer of 
a fluorescent lipid from labeled to unlabeled cells on fusion. The addition of Ca2+ to 
fusion-competent myoblasts in 'Ca2+-free'medium resulted in membrane continuity 
within 20 - 30 minutes. This has a similar time course to that observed for sn -1,2- 
DAG generation in the membranes of fusion-competent myoblasts (Fig. 3.1.1.1?.).
3.8 .  Evidence for protein kinase C involvement in fusion.
PKC is a Ca2+/phospholipid-dependent enzyme whose activation is considered 
to play a role in cell growth and differentiation (Nishizuka, 1986). Its activity is 
regulated by the binding of the activator, sn -1,2-DAG which reduces the Ca2+ 
concentration required for activation, so that the enzyme is stimulated at physiological 
resting Ca2+ concentrations (Yamanishi et al., 1979).
84
Phorbol esters, of which TPA is an example, bind to the regulatory domain of
PKC at the sn -1,2-DAG binding site and cause its sustained activation (Castagna et al.,
1982). These molecules resemble sn -1,2-DAG in structure since they possess ester
bonds at positions 12 and 13. This allows them to mimic, and thus substitute for sn -
1,2-DAG. TPA can be used to directly activate PKC in intact cells, where it effectively
by-passes the requirement for agonist-stimulated generation of sn -1,2-DAG. It thus
provides a biochemical tool for examining the involvement of PKC in myoblast fusion.
Long term treatment of myoblasts with lOOnM TPA resulted in the inhibition of 
fusion to levels obtainedfor myoblasts cultured in 'Ca2+-free' medium (Fig. 3.2.1,1.). 
Previous studies have also demonstrated that TPA inhibits myoblast fusion (Cohen et 
al., 1977; Sulakhe et al., 1985). The results in fig. 3.2.1.1. are consistent with these 
observations since TPA was present at high concentrations and for prolonged exposure 
periods; Sulakhe and co-workers studied the effect of addition of lOOnM to myoblast 
from 8 hours after initial plating until 96 hours in culure.
The inhibition of fusion resulting from long term TPA treatment was dose- 
dependent with an IC50 value of 8-3 ± l-3nM (Fig. 3.2.1.2.). This is the same order of 
magnitude as the half maximal concentration required for activation of rat brain PKC 
(Castagna et al., 1982). The structural analogue of TPA, p-phorbol, which is unable to 
activate PKC, was without effect at concentrations up to 500nM (Fig. 3.2.1.3.). The 
vehicle for addition was also without effect. These results are consistent with the 
activation of PKC by TPA.
Long term treatment of TPA has been demonstrated to result in the down- 
regulation of both phorbol ester binding sites (Collins and Rozengurt, 1982) and PKC 
activity (Rodriguez-Pena and Rozengurt, 1984). This is due to an increase in the rate 
of proteolytic degradation of PKC so that there is a reduction in the steady-state levels 
of the enzyme (Young et al., 1987). This results in a decrease in PKC activity and 
phorbol ester binding sites, which correlates with PKC activity (Stabel et al., 1987), 
since PKC is the phorbol ester ’receptor’.
- The effect of long term TPA treatment-of myoblasts on PKC levels was—
phorbol ester, p i I] phorbol 12—l ~^dibutyrate-(-PDB u) .-Long term-treatment-of
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The effect of long term TPA treatment of myoblasts on PKC levels was 
therefore assessed by determining changes in the specific binding of the radiolabelled 
phorbol ester, [3H] phorbol 12,13 dibutyrate (PDBu). Long term treatment of 
myoblasts from 24 hours after initial plating in Ca2+ free medium to fusion-competence 
results in a 45-7 ± 7% reduction in the levels of [3H PDBu] binding relative to the 
control (Fig. 3.2.2.2.). This is interpreted as reflecting a loss of the TPA sensitive 
isoform of PKC. This down-regulation was specific for TPA since the PKC inactive 
p-phorbol and the vehicle for phorbol addition were without effect The data obtained 
using TPA suggest a role for PKC in fusion.
PKC involvement was further investigated by examining the effects of two 
putative PKC inhibitors on fusion. Those tested were polymyxin B and staurosporine.
U J t c l
PKC inhibitors have been^extensively to define its physiological functions. They can 
be classified into two groups, depending upon their site of action, at either the 
regulatory or catalytic domain of the enzyme. Polymyxin B interacts with Ca2+ and 
acidic phospholipids and inhibits PKC by binding at the regulatory domain. 
Staurosporine probably interacts with the catalytic domain to exert its effect The 
addition of these compounds to myoblasts cultured in medium containing 1.4mM Ca2+, 
resulted in the inhibition of fusion, to control levels, obtained for myoblasts cultured in 
'Ca2+-free' medium (Figs. 3.3.1.1. and 3.3.2.1). This inhibition was dose-dependent 
with IC50 values for fusion inhibition of 7*2 ± 3-2|iM and 7-1 ± 2-4nM, respectively. 
These inhibitors were added at 24 hours after initial plating. At this time, myoblasts are 
extensively aligned in culture, in preparation for fusion (Wakelam, 1985). Thus the 
inhibition of fusion obtained with these compounds is probably due to inhibition of the 
fusion event itself. Further information on their mode(s) of fusion inhibition is difficult 
to obtain using this culture system, since fusion occurs asynchronously, which hinders 
the mechanistic analysis of fusion.
The mechanism of fusion inhibition by the PKC modulators TPA, polymyxin B
and staurosporine may be more clearly defined using the low Ca2+ culture system, in
which rapid synchronous fusion occurs in the presence of extracellular Ca2+. Their
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effects on fusion were therefore determined using this system. Myoblasts were 
cultured in ’Ca2+-free' medium until fusion-competence and then preincubated for 10 
or 15 minutes in the presence and absence of the PKC modulators prior to the addition 
of fusion mix. Fusion was assessed 20 hours later.
Treatment with polymyxin B, staurosporine resulted in a dose-dependent 
inhibition of fusion (figs 3.4.1., 3.4.2. and 3.4.3. respectively). .Maximal inhibition 
caused a reduction in fusion to levels obtained for cells cultured in 'Ca2+-free' medium. 
The IC50 values for inhibition by polymyxin B, staurosporine and TPA were 9*3 ± 
l-7|iM, 13-5 ± 2-8nM and 10 ± l-2nM respectively. These are of the same order of 
magnitude as the IC50 values obtained for the inhibition of fusion by long term 
treatment with these PKC modulators, p-phorbol was without effect at concentrations 
up to 500nM (Fig. 3.2.1.2.. and 3.4.4.). The results obtained using two different 
culture systems are thus consistent with the same target site of action for these 
compounds.
The results obtained with the protein kinase C inhibitors should be interpreted 
with caution since neither of these inhibitors is completely selective for PKC. The 
entry of Ca2+ which occurs just prior to fusion (David et al., 1981) will also potentially 
affect events regulated by calmodulin (CaM) the intracellular Ca2+ receptor protein, 
calmodulin (CaM) (Means, 1982). Staurosporine has been reported to inhibit myosin 
light chain kinase (MLCK) which is a Ca2+/CaM dependent enzyme (Watson et al., 
1988). Polymyxin B also inhibits this enzyme by competing for CaM (Kuo et al.,
1983). They do, however, exhibit some selectivity for PKC over MLCK in vitro, with 
IC50 values of 2jiM (PKC) and 105|iM (MLCK) for polymyxin B (Kuo et al., 1983) 
and 3nM (PKC) and lOOnM (MLCK) for staurosporine (Watson et al., 1988).
Staurosporine also inhibits protein kinase A (PKA), (IC50 value: 8nM (Ruegg
and Burgess, 1988), which is activated by cyclic adenosine 5' monophosphate (cyclic
AMP). Cyclic AMP has been proposed as the signal which initiates the onset of fusion
(Zalin and Montague, 191%. This was based on the observation that a transient rise in
cyclic AMP precedes fusion (Zalin and Montague, 1974) and that prostaglandin Ei and
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isoproterenol induce precocious fusion by elevating levels of cyclic AMP (Zalin and
Montague, 1975). These findings have however been challenged by Schutzle and co­
workers, who were unable to detect this rise in cyclic AMP prior to fusion. They
demonstrated instead that its levels are elevated following fusion, and suggest that this 
increase is a consequence, rather than a cause of fusion (Schutzle et al., 1984).
Another line of evidence against cyclic AMP involvement in fusion comes from the 
demonstration that that chronic exposure of myoblasts to TPA, which prevents fusion, 
results in the activation of p-adrenergic receptors and consequently cyclic AMP levels 
are increased (Sulakhe et al., 1985). PKA activation is therefore unlikely to play a role 
in fusion, unless TPA prevents cyclic AMP mediated fusion by blocking some event in 
the fusion process which ocurs subsequent to activation of this enzyme.
If the data obtained using staurosporine and polymyxin B are taken in 
conjunction with for TPA; the results presented suggest a role for PKC activation in 
myoblast fusion. Supporting evidence for PKC involvement in fusion comes from the 
observation that changes in PKC activity and its subcellular distribution occur during 
chick embryonic myoblast differentiation (Adamo et-al., 1989). This enzyme is active 
in the membrane inserted 'particulate' form (May et al., 1985) and soluble PKC thus 
represents a potential source of enzyme activity for recruitment to the plasma membrane 
upon agonist stimulation of the cell. At the time of fusion, PKC is predominantly 
particulate whereas, following fusion, there is a decrease in particulate and an increase 
in cytosolic activity (Adamo et al., 1985). This probably reflects detachment of PKC 
from the membrane and its recovery in the cytosolic fraction. These results suggest that 
PKC is active when myoblasts fuse to form myotubes. The subsequent decline in 
particulate and rise in cytosolic PKC activity probably corresponds to myotube 
maturation following muscle specific proteins synthesis. This would be consistent with 
data indicating that PKC is predominantly cytosolic in cultured mouse myotubes 
(Cossu et al., 1986).
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3 .9 .  Mechanism of the inhibition of fusion by short term preincubation 
with TPA.
The data presented in this chapter demonstrate that TPA treatment of myoblasts 
resulted in the inhibition of fusion, to levels seen in the control, 'non-fused' samples. 
The percentage of fusion is never zero, due to the presence of preformed myotubes at 
the time of plating, and is approximately 5-10%. The inhibition of fusion by TPA is 
dose-dependent and is consistent with activation of PKC. This is confirmed by the 
inability of p-phorbol, a structural analogue of TPA, which is unable to activate PKC, 
to inhibit fusion. This lack of inhibition with p-phorbol also implies that the effect of 
TPA on fusion is probably not due to its hydrophobic properties resulting in non­
specific perturbation of the membrane. This was further demonstrated by use of the 
fluorescent lipid probe, AF C-18, a molecule which is considered to behave like a 
phospholipid since it possesses an acyl chain which has 18 carbon atoms. It is believed 
to insert alongside to endogenous phospholipids of the myoblast membrane. The 
fluorescence observed after AF C-18 labelling was not due to fluorescent micelles 
adhering to the membrane surface, since the fluorescent label, aminofluorescein, self- 
quenches when it is present in micelles. The location of AF C-18 in the plasma 
membrane was confirmed by quenching of its fluorescence by trypan blue (fig.
3.5.1.3.). This is due to resonance energy transfer which occurs due to the overlap 
between the emission spectrum of AF C-18 and the absorption spectrum of trypan blue.
The effect of TPA on membrane fluidity was investigated by Fluorescence 
Recovery After Photobleaching (FRAP) using the fluorescent lipid probe AF-C18. The 
lateral diffusion coefficient (Dl) and percentage recovery of fluorescence was 
determined in the presence and absence of TPA (Table 3.5.1.). TPA was found to 
have no effect on either the rate of diffusion of the probe in the membrane or its 
percentage mobility. These observations suggest that TPA inhibition of fusion is 
mediated through PKC activation rather than by non-specific perturbation of the plasma 
membrane bilayer structure.
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Activation of PKC is considered to be involved in the process of cell 
proliferation (Rodriguez-Pena and Rozengurt, 198^). Myoblasts must withdraw from 
the cell cycle prior to fusion. The effect of TPA on myoblast proliferation was 
therefore examined as a possible mechanism for its inhibition of fusion. The 
incorporation of [methyl-3H] thymidine into acid-insoluble material was used to 
determine DNA synthesis (Adams, 1969) as a measure of proliferation. TPA inhibited 
the incorporation of [methyl-3H] thymidine into myoblasts (fig.3.5.2.1), by a 
maximum of 31-1 ± 2-4%. This inhibition was dose-dependent with an IC50 value of 
6*6 ± 2-9nM which is consistent with activation of PKC (Castagna et al., 1982) and is 
supported by the lack of inhibition obtained in the presence of (3-phorbol (fig.
3.5.2.2.). The maintenance of myoblasts in the cell-cycle to prevent them from fusing, 
does not therefore provide an explanation for TPA inhibition of fusion. In fact, TPA 
inhibits myoblast proliferation by a mechanism which apparently involves activation of 
PKC.
The activation of PKC by sn -1,2-DAG is a transient event due to its removal 
from the plasma membrane by phosphorylation or hydrolysis. TPA activation is 
however long lived and prolonged exposure of cells to this compound results in the 
PKC down-regulation (Collins and Rozengurt, 1982). This is due to an increase in the 
rate of degradation of the enzyme leading to reduced steady-state levels (Young et al.,
1987). The inhibition of proliferation observed with TPA is, therefore, probably due to 
a reduction in the amount of PKC present in myoblasts which occurs following long 
term treatment TPA, as demonstrated by a decrease in the specific binding of [3H] 
PDBu (Fig. 3.2.2.2.)
Short term treatment of cells with TPA prior to challenge with agonist has been
demonstrated to inhibit inositol phospholipid breakdown (Rittenhouse and Sassan,
1985; Brown et al., 1987). The effect of TPA on the generation of total [3H] inositol
phosphates was therefore examined as a possible mechanism for its inhibition of
myoblast fusion. Ten minute pretreatment of fusion-competent myoblasts with TPA
resulted in a 38-9 ± 4-4% maximal inhibition of stimulated inositol phospholipid
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breakdown, in response to fusion mix as determinedby measuring total inositol 
phosphate generation using the Li+ assay (fig 3.5.3.1). The IC50 value for this 
inhibition is 4-1 ± 07nM which is consistent with activation of PKC (Castagna et al., 
1982), and is supported by" the lack of effect of the PKC inactive p-phorbol at a 
concentration of 500nM and the vehicle for TPA/p-phorbol addition. These results 
suggest that the inhibition of Ptdlns 4,5 P2 hydrolysis is mediated by activation of 
PKC.
There are several possible sites at which TPA could act to exert this effect via 
PKC activation. It may inhibit binding of the agonist to its receptor, as has been 
demonstrated for TPA inhibition of total inositol phosphate generation in hepatocytes, 
in response to al-adrenergic stimulation by noradrenaline (Corvera et al., 1986). 
Alternatively, TPA may uncouple agonist stimulated Ptdlns 4,5 P2 breakdown by
j
phosphorylation of either PLC itjjlf (Geny et al., 1989) or the putative G-protein 
coupling it to the receptor. Phosphorylation of this G-protein could potentially interfere 
with the receptor-G-protein and/or G-protein-PLC interaction(s). Such effects of TPA 
treatment on G-protein function have been demonstrated to occur (Plevin et al., 1990; 
Smith et al., 1987).
For example, it has been shown that pre-incubation of electropeimeabilised 
Swiss 3T3 fibroblasts with TPA resulted in the inhibition of bombesin stimulated total 
pH] inositol phosphate generation and the potentiation of this response by GTPyS.
The stimulation obtained with GTPyS alone was however unaffected. It was therefore 
suggested that, in these cells, TPA impairs the coupling of the bombesin receptor to the 
G-protein (Plevin et al., 1990). A different mechanism for the TPA inhibition of 
agonist stimulated Ptdlns 4,5 P2 breakdown has been proposed to occur in human 
neutrophils (Smith et al., 1987). In these cells TPA inhibits GTPyS stimulated total 
inositol phosphate generation and therefore probably impairs the interaction of the G- 
protein with PLC.
Long term treatment of myoblasts with TPA, which inhibits fusion, also results 
in an inhibition of total pH] inositol phosphate generation in response to the fusion
stimulator, fusion mix. Such long term treatment resulted in a 22-5 ± 2-5% inhibition 
of fusion mix stimulated total [3H] inositol phosphate generation. This effect is specific 
for TPA since it was not obtained in the presence of p-phorbol or the vehicle for 
TPA/p-phorbol addition to myoblasts.
It therefore appears that fusion mix stimulated myoblast fusion and total [3Hj 
inositol phosphate generation show different sensitivities to inhibition by TPA. Long 
or short term treatment of myoblasts with TPA results in the complete inhibition of 
fusion to control ’non-fused' levels (figs. 3.2.1.1 and 3.4.3. respectively), but only 
partially inhibits total [3H] inositol phosphate generation in response to fusion mix 
(figs.3.5.3.2. and 3.5.3.1.respectively). A possible explanation for this may be that 
there is a threshold level of Ptdlns 4,5 P2 breakdown required for fusion, below which 
fusion cannot occur. In this case, TPA could prevent fusion by inhibiting this 
breakdown so that the required threshold level is not reached. Alternatively, there may 
be two or more isoforms of PKC present in fusion-competent myoblasts, one of which 
regulates the breakdown of Ptdlns 4,5 P2 by negative control whilst another isoform is 
involved in the fusion process itself. This may be possible since there are at least seven 
isozymes of PKC, designated a-, pi and p2, 5-, e-, J~ and which share common 
structural features but have distinct biochemical properties (Knopf et al., 1986; Parker 
et al., 1986; Nishizuka, 1988) in that they exhibit different sensitivities to sn -1,2 
DAG, phosphatidylserine, fatty acids and Ca2+ (Nishizuka, 1988). Although some cell 
types eg NIH 3T3 cells exhibit only the a  subtype (McCaffrey et al., 1987), most co­
express several isozymes of PKC in differing ratios (Farago and Nishizuka, 1990) and 
these differ in their intracellular and cellular locations, depending on the state of growth 
or differentiation of the cell. PKC isozymes are not equally susceptible to proteolysis 
(Kishimoto et al., 1989) and are subject to differential down-regulation by TPA (Huang 
et al., 1989). These differences suggest that PKC isozymes are involved in different 
aspects of cell regulation and provide support for the proposal that there are at least 2  
such isozymes involved in the regulation of fusion-mix stimulated fusion and Ptdlns 
4,5 P2 hydrolysis.
From section 3.2, long term TPA treatment of myoblasts resulted in a 45-7% 
decrease in PKC levels. It is thus possible that the isozyme of PKC involved in 
myoblast fusion was completely down-regulated in response to long term treatment 
with TPA whilst the other PKC isozyme(s) are either unaffected or down-regulated to a 
lesser extent. The PKC isozyme which mediates the negative feedback regulation of 
Ptdlns 4,5 P2 breakdown was probably only partially down-regulated since the TPA 
inhibition of fusion mix stimulated total pH] inositol phosphate generation was reduced 
from 38-9 to 22-5%, following long term treatment with TPA. If there was complete 
down-regulation of this PKC isozyme, then it would be predicted that the agonist- 
stimulated generation of total pH] inositol phosphates would be enhanced, due to the 
loss of the negative feedback control. This has been demonstrated to occur in Swiss 
3T3 fibroblasts (Brown et al., 1987) and rat basophilic leukaemia (RBL-2H3) cells 
(Gat-Yablonski and Sagi-Eisenberg, 1990), following complete down-regulation of 
PKC by long term TPA treatment The reduced ability of TPA to inhibit the fusion mix 
stimulated breakdown of Ptdlns 4,5 P2 in myoblasts exposed to lOOnM TPA from 24 
hours after initial plating in 'Ca2+-ffeef medium to fusion-competence, is probably due 
to TPA activation of the residual PKC isozyme which mediates the negative feedback 
control of this event.
The putative PKC inhibitors, polymyxin B and staurosporine, inhibited 
myoblast fusion but were without effect on the stimulation of total pH] inositol 
phosphate generation in response to fusion mix. This is consistent with previous 
studies which have demonstrated that staurosporine has no effect on thrombin 
stimulated formation of total pH] inositol phosphates (Watson et al., 1988) and that the 
putative PKC inhibitor, sphingosine, does not inhibit antigen induced total inositol 
phosphate generation in rat basophilic leukaemia (RBL-2H3) cells (Gat-Yablonski and 
Sagi-Eisenberg, 1990). Polymyxin B and staurosporine therefore probably inhibit 
fusion by exerting their effect on some PKC mediated event that is downstream of 
Ptdlns 4,5 P2 breakdown.
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The precise role of PKC in fusion remains to be defined, but it may be involved 
in the entry of extracellular Ca2+ which is essential for and occurs prior to fusion. This 
entry of Ca2+ into myoblasts may be involved in fusion associated_rearrangements of 
the cytoskeleton (Kalderon and Gilula, 1979; Fulton et al., 1981) which are proposed 
facilitate the local removal of cytoskeletal anchored membrane proteins and thus clear 
the fusion site to permit mixing of the plasma membranes at their point of contact. A 
Ca2+-activated neutral protease which has been reported to be active at the time of 
fusion (Kaur and Sanwal., 1984) may play a role in these rearrangements. In this 
regard, TPA has been recently demonstrated to (i) enhance Ca2+ entry into myoblasts 
as determined using 45Ca2+ and (ii) to induce precocious fusion (David et al., 1990) 
over the same time course as the Ca2+ ionophore, A23187 (David et al., 1981) i.e. in 
the 9 hour period prior to the initiation of fusion normally observed in these cultures. 
However, TPA has also been demonstrated to inhibit Ca2+ fluxes into myoblasts 
(Grove and Schimmel, 1982). These conflicting reports could probably be clarified by 
use of a fluorescent Ca2+ indicator such as Quin 2 or Fura 2 to examine Ca2+ fluxes in 
fusion-competent myoblasts treated with TPA in the presence of extracellular Ca2+. If 
extracellular Ca2+ enters myoblasts in a PKC dependent manner then it should (i) occur 
upon short term treatment with TPA and (ii) be sensitive to treatment with putative PKC 
inhibitors such as, polymyxin B and staurosporine. The effect of short and long term 
pretreatment of myoblasts with TPA on the influx of extracellular Ca2+, in response to 
agonist stimulation of fusion-competent myoblasts could also be investigated, to 
determine whether TPA inhibits myoblast fusion by preventing the entry of extracellular 
Ca2+. In this case, agonist-stimulated generation of sn -1,2-DAG in fusion-competent 
myoblast plasma membranes could therefore initiate fusion by co-ordinating both (i) the 
formation of lipid fusion intermediates and (ii) Ca2+ entry leading to cytoskeletal 
rearrangements.
In summaiy, the results presented in this chapter suggest that the generation of 
sn -1,2-DAG upon fusion stimulation, and the consequent activation of PKC, represent
key events in the regulation of myoblast fusion.
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Chapter 4
Guanine nucleotide binding proteins (G proteins) and myoblast
differentiation
Introduction.
The fusion of myoblasts is a receptor mediated event which is accompanied by 
an increase in the synthesis of muscle specific proteins including the (3-adrenergic and 
nicotinic acetylcholine neurotransmitter receptors. The transfer of information from 
many such agonist activated cell surface receptors to effector enzymes or ion channels 
is mediated by a family of guanine nucleotide binding proteins' (G-proteins), which are 
heterotrimeric entities composed of 3 distinct subunits, designated a  P and y. The 
function and specificity of each G-protein is defined by the nature of its a  subunit 
(Gilman , 1987) whilst the p subunits associate with y to form py subunit complexes 
which are functionally interchangeable between different G-proteins (Northup et al., 
1983; Katada et al., 1984).
G-proteins are known to occur in both adult skeletal muscle (Toutant et al., 
1988; Takamori and Yoshikawa, 1989) and in myoblast cell lines (Gardner et al., 1989; 
Kelvin et al., 1989). The G-proteins present in the membranes of 12-day-old chick 
embryonic myoblasts were characterised by using two different experimental 
approaches. These methods both identify Ga subunits and thus define the G-proteins 
present because these are unique for each G-protein type. In the first approach, G- 
proteins present in myoblast membranes were examined as possible substrates for the 
cholera and pertussis toxins which are bacterial toxins, derived from Vibrio cholerae 
and Bordatella pertussis respectively. This was carried out because many Ga subunits 
are substrates for ADP-ribosylation by these toxins, which catalyse the transfer of the 
ADP-ribose moiety of nicotinamide adenine dinucleotide (NAD+) to the a  subunit.
[32p] NAD+ was used as the donor of the ADP-ribose to enable the toxin substrates to 
be visualised autoradiographically, following resolution by SDS-PAGE. The second 
approach taken was immunoblotting with a panel of selective anti-G-protein anti­
peptide antisera that were raised against sequences unique to the various a  subunits of 
the cholera and pertussis toxin substrates. To date, nine G-proteins have been 
identified which are currently considered to be involved in signal transduction
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pathways. These are listed in Table 4.1 together with their known functions and 
sensitivity to cholera and pertussis toxins.
Table 4.1.
G-proteins, their functions and sensitivity to pertussis and 
cholera toxin-catalysed ADP-ribosylation.
G-protein Signal transducing Sensitivity to ADP-ribosylation
system by pertussis and cholera toxins
Gs Adenylate cyclase (stimulatory) Cholera toxin sensitive
G0lf Adenylate cyclase (stimulatory) 
in olfactory sensory neurones
Cholera toxin sensitive
Gil Unknown Pertussis toxin sensitive
G[2 Adenylate cyclase (inhibitory) Pertussis toxin sensitive
Gj3 K+ channels Pertussis toxin sensitive
G0 Ca2+ channels Pertussis toxin sensitive
Gz Unknown, PI-PLC (stimulatory)? Cholera and pertussis toxin 
insensitive
TD1 cyclic GMP PDE in rod outer segments Cholera and pertussis toxin 
sensitive
TD2 cyclic GMP PDE in cone outer segments Cholera and pertussis toxin 
sensitive
Abbreviations:
cyclic GMP PDE=cyclic guanosine 3',5’monophosphate phosphodiesterase 
PI-PLC=phosphoinositide phospholipase C
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The addition of the agonist, fusion mix (10% (v/v) heat inactivated horse 
serum, 5% chick embryo extract and 1.4mM Ca2+), to fusion-competent myoblasts 
results in the stimulation of both inositol phospholipid breakdown_and myoblast fusion. 
This receptor-phosphoinositide phospholipase C (PI-PLC) interaction may, in common 
with other agonist stimulated events, be G-protein mediated. The possible role of G- 
proteins in this process was therefore investigated.
Myoblast differentiation is accompanied by the appearance of neurotransmitter 
receptors such as (3-adrenergic receptors (Parent et al., 1980). Such development of 
hormonal responsiveness is a common feature of the differentiation of various cell 
types during embryogenesis. Given the major importance of G-proteins in signal 
transduction, it is probable that there are changes in the types and relative amounts of 
these proteins during myoblast differentiation. Evidence for this comes, for example, 
from studies on the neuroblastoma x glioma hybrid cell line NG108-15, where 
differentiation with dibutyryl cyclic AMP results in changes in the relative amounts of 
the G-proteins Gi a  and G0a  (Mullaney et al., 1988). Membranes prepared from chick 
embryonic skeletal myoblasts were therefore studied in order to determine whether 
there are changes in the relative amounts of the various G-proteins during 
differentiation.
Results.
4.1 Pertussis-toxin/cholera-toxin catalysed ADP-ribosylation of 
myoblast membrane proteins.
G-proteins present in myoblast membranes were tested as possible substrates 
for cholera toxin and pertussis toxin catalysed ADP-ribosylation. The results are 
shown in figs. 4.1.1, 4.1.2 and 4.1.3.
Fig. 4.1.1 shows membrane samples ADP-ribosylated with 2.5jig/assay thiol 
preactivated cholera toxin using [32P] NAD+ in the presence of exogenous GTP. Under 
these conditions the a  subunit of mammalian Gs is specifically ribosylated (Milligan, 1988).
Samples were resolved by SDS-PAGE and subsequently autoradiographed.
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Figure 4.1.1.
Cholera-toxin-catalysed ADP-ribosylation
Membrane samples from
a) rat glioma C6  BUI cells (30jig)
b) fusion-competent myoblasts (30|ig)
c) fusion-competent myoblasts (30jig)
were treated with p 2P] NAD+ and cholera toxin except for sample b) to which no 
cholera toxin was added. Samples were resolved by SDS-PAGE [10% acrylamide]. 
The gel was autoradiographed following drying.
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42kDa
Rat glioma C6  BUI cells (lane a) possess two forms of Gsa  of molecular weights 
42kDa and 45kDa. They were used to provide a suitable positive control. Samples in 
lanes b and c are membranes prepared from fusion-competent myoblasts which were 
incubated with [32P] NAD+ in the presence (lane c) and absence (lane b) of cholera 
toxin. Comparison of these membrane samples revealed specific cholera-toxin- 
catalysed ADP-ribosylation of a 42kDa polypeptide.
Figs. 4.1.2 and 4.1.3 show membrane samples ADP-ribosylated with 
0.5|ig/assay thiol preactivated pertussis toxin and [32P] NAD+. Samples were alkylated 
with N-ethylmaleimide prior to resolution by SDS-PAGE [12.5% acrylamide/0.06% 
bisacrylamide] because this treatment has been shown to enhance the resolution of 
mammalian pertussis toxin sustrates (Stemweis and Robishaw,1984). From fig.
4.1.2., (lane b), it can be seen that rat glioma C6  BUI cells possess a 40kDa 
polypeptide which was ADP-ribosylated by pertussis toxin. This corresponds to Gi2a 
which is the major pertussis toxin sensitive sustrate of these cells (Goldsmith et al., 
1987). These membranes were used to provide a positive control for pertussis-toxin- 
catalysed ADP-ribosylation. Samples in lanes a and c are membranes prepared from 
fusion-competent myoblasts which were incubated with [32P] NAD+ in the presence 
(lane a) or absence (lane C) of pertussis toxin. Comparison of these samples shows that 
pertussis-toxin-catalysed [32P] ADP-ribosylation of myoblast membranes resulted in 
the specific incorporation of radioactivity into polypeptides of apparent molecular 
weights of 38kDa and 41kDa. In later experiments, greater resolution of mammalian 
G-proteins was achieved (fig. 4.1.3.) so that three well resolved pertussis toxin 
substrates of apparent molecular weights 39kDa, 40kDa and 41kDa were detected in rat 
cerebral cortex (lane a). These correspond to G0a  G[2a and G ila  respectively. 
(Goldsmith et al., 1987). The 41kDa pertussis toxin substrate present in chick 
embryonic myoblasts in fig. 4.1.2. was further resolved into two polypeptides of 
apparent molecular weights 40.5kDa and 41.5kDa. (lane c).
In conclusion, there were apparendy one cholera toxin and at least three 
pertussis toxin substrates for ADP-ribosylation present in myoblast membranes.
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Figure 4.1.2.
Pertussis-toxin-catalysed ADP-ribosylation.
Membrane samples from
a) fusion-competent myoblasts (30|ig)
b) fusion-competent myoblasts (30pg)
c) fusion-competent myoblasts (30jig)
d) rat glioma C6  BUI cells (30pg)
e) rat cerebral cortex (10|ig)
were treated with p 2P] NAD+ and pertussis toxin except for sample c) to which no 
pertussis toxin was added. Samples were alkylated prior to resolution by SDS-PAGE 
[12.5% acrylamide/0.06% bisacrylamide]. The gel was autoradiographed following 
drying.
100
Figure 4.1.2.
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Figure 4.1.3.
Pertussis-toxin-catalysed ADP-ribosylation.
Membrane samples from
a) rat cerebral cortex (lOjig)
b) rat glioma C6 BU1 cells (30fig)
c) fusion competent myoblasts (30{ig)
d) fusion-competent myoblasts (30|ig)
e) fusion-competent myoblasts (30{ig)
were treated with [32P] NAD+ and pertussis toxin except for sample c) to which no 
pertussis toxin was added. Samples were alkylated prior to resolution by SDS-PAGE 
[12.5% acrylamide/0.06% bisacrylamide]. The gel was autoradiographed following 
drying.
101
Figure 4.
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4.2 Western immunoblotting using anti-peptide anti-G-protein antisera.
Selective anti-G-protein anti-peptide antisera against sequences unique to the 
various cholera toxin and pertussis toxin substrates were used as the primary reagents. 
The secondary antiserum was donkey anti-rabbit IgG coupled to horse radish 
peroxidase and ortho-diansidine hydrochloride was used as the enzyme substrate to 
detect the antibody complex. The product of this reaction was visualised by its rust- 
brown colour. Rat cerebral cortex, rat glioma C6  BUI cells and human monocyte 
U937 cells were the sources of mammalian G-proteins used to provide suitable positive 
controls for the various antisera employed in these experiments. Table 4.2.1. list these 
membrane types together with the G-proteins for which they were used as controls. 
Table 4.2.2. lists the sequences of the peptides employed as antigens and the 
specificities of the anti - G-protein antisera generated.
4.2.1 Identification of Gsa  immunoreactivity.
Fig. 4.2.1.1. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the CS1 antiserum. CS1 was raised against the synthetic peptide 
RMHLRQYELL which corresponds to the C terminal amino acid sequence, (residues 
385-394), of mammalian Gsa. Rat glioma C6  BUI cell membranes (lane a) possess 
two forms of the cholera toxin substrate, Gsa, of molecular weights 42kDa and 45kDa. 
In myoblast membranes (lane b) an immunoreactive polypeptide was identified which 
co-migrated with the 42kDa form of Gsa  from rat glioma C6  BUI cell membranes.
4.2.2. Identification of G ila  and Gi2a immunoreactivity.
Figs.4.2.2.1. and 4.2.2.2. show membrane samples resolved by SDS- 
PAGE and immunoblotted with the anti-peptide antiserum SGI. This was raised 
against the synthetic peptide KENLKDCGLF which corresponds to the amino acid 
sequence of transducin, residues 341-350, and recognises mammalian G jla and 
Gi2a in non-photoreceptor containing tissues (Mitchell et al., 1989). Mammalian
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G ila  and Gi2 a  are recognised equally because these proteins possess identical 
amino acid sequences in the region against which the antiserum was raised.
Table 4.2.1.
Membrane sources of G-proteins used as positive controls for Western 
Blotting experiments.
Membrane type Ga for which samples were Molecular weight
used to provide a suitable control kDa
C6  BUI Gs 45 and 42
Gi2 40
Gi3 41
U937 Gi3 41
rat cerebral cortex Gil 41
Gj2 40
Gi3 41
G0 39
Gsa  is a substrate for cholera-toxin-catalysed ADP-ribosylation 
(in the presence of GTP)
Giloc, Gi2a, Gi3a and G0a  are substrates for pertussis-toxin-catalysed ADP- 
ribosylation.
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Table 4.2.2
Generation and specificities of the anti-peptide anti-G-protein antisera.
Antiserum Peptide corresponding G-protein a  subunit
sequence recognition
CS1 RMHLRQYELL Gs 385-394 Gs
SGI KENLKDCGLF TD1 341-350 TD1,TD2, 
Gjl and Gi 2
I3B KNNLKECGLY Gi3 345-354 Gj 3, G0
ONI GCTLSAEERAALERSK G0 1-16 Go
IM1 NLKEDGISAAKDVK G0 22-35 G0
I1C LDRIAQPNYI G il 159-168 O il
BN1 MSELDQLRQE P 1-10 PI
TD = Transducin
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Figure 4.2.1.1.
Identification of Gsa  immunoreactivity in myoblasts.
Membrane samples from
a) fusion-competent myoblasts (250|xg)
b) rat glioma C6  BU1 cells (lOOjig)
were resolved using SDS-PAGE [10% aciylamide] and 
immunoblotted using the antipeptide antiserum CS1 (1:200) 
as the primary reagent.
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Figure 4.2.1.1.
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Antiserum SGI recognised two polypeptides of 41kDa (Gila) and 40kDa (Gi2a) in rat 
cerebral cortex with G ila present in greater abundance than Gj2a (fig. 4.2.2.1., lane
b). Rat glioma C6 BUI cells possess Gi2a (Mitchell et ai, 1989) which co-migrated 
with the 40kDa polypeptide from rat cerebral cortex (fig. 4.2.2.1., lane a). From fig.
4.2.2.1., antiserum SGI identified two polypeptides of approximately 38kDa and 
41kDa, which were present in apparently equal amounts, in chick embryonic myoblast 
membranes (lane d). A similar pattern of immunoreactivity was also detected for 12- 
day-old chick embryonic brain membrane samples (lane c). In later experiments, of 
which that shown in fig. 4.2.2.2. is an example, an additional polypeptide of apparent 
molecular weight 41.5kDa was identified as being immunoreactive with SGI (lanes b 
and c). This may be a reflection of improved resolution by SDS-PAGE as seen in fig.
4.1.3. as these pertussis-toxin -catalysed ADP-ribosylation and immunoblotting 
experiments were carried out in the same period.
Fig. 4.2.2.3. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the anti-peptide antiserum IIC. This was raised against the 
synthetic peptide LDRIAQPNYI, which corresponds to the amino acid sequence, 
residues 159-168, of mammalian Gjla. I1C is able to recognise mammalian G jla  as 
distinct from Gi2a  and it was therefore used to further the conclusions obtained using 
the SGI antiserum. From fig. 4.2.2.3., lane a, antiserum I1C recognised a single 
polypeptide of 41kDa in rat cerebral cortex (Gila). A single polypeptide of apparent 
molecular weight 41.5kDa showed immunoreactivity in chick embryonic myoblasts 
(lane c). A similar pattern of immunoreactivity was seen for 12-day-old chick 
embryonic brain (lane b).
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Figure 4.2.2.1
Identification of G jla  and Gj2a immunoreactivity in
myoblasts (i).
Membrane samples from
a) rat glioma C6  BUI cells (lOOjig)
b) rat cerebral cortex (lOOjig)
c) 12-day-old chick embryonic brain (100}ig)
d) fusion-competent myoblasts (250}ig)
were alkylated prior to resolution by SDS-PAGE using a 
12.5%/0.06% bisacrylamide slab gel followed by immunoblotting 
using the anti-peptide antiserum SGI (1:200) as the primary reagent.
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Figure 4.2.2.1.
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Figure 4.2.2.2
Identification of G ila  and Gj2a immunoreactivity (ii).
Membrane samples from
a) rat glioma C6  BUI cells (lOOjig)
b) 12-day-old chick embryonic brain (lOOjig)
c) fusion-competent myoblasts (250jig)
d) rat cerebral cortex (100p.g)
were alkylated prior to resolution by SDS-PAGE using a 12.5% 
acrylamide/0.06% bisacrylamide slab gel followed by . 
immunoblotting using the anti-peptide antiserum SGI (1:200) as the 
primary reagent
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Figure 4.2.2.3.
Identification of G ila  immunoreactivity in myoblasts.
Membrane samples from
a) rat cerebral cortex (1 OOjig)
b) 12-day-old chick embryonic brain (lOOjig)
c) fusion-competent myoblasts (250jig)
were resolved by SDS-PAGE [12.5% acrylamide/0.06% 
bisacrylamide] followed by immunoblotting using the anti-peptide 
antiserum I1C (1:2 0 0 ) as the primary reagent. - .
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Figure 4.2.2.3.
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4.2.3 Identification of Gi3a and G0a immunoreactivity.
Fig. 4.2.3.1. shows samples resolved by SDS-PAGE and immunoblotted with 
the anti-peptide antiserum I3B. I3B was raised against the synthetic peptide 
KNNLKECGLY which corresponds to the C terminal sequence, residues 345-354 of 
mammalian Gi3a. It cross-reacts weakly with mammalian G0a  and may therefore be 
used to detect mammalian Gi3a and G0oc. Antiserum I3B detected a single polypeptide 
of 41kDa (Gi3a) in rat glioma C6 BUI cells and human U937 monocyte cells (lanes b 
and e respectively). An additional band of 39kDa (G0a) was detected in rat cerebral 
cortex (lane a). Antiserum I3B recognised a single polypeptide of 41.5kDa in 
myoblasts (lane c) and two immunoreactive polypeptides of apparent molecular weights 
41.5kDa and 40kDa in 12 day old chick embryonic brain (lane d).
Fig. 4.2.3.2. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the anti-peptide antiserum ONI. This was raised against the 
synthetic peptide GCTLS AEERAALERSK, which corresponds to the N terminal 
amino acid sequence of mammalian G0a, residues 1-16. G0oc was detected as a single 
polypeptide of 39kDa in rat cerebral cortex (lane c). Antiserum ONI recognised a 
single polypeptide of apparent molecular weight 40kDa in chick embryonic myoblasts 
(lane a). A similar pattern of immunoreactivity was seen for 12-day-old chick 
embryonic brain (lane b) where it appeared to be present in much greater abundance in 
comparison to myoblasts.
4.2.4. Effect of alkylation on the relative mobilities of mammalian 
G ila , Gi2a Gi3a and G0a in comparison with the corresponding 
immunoreactive polypeptide(s) in SDS polyacrylamide gels.
Myoblasts and 12 day old chick embryonic brain possess Gila-,Gi2a-, Gi3a- 
and G0a-like immunoreactivity. The mobilities of these polypeptides in SDS 
polyacrylamide gels are different to those observed for the mammalian forms.
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Figure 4.2.3.1
Identification of Gi3a immunoreactivity in myoblasts.
Membrane samples from
a) rat cerebral cortex (1 OOpg)
b) rat glioma C6 BUI cells (lOOjig)
c) fusion-competent myoblasts (250p.g)
d) i2-day-old chick embryonic brain (lOOfig)
e) human monocyte U937 cells (150pg)
were alkylated prior to resolution by SDS-PAGE using a 12.5% 
acrylamide 0.06% bisacrylamide slab gel followed by 
immunoblotting using the anti-peptide antiserum I3B (1:200) as 
the primary reagent
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Figure 4.2.3.2
Identification of G0a  immunoreactivity in myoblasts.
Membrane samples from
a) fusion-competent myoblasts (250p.g)
b) 12-day-old chick embryonic brain (lOfig)
c) rat cerebral cortex (lOjig)
were alkylated prior to resolution by SDS-PAGE using a 
12.5% acrylamide/0.06% bisacrylamide slab gel followed by 
immunoblotting using the anti-peptide antiserum ONI (1:200) as the 
primary reagent.
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Samples were alkylated using N-ethylmaleimide prior to SDS-PAGE in order to 
enhance resolution of the various G-proteins. The differing mobilities may therefore 
reflect differences in the number of cysteine residues available as sites for alkylation. 
This has been investigated-by comparing the effects of alkylation on the relative 
mobilities of mammalian Gila, Gi2a Gi3a and G0a  and the corresponding 
immunoreactive polypeptides present in chick myoblasts and 1-2-day-old chick 
embryonic brain.
4.2.4.1 Effect of alkylation on the relative mobilities of G jla and Gi2a 
immunoreactive polypeptides.
Fig. 4.2.4.1.1. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the anti-peptide antiserum SGI which recognises equally 
mammalian G jla and Gi2a in non-photoreceptor containing tissues. Membrane 
samples in lanes a,b,c and d were alkylated prior to SDS-PAGE. Comparison of lanes 
a with h, b with g, c with f, and d with e shows that alkylation reduced the mobility of 
all the polypeptides detected by antiserum SGI but, the relative mobilities of the chick 
Gila-like and Gi2a-like polypeptides, were unchanged when compared to the 
mammalian G ila  and Gi2a. Alkylation of myoblast and 12-day-old chick embryonic 
brain membrane samples did however, result in the enhanced resolution of the 40.5kDa 
and 41. 5kDa immunoreactive polypeptides.
Fig. 4.2.4.1.2. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the anti-peptide antiserum IIC which is specific for mammalian 
Gila. Membrane samples in lanes d e and f were alkylated prior to SDS-PAGE. 
Comparison of lanes a with f, b with e and c with d revealed that alkylation reduced the 
mobility of G ila from rat cerebral cortex and the Gila-like immunoreactive 
polypeptide, present in myoblasts and 12-day-old chick embryonic brain. The relative 
mobility of mammalian Gila- and the Gila-like immunoreactive polypeptides was 
however unchanged.
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Figure 4.2.4.1.1.
Effect of alkylation on the relative mobilities of the 
Gi2a and G ila  immunoreactive polypeptides in SDS- 
PAGE gels
Membrane samples from
a) rat cerebral cortex (lOOfig)
b) 12-day-old chick embryonic brain (lOOfig)
c) fusion-competent myoblasts (250jig)
d) rat glioma C6 BUI cells (lOOjig)
e) rat glioma C6 BUI cells (lOOjig)
f) fusion-competent myoblasts (250jig)
g) 12-day-old chick embryonic brain (lOOjig)
h) rat cerebral cortex (lOOfig)
were resolved by SDS-PAGE using a 12.5% acrylamide/0.06% 
bisacrylamide slab gel. Samples a) -d) were alkylated prior to gel 
electrophoresis. Immunoblotting was performed using the anti­
peptide antiserum SGI (1:200) as the primary reagent.
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Figure 4.2.4.1.1.
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Figure 4.2.4.1.2.
Effect of alkylation on the relative mobilities of the 
G ila  immunoreactive polypeptides on SDS-PAGE.
Membrane samples from
a) rat cerebral cortex (lOOjig)
b) 12-day-old chick embryonic brain (lOOjig)
c) fusion-competent myoblasts (250|ig)
d) fusion-competent myoblasts (250}ig)
e) 12-day-old chick embryonic brain (lOOjig) .
f) rat cerebral cortex (100}ig)
were resolved by SDS-PAGE using a 12.5% acrylamide/0.06% 
bisacrylamide slab gel. Samples d) - f) were alkylated prior to gel 
electrophoresis. Immunoblotting was performed using the anti­
peptide antiserum 11C (1:200) as the primary reagent.
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4.2.4.2 Effect of alkylation on the relative mobilities of the Gi3a and 
G 0cc immunoreactive polypeptides in SDS polyacrylamide gels.
Fig. 4.2.4.2.I. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the anti-peptide antiserum I3B which was raised against 
mammalian Gi3a and cross reacts weakly with mammalian G0cc. Membrane samples 
in lanes a, b, c d and e were alkylated prior to SDS-PAGE. Comparison of lanes a 
with j, b with i, c with h, d with g and e with f reveals that alkylation reduced the 
mobility of mammalian Gi3a together with the Gi3a-like and G0a-like immunoreactive 
polypeptides. The relative mobilities of the mammalian Gj3a and the chick embryonic 
Gi3a-like immunoreactive polypeptide were however unchanged. The non-alkylated 
forms of mammalian G0a  (lane j) and the chick embryo G0a-like immunoreactive 
polypeptide (lane i) co-migrated in the SDS-polyacrylamide gel but alkylation caused 
their mobility to change with respect to each other, so that they no longer co-migrated 
when resolved by SDS/PAGE. - .
This observation was confirmed by immunoblotting membrane samples 
resolved by SDS-PAGE with the IM1 anti-peptide antiserum which recognises G0a  
(Mullaney et al., 1988) and is raised against the synthetic peptide 
NLKEDGISAAKDVK, which corresponds to the amino acid sequence, residues 22- 
35, of mammalian G0(X. Alkylation of the chick embryonic G0oc-like immunoreactive 
polypeptide (fig. 4.2.4.2.2., lane c) reduced its mobility, so that it ran with a higher 
apparent molecular weight of 40kDa compared to the non-alkylated form (lane b) which 
co-migrated with mammalian G0oc (lane a) of molecular weight of 39kDa.
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Figure 4.2.4.2.1.
Effect of alkylation on the relative mobilities of the 
G|3a and G0cx immunoreactive polypeptides in SDS- 
PAGE gels.
Membrane samples from
a) rat glioma C6 BUI cells (lOOjig)
b) rat cerebral cortex (lOOfig)
c) 12-day-old chick embryonic brain (lOOjig)
d) fusion-competent myoblasts (250|ig) - .
e) human monocyte U937 cells (150}ig)
f) human monocyte U937 cells (150fig)
g) fusion-competent myoblasts (250}ig)
h) rat cerebral cortex (lOOfig)
i) 12-day-old chick embryonic brain (lOOfig) 
j) rat glioma C6  BUI cells (lOOpg)
were resolved by SDS-PAGE using a 12.5% aciylamide/0.06% 
bisacrylamide slab gel. Samples a) - e) were alkylated prior to gel 
electrophoresis. Immunoblotting was performed using the anti­
peptide antiserum I3B (1:200) as the primary reagent.
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Figure 4 .24 .2 .2 .
Effect of alkylation on the relative mobilities of G0a  
immunoreactive polypeptides on SDS-PAGE.
Membrane samples from
a) rat cerebral cortex (lOOjig)
b) 12-day-old chick embryonic brain (lOOjig)
c) 12-day-old chick embryonic brain (lOOjig)
d) rat cerebral cortex (lOOjig)
were resolved by SDS-PAGE using a [12.5% acrylamide/0.06% 
bisacrylamide] slab gel. Samples c) and d) were alkylated prior to 
gel electrophoresis. Immunoblotting was performed using the anti­
peptide antiserum IM1 (1:200) as the primary reagent
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4.2.5. The effect of protease inhibitors on the immunoreactivity of 
myoblast membrane polypeptides.
The 40.5kDa and 38kDa immunoreactive polypeptides detected by the SGI 
antiserum in membranes of myoblasts and chick embryonic brain may represent 
proteolytic fragments of the 41.5kDa immunoreactive polypeptide. Similarly the 40kDa 
polypeptide detected by antiserum I3B may be derived by proteolysis of the 41.5kDa 
immunoreactive polypeptide. This possibility was investigated by immunoblotting 
membrane samples from myoblasts and 12-day-old chick embryonic brain which were 
prepared in the presence or absence of protease inhibitors. The patterns of 
immunoreactivity were then compared. The protease inhibitors used were 
benzamidine, soybean trypsin inhibitor and leupeptin because they inhibit the 
proteolysis of Gi2a and G[3a in human U937 monocyte cell membranes (Fiona 
Mitchell, personal communication).
Fig. 4.2.5.1. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the SGI antiserum. Samples in lanes c and e were prepared in the 
presence of protease inhibitors. Comparison of lanes b with c and d with e reveals that 
inclusion of protease inhibitors in the membrane sample preparation resulted in no 
change in the pattern of immunoreactivity detected by SGI.
Fig. 4.2.5.2. shows membrane samples resolved by SDS-PAGE and 
immunoblotted with the I3B antiserum. Comparison of membrane samples from 12- 
day-old chick embryonic brain prepared in the presence (lane d) and absence (lane c) of 
protease inhibitors reveals that the pattern of immunoreactivity detected was unchanged. 
It should be noted that mammalian Gi3a and G0a  co-migrate in [10% acrylamide] 
SDS-PAGE but the Gi3a- and G0oc- like polypeptides in 12-day-old chick embryonic 
brain, were however, well resolved, in comparison.
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Figure 4.2.5.1.
Effect of protease inhibitors on the immunoreactivity of 
myoblast membrane polypeptides with the antiserum 
SGI .
Membrane samples from
a) rat cerebral cortex (1 OOjig)
b) 12-day-old chick embryonic brain (1 OOjig)
c) 12-day-old chick embryonic brain (100|ig)+ protease 
inhibitors - .
d) fusion-competent myoblasts (250pg)
e) fusion-competent myoblasts (250jig) + protease inhibitors
f) rat glioma C6 BUI cells (lOOfig)
were resolved by SDS-PAGE using a 12.5% acrylamide/0.06% 
bisacrylamide slab gel. Samples c) and e) were prepared in the 
presence of a cocktail of protease inhibitors(3mM benzamidine, 
2mg/ml soybean trypsin inhibitor, 5mg/ml leupeptin). 
Immunoblotting was performed using the anti-peptide antiserum 
SGI (1:200) as the primary reagent.
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Figure 4.2.5.2
Effect of protease inhibitors on the immunoreactive 
membrane polypeptides detected by the antiserum I3B.
Membrane samples from
a) rat cerebral cortex (1 OOpg)
b) fusion-competent myoblasts (250jig)
c) 12-day-old chick embryonic brain (250jig)
d) 12-day-old chick embryonic brain (250jig)+ protease 
inhibitors -
e) rat glioma C6 BUI cells (lOOpg)
were resolved by SDS-PAGE [10% acrylamide]. Membranes in 
lane d were prepared in the presence of protease inhibitors (3mM 
benzamidine, 2mg/ml soybean trypsin inhibitor, 5mg/ml leupeptin). 
Immunoblotting was performed using the anti-peptide antiserum I3B 
(1:200).
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4.2.6 Identification of p subunit immunoreactivity in myoblasts
Fig. 4.2.6.1. shows membrane sample resolved by SDS-PAGE and 
immunoblotted with the BN1 antiserum. This was raised against the synthetic peptide 
MSELDQLRQE which corresponds to the N terminal sequence, residues 1-10, of the 
mammalian pi G-protein P subunit. A single polypeptide of 35kDa was detected in 
myoblasts (lane d) and 12-day-old chick embryonic brain (lane b). This polypeptide 
co-migrated with the mammalian P subunit present in rat cerebral cortex (lanes a and e) 
indicating that the membrane preparations from chick embryonic myoblasts possess p 
subunit immunoreactive polypeptide(s).
4.3. Role of G-proteins in myoblast fusion.
G-proteins mediate agonist regulation of several signal transduction systems, 
including adenylate cyclase, K+ channels and Ca2+ channels. The interaction between 
receptors linked to inositol phospholipid hydrolysis and PI-PLC is also considered to 
be G-protein mediated (Cockcroft and Gomperts, 1985; Gilman, 1987). Myoblast 
fusion represents such an event, where the addition of the agonist, fusion mix, to 
fusion-competent myoblasts results in the stimulation of both inositol phospholipid 
breakdown and fusion. The possible involvement of G-proteins in this receptor-PI- 
PLC interaction was therefore examined and is described in the following section.
4.3.1. The ability of fusion mix to stimulate GTPase activity in 
myoblast membranes.
All known G-proteins bind and hydrolyse GTP. The a  subunit possesses an 
intrinsic GTPase activity which catalyses GTP hydrolysis to generate GDP and 
inorganic phosphate (Pi). The interaction of an agonist-occupied receptor and a G- 
protein stimulates this GTPase activity by facilitating the exchange of GDP for GTP, 
thus increasing the amount of GTP available as substrate. Agonist stimulation of 
GTPase activity is therefore indicative of receptor G-protein interaction.
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Figure 4.2.6.1
Identification of p subunit immunoreactivity in
m yoblasts.
Membrane samples
a) rat cerebral cortex (1 OOjig)
b) 12-day-old chick embryonic brain (1 OOjig)
c) 12-day-old chick embryonic brain (100jig)+ protease 
inhibitors
d) fusion-competent myoblasts (250jig)
e) rat brain cerebral cortex (1 OOjig)
were resolved by SDS-PAGE [10% acrylamide] followed by 
immunoblotting using the anti-peptide antiserum BN1 (1:200) as the 
primary reagent.
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35kDa
Figure 4.3.1.1.
Fusion mix stimulation of GTPase activity in fusion- 
competent myoblast membranes.
Fusion mix was added to GTPase assays of fusion- 
competent cell membranes. The basal activity was that obtained in 
the absence of 100pm GTP. Results are means ± S.D. (n=4) from 
a single experiment typical of 3.
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In order to assess whether fusion mix exerts its effect via G-protein activation, it was 
tested for its ability to stimulate the hydrolysis of GTP in membranes prepared from 
fusion-competent myoblasts. GTPase activity was assayed by measuring the release of 
[32p] pi from [y-32p] GTP, as described in section 2.10. The results obtained are 
shown in fig. 4.3.1.1. and the data are expressed as pmoles GTP hydrolysed per 
minute per mg of membrane protein. The basal and non-specific, activities were defined 
as those obtained in the absence and presence of IOOjiM GTP respectively. Fusion mix 
itself possessed an intrinsic GTPase activity which was defined as that obtained in the 
absence of the myoblast membrane sample. The 'agonist stimulated' GTPase activity 
of fusion mix was calculated by subtracting this intrinsic i.e. 'background' GTPase 
activity from the total GTPase activity that was obtained using fusion mix in the 
presence of fusion-competent myoblast membranes. From fig. 4.3.1.1, fusion mix 
stimulated GTPase activity in membranes prepared from fusion-competent myoblasts. 
GTPase activity was increased 1*93 -  0-26 fold over-the basal activity ( mean of 3 
separate experiments ± S.E.M.).
4.3.3. The effects of GTPyS on total [3H] inositol phosphate generation
GTP serves to activate G-proteins by promoting the dissociation of their 
subunits. Deactivation occurs upon hydrolysis of the bound GTP by the intrinsic 
GTPase of the a  subunit. Thus, analogues of GTP that are resistant to this hydrolysis, 
result in persistant G-protein activation. Guanosine-5'-0-(3-thiotriphosphate), (GTPyS) 
is one such analogue and it provides a biochemical tool with which to directly to 
activate G-proteins. This molecule is membrane impermeant but was introduced into 
cells by the technique of electropermeabilisation (section 2 .11) which facilitates the 
rapid entry of small molecules (< lkDa molecular weight) into the cytosol by producing 
small pores in the plasma membrane (Knight and Scrutton, 1986). Fig. 4.3.2.1. 
shows the effect of pulse number on the stimulation of inositol phospholipid 
breakdown in response to fusion mix.
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Figure 4 .3 .2 .I.
Effect of electropermeabilisation on fusion mix 
stimulated total pH] inositol phosphate generation.
Fusion-competent myoblasts that were equilibrium labelled 
with pH] inositol were subjected to increasing numbers of 
discharge pulses (0 - 5) of 1600V/cm. The cells were then 
incubated in the presence and absence of fusion mix for 30 minutes 
at 37°C in the presence of lOmM LiCl. Total pH] inositol 
phosphates were batch eluted from Dowex formate anion exchange 
resin. Results are mean ± S.D. (n=3) from a single experiment 
typical of 3.
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Figure 4.3.2.2.
Effect of GTP[S] on total [3H] inositol phosphate 
generation in fusion-competent myoblasts.
Fusion-competent myoblasts were electropermeabilised with 
3 discharge pulses of 1600V/cm and incubated with increasing 
concentrations of GTPyS (GTP[S]) for 30 minutes at 37°C, in the 
presence of lOmM LiCl. Total [3H] inositol phosphates were batch 
eluted from Dowex-formate anion exchange resin. Results are 
means ± S.D. (n=3) from a single experiment typical of 2.
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Figure 4.3.2.3.
Effect of GTP[S] on agonist stimulated total [3H] 
inositol phosphate generation in fusion-competent 
myoblasts.
Fusion-competent myoblasts labelled to equilibrium with 
pH] inositol were electropermeabilised by 3 discharge pulses of 
1600V/cm or non-permeabilised (control). Cells were incubated 
with the agonists, angiotensin II (lOOnM) or fusion mix, in the 
presence and absence of IOOjiM GTPyS (GTP[S]) in buffer 
containing lOmM LiCl. Total pH] inositol phosphates were batch 
eluted from Dowex-formate anion exchange resin. Results are 
means ± S.D. (n=3) from a single experiment typical of 2.
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Permeabilisation resulted in an increase in the fold stimulation of total pH] inositol 
phosphate generation which was maintained for up to 3 pulses. Further pulsing 
resulted in a decreased response. Thus, for subsequent experiments, the pulse number 
chosen was 3 because, under these conditions of electropermeabilisation, the cells were 
100% permeabilised (as assessed by uptake of a membrane-impermeant molecule, 
propidium iodide, which is fluorescent upon intercalation into nucleic acids and thus 
identified cells whose membrane integrity was compromised) and fusion mix stimulated 
total pH] inositol phosphate generation was unimpaired (fig. 4.3.2.1). Fig. 4.3.2.2. 
shows the effect of GTPyS on total pH] inositol phosphate generation. It can be seen 
that GTPyS stimulated the generation of total pH] inositol phosphates in a dose- 
dependent manner and lOOmM GTPyS resulted in a fold increase in total pH] inositol 
phosphates of 1-49 ± 0-13 (mean ± S.E.M.). Fig.4.3.2.3. shows the effect of lOOmM 
GTPyS, both alone and in combination with fusion mix or lOOnM angiotensin I I , on 
total pH] inositol phosphate generation. GTPyS was synergistic with fusion mix and 
angiotensin II in stimulating total pHj inositol phosphate generation.
4.3.3. Sensitivity of fusion mix stimulated total pH] inositol phosphate 
generation and fusion to pertussis and cholera toxins.
Many G-protein a  subunits are substrates for pertussis or cholera toxin- 
catalysed ADP-ribosylation. In some cells, pretreatment with these toxins leads to an 
inhibition of agonist stimulated inositol phosphate generation (Lo and Hughes, 1987; 
Paris and Pouyssegur, 1986) and this is proposed to result from ADP-ribosylation of 
the G-protein coupling the receptor to PI-PLC. The effects of pretreatment with 
pertussis or cholera toxins on fusion mix stimulation of myoblast fusion and the 
generation of total pH] inositol phosphates were therefore examined, in order to 
indicate whether a pertussis or cholera toxin sensitive G-protein is involved.
Myoblasts were cultured in 'Ca2+-free' medium and cholera toxin (lOOng/ml),
pertussis toxin (lOOng/ml) or no addition were added to myoblasts from 34 hours after
initial plating to fiision-competence (i.e. for 16 hours). At this time, the cells were
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harvested and stimulated to fuse by plating in fresh 'Ca2+-free' DMEM in the presence 
of fusion mix with no addition or with cholera or pertussis toxin (lOOng/ml). The 
results are shown in fig. 4.3.3.1. and the data are expressed in terms of fusion index. 
The percentage fusion obtained for myoblasts cultured in the absence of cholera or 
pertussis toxin, was arbitrarily assigned a fusion index of 1. This is the control for 
fusion and represents the amount of fusion obtained in the absence of these toxins. It 
may be seen that cholera and pertussis toxins were unable to inhibit myoblast fusion.
To test the effects of cholera and pertussis toxin pretreatment on the agonist 
stimulation of total pH] inositol phosphate generation, myoblasts were treated as above 
until fusion-competence. Following harvesting, the cells were incubated in the 
presence and absence of fusion mix and total pH] inositol phosphate generation was 
determined using the Li+ assay. The results are shown in fig. 4.3.3.2. and expressed 
as fold stimulation over the control sample which was incubated in the absence of the 
agonist, fusion mix. From the fig., it may be seen that.cholera and pertussis toxin did 
not inhibit fusion mix stimulated total pH] inositol phosphate generation.
Cholera and pertussis toxin pretreatments may not have resulted in the complete 
ADP-ribosylation of all the available G-protein substrates. This possibility was 
investigated, by challenging membranes prepared from cholera or pertussis toxin 
pretreated (as above) myoblasts with fresh toxin and [32P] NAD+. Any G-proteins that 
were not ADP-ribosylated by these toxins during the in vivo pretreatment will be 
available for this modification in vitro. The samples were resolved by SDS-PAGE 
[12.5% acrylamide] and the resulting gel was dried and autoradiographed. The 
autoradiograph is shown in figs. 4.3.3.3. and 4.3.3.4. Membranes from rat cerebral 
cortex and rat glioma C6 BUI cells were used to provide positive controls for the 
cholera and pertussis toxin ADP-ribosylation. The incubation of myoblasts with 
cholera toxin (lOOng/ml) or pertussis toxin (lOOng/ml), for 16 hours prior to fusion- 
competence, prevented the incorporation of radioactivity into their substrates, when 
membranes of these pretreated cells were challenged in vitro with [32P] NAD+ and
fresh toxin. Thus there were no available substrates for further ADP-ribosylation.
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Figure 4.3.3.1.
Effect of cholera and pertussis toxin treatment on 
myoblast fusion.
Myoblasts were treated for 16 hours prior to fusion- 
competence with either no addition (control), lOOng/ml cholera toxin 
or lOOng/ml pertussis toxin. At this time, myoblasts were plated 
into medium containing fusion mix in the presence and absence of 
lOOng/ml cholera toxin or lOOng/ml pertussis toxin. Fusion was 
assessed 20 hours later. Results are means ± S.D. (n=3) from a 
single experiment typical of 3.
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Figure 4.3.3.2.
Effect of cholera and pertussis toxin treatment on fusion 
mix stimulated total [3H] inositol phosphate generation 
in fusion-competent myoblasts.
Myoblasts were labelled with [3H] inositol (from 24 hours in 
culture) and treated for 16 hours prior to fusion-competence with 
either no addition (control), lOOng/ml cholera toxin or lOOng/ml 
pertussis toxin. At this time, myoblasts were washed and 
incubated, in the presence and absence of fusion mix, for 30 
minutes at 37°C, in buffer containing lOmM LiCl. Total [3H] 
inositol phosphates were batch eluted from Dowex-formate anion 
exchange resin. Results are means ± S.D. (n=3) from a single 
experiment typical of 3.
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Figure 4.3.3.3
Cholera toxin catalysed ADP-ribosylation of myoblast 
G-proteins in primary culture.
Membrane samples from
a) C6  BUI rat glioma cells (30jig)
b) fusion-competent myoblasts (50|ig)
c) fusion-competent myoblasts (50pg)
d) cholera toxin pretreated fusion-competent myoblasts 
(50pg)
e) cholera toxin pretreated fusion-competent myoblasts 
(50 pg)
f) cholera toxin pretreated fusion-competent myoblasts 
(50|ig)
g) fusion-competent myoblasts (50jug)
were treated with [32P] NAD+ and cholera toxin except for sample f 
to which no toxin was added. Samples were resolved by SDS- 
PAGE [12.5% acrylamide/0.06% bisacrylamide] and subjected to 
autoradiography.
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Figure 4.3.3.4.
Pertussis toxin catalysed ADP-ribosylation of myoblast 
G-proteins in primary culture.
Membrane samples from
a) fusion-competent myoblasts (50|ig)
b) pertussis toxin pretreated fusion-competent myoblasts 
(50jig)
c) pertussis toxin pretreated fusion-competent myoblasts 
(50pg)
d) cholera toxin pretreated fusion-competent myoblasts 
(50pg)
e) fusion competent myoblasts (50jig)
f) C6  BUI rat glioma cells (30|ig)
were treated with [^ 2P] NAD+ and pertussis toxin except for sample e to which no toxin 
was added. Samples were resolved by SDS-PAGE [12.5% acrylamide/0.06% 
bisacrylamide].and subjected to autoradiography.
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4.4. Changes in levels of myoblast G-proteins on differentiation.
Membrane samples of myoblasts at various stages of differentiation were examined 
for changes in the levels of pertussis toxin and cholera toxin sensitive G-proteins. These 
samples were prepared from myoblasts cultured for 24, 50 and 98 hours in 'Ca2+-free' 
medium. At these times myoblasts are predominantly proliferating, fusion-competent and 
non-fused respectively. Myoblast fusion was initiated by addition of 1.4mM Ca2+ to 
fusion-competent myoblasts and the resulting myotubes were further cultured for 48 hours 
before harvesting (total time in culture 98 hours). These samples were incubated with 
cholera or pertussis toxin in the presence of [32P] NAD+, resolved by SDS-PAGE and 
autoradiographed. The results are shown in fig. 4.4.1., from which it may be seen that 
there was an increase in the cholera toxin substrate and pertussis toxin sustrates upon 
differentiation of fusion-competent myoblasts (lanes b) into myotubes (lanes c ). This 
increase was apparently dependent on the presence of extracellular Ca2+ since it was not 
seen in the non-fused samples (lanes d).
These changes may result from the activation of second messenger system(s) i.e. be 
mediated by second messenger signalling molecule(s). This possibility was investigated by 
treating myoblasts with (i) forskolin which activates the catalytic unit of adenylate cyclase 
directly to elevate intracellular levels of cyclic adenosine 5' monophosphate(cyclic AMP) 
and (ii) TPA which activates protein kinase C (PKC) directly and (iii) polymyxin B which 
is a putative of inhibitor PKC.
Figs. 4.4.2. and 4.4.3. show pertussis toxin and cholera toxin catalysed ADP- 
ribosylation of membranes from fusion-competent myoblasts and myotubes respectively. 
Myoblasts were treated with various agents at fusion-competence and harvested 48 hours 
later. Membranes from the same sets of samples were used in both experiments. 
Comparison of these two figures revealed that the increases in the pertussis toxin and 
cholera toxin substrates, which occur on differentiation (lane h), were mimicked in the 
presence of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA) (lanes k and 1) 
but inhibited by polymyxin B (lane m). Treatment with forskolin (lanes d and e) mimicked 
the increase in the cholera toxin substrate but not that of the pertussis toxin substrates.
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Figure 4.4.1.
Cholera and pertussis toxin-catalysed ADP-ribosylation 
of myoblast membranes from differentiating myoblasts.
Membrane samples (50jig) from
a) a) proliferating myoblasts
b) fusion-competent myoblasts
c) fused myoblasts i.e. predominantly myotubes
d) non-fused myoblasts
Membrane samples (75|ig) from
b) a) proliferating myoblasts
b) fusion-competent myoblasts
c) fused myoblasts i.e. predominantly myotubes
d) non-fused myoblasts
were incubated with p 2P] NAD+ and either I) cholera toxin or II) 
pertussis toxin. Samples were resolved by SDS-PAGE 
[10% acrylamide]. The gel was dried and subjected to 
autoradiography.
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Figure 4.4.2.
The effect of various pharmacological agents on the 
differentiation-related increase in pertussis toxin 
substrates.
Membrane samples from
a) rat glioma C6  BUI cells (30jig)
b) - n) myoblasts treated after 50 hours in culture 
(i.e. at fusion-competence) with various agents and 
harvested 48 hours later (50jig)
b) and c) 10pM PGEi
d) and e) lOjiM forskolin
f) and g) fusion-competent myoblasts harvested 50 hours 
after initial culture in ‘Ca2+-free’ medium.
h) 1.4mM Ca2+/10% (v/v) horse serum and-5% (v/v) 
chick embryo extract i.e. myotubes.
i) and j) ‘Ca2+-free’ medium i.e. non-fused myoblasts 
k) and 1) treatment with lOOnM TPA for 15 minutes prior
to theaddition of 1.4mM Ca2+/10% (v/v) horse serum and 
5% (v/v) chick embryo extract 
m) treatment with 30jiM polymyxin B for 15 minutes prior 
to the addition of 1.4mM Ca2+/10% (v/v) horse serum and 
5% (v/v) chick embryo extract 
n) rat cerebral cortex (lOpg)
o) fusion-competent myoblast 
were incubated with [32P] NAD+ and pertussis toxin except for 
sample o) to which no toxin was added. Samples were resolved by 
SDS-PAGE [12.5% acrylamide/0.06% bisaciylamide]. The gel was 
dried and autoradiographed.
137
Figure 4.4.2
Molecular weight
40kDa
a*
G±1 o(ir
~JG n <x
a b c d e f g h i  j k l m n o
Figure 4.4.3.
The effect of various pharmacological agents on the 
differentiation-related increase in cholera toxin 
substrates.
Membrane samples from
a) rat glioma C6  BUI cells (30}ig)
b) - n) myoblasts treated after 50 hours in culture 
(i.e. at fusion-competence) with various agents and 
harvested 48 hours later (50|ig)
b)andc) lOpMPGEi
d) and e) lOfiM forskolin
f) and g) fusion-competent myoblasts harvested 50 hours 
after initial culture in ‘Ca^-free* medium.
h) 1.4mM Ca2+/10% (v/v) horse serum and-5% (v/v) 
chick embryo extract i.e. myotubes.
i) and j) ‘Ca2+-free’ medium i.e. non-fused myoblasts
k) and 1) treatment with lOOnM TPA for 15 minutes prior 
to theaddition of 1.4mM Ca2+/10% (v/v) horse serum and 
5% (v/v) chick embryo extract 
m) treatment with 30|iM polymyxin B for 15 minutes prior 
to the addition of 1.4mM Ca2+/10% (v/v) horse serum and 
5% (v/v) chick embryo extract 
n) fusion-competent myoblasts 
were incubated with [32P] NAD+ and cholera toxin except for 
sample n) to which no toxin was added. Samples were resolved by 
SDS-PAGE [12.5% acrylamide/0.06% bisacrylamide]. The gel was 
dried and autoradiographed.
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Discussion
4 . 5 .  Characterisation of G-proteins present in myoblast membranes
Membrane samples of myoblasts prepared from chick embryonic skeletal 
muscle were studied in order to characterise the G-proteins present. Two experimental 
approaches were adopted to define the G a subunits present since they are unique for 
each G-protein type. These were (i) cholera toxin or pertussis toxin catalysed ADP- 
ribosylation and (ii) western immunoblotting using a panel of selective anti-G-protein 
anti-peptide antisera raised against amino acid sequences unique to the various a  
subunits of these toxin substrates.
Cholera and pertussis toxins are multi subunit proteins which catalyse the ADP- 
ribosylation of Ga protein subunits in both whole cells and membrane preparations. 
Cholera toxin is composed of 2 subunit types and exists as A IB 5 multimer. It binds its 
cell surface receptor, the ganglioside GM1, via the B subunits. This leads to the 
formation of a pore through which the catalytically active A subunit is extruded into the 
cytosol. Pertussis toxin consists of 6  subunits of which 5 are dissimilar. The SI 
subunit contains the ADP-ribosyltransterase activity whilst the others mediate its 
attachment and entry into cells (Foster and Kinney, 1984). Both these toxins are 
inactive in the holomeric form and thus require preactivation (to dissociate the 
catalytically active subunits) for use with membrane preparations. This was achieved 
by treatment with the reducing agent dithiothreitol.
Cholera-toxin-catalysed ADP-ribosylation was performed in the presence of 
guanine nucleotides which resulted in the specific ADP-ribosylation of the a  subunit of 
Gs. A 42kDa form of Gsa  was present in myoblasts, as determined by cholera-toxin - 
catalysed ADP-ribosylation (fig. 4.1.1.) and immunoblotting with the anti-peptide 
antiserum CS1 which identifies the C terminus of mammalian Gsa  (Fig. 4.2.1.1.). 
Three pertussis toxin sensitive substrates were present in myoblast membranes 
(fig. 4.1.3.) with apparent molecular weights of 38kDa, 40.5kDa and 41kDa.
In order to further characterise the G-proteins present in myoblasts, membrane
samples were immunoblotted using selective anti -G-protein antisera. Immunoblotting
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with the antiserum SGI, which identifies the C terminal sequence of mammalian G ila 
and Gi2 a, in non-photo-receptor containing tissues, identified three immunoreactive 
polypeptides of 38kDa, 40.5kDa and| 41.5kDaj(fig. 4.2.2.2.). Antiserum IIC was 
used to further characterise these G jla  and Gj2a immunoreactive polypeptides, since it 
is capable of discriminating between mammalian G jla and Gi2a. Using this antiserum 
a G ila -like polypeptide of 41.5kDa was detected (fig. 4.2.2.-3.).
Antiserum I3B was raised against the C terminal region of mammalian Gi3a but 
it cross-reacts weakly with mammalian G0a  and therefore recognises both mammalian 
Gi3a and G0a. Western blotting with this antiserum identified a single 
immunoreactive polypeptide of 41.5kDa in membranes prepared from myoblasts and 
12-day-old chick embryonic brain. An additional immunoreactive polypeptide of 
40kDa was also detected in 12-day-old chick embryonic brain membranes (fig.
4.2.3.1.). Antiserum ONI, which recognises the N terminal amino acid sequence of 
mammalian G0a, identified this 40kDa polypeptide as a G0a  like polypeptide. It also 
identified a similar immunoreactive polypeptide in myoblast membranes.(fig. 4.2.3.2.). 
This polypeptide was only detectable in trace amounts and was probably recognised by 
ONI, and not antiserum I3B, because this antiserum is a much more sensitive probe for 
G0a  immunoreactivity than I3B. In conclusion, these results demonstrated that chick 
myoblasts possess Gila-, Gi2a- Gi3a- and G0a-like immunoreactivity.
The mobilities of these G ila, Gi2a Gi3a and G0a  immunoreactive proteins in
SDS polyacrylamide gels were different to those for the mammalian forms. These
membrane samples were alkylated prior to SDS-PAGE since this treatment has been
shown to enhance the resolution of mammalian pertussis toxin substrates (Stemweis
and Robishaw, 1984). Alkylation of proteins results in an increase in their molecular
weight so that they are less mobile in SDS-polyacrylamide gels. The differing
mobilities may therefore reflect differences in amino acid sequence between the
mammalian and chick G-proteins, since this could result in relatively more or less
cysteine residues available for alkylation. This is probably true for the G0a
immunoreactive polypeptide, since alkylation caused it to be less mobile upon SDS-
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PAGE than the non alkylated form which has a similar mobility to mammalian G0a  
(figs. 4.2.4.2.I. and 4.2.4.2.2.). Alkylation, however, does not explain the difference 
in the relative moblities of the Gil a , Gi2a and Gj3a immunoreactive polypeptides 
when compared to the mammalian G-proteins (see figs. 4.2.4.1.1., 4.2.4.1.2. and
4.2.4.2.I.). These differences in mobilities are seen, in both myoblasts and 12 day old 
chick embryonic brain, and may reflect species differences in the amino acid sequences 
of mammalian and chick G-proteins. Unfortunately, this could not be further 
investigated as, to date, there is no avian G-protein amino acid sequence data available 
for comparison with mammalian G-proteins.
In order to determine whether the polypeptides recognised by the antisera SGI 
and I3B represent distinct immunoreactive entities, membrane samples from myoblasts 
and 12-day-old chick embryonic brain were prepared in the presence and absence of 
protease inhibitors and immunoblotted using these antisera. The pattern of 
immunoreactivity detected for each membrane type was the same for both sets of 
samples (figs. 4.2.5.1. and 4.2.5.2.). The polypeptides recognised by these antisera 
thus represent distinct immunoreactive entities and the differences in their molecular 
weights are not a consequence of proteolytic cleavage of the 41.5kDa polypeptide.
Membrane samples from myoblasts and 12-day-old chick embryonic brain were 
also immunoblotted using the antiserum BN1 which is raised against the N terminal 
amino acid sequence of the mammalian P G-protein subunit An immunoreactive 
polypeptide of 35kDa which co-migrated with the mammalian P subunit was detected 
(fig. 4.2.6.1.) which suggests that chick embryonic myoblast G-proteins probably 
exist as classical heterotrimers.
4 .6 .  Role of G-proteins in myoblast fusion.
G-proteins are involved in the signal tranduction of many hormones and
agonists. These systems are membrane associated and comprise an agonist-specific cell
surface receptor, G-protein and an effector which may be an intracellular second
messenger forming enzyme or an ion channel. The receptor and effector interaction is
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mediated by G-proteins, which are heterotrimeric proteins, consisting of a, (3 and y 
subunits. The primary specificity for both the receptor and target effector is determined 
by the unique nature of the a  subunit The structural variability which is essential for 
their function, is found only in the regions involved in receptor and effector 
recognition, whilst the structure of the guanine nucleotide binding site is conserved.
Agonist occupation of the receptor promotes a GTP and Mg2+-dependent 
dissociation of the oligomer into a fty subunit complex and an activated a  subunit 
which transduces information from the receptor to the specific target effector. 
Subsequent hydrolysis of GTP to GDP and Pi by the intrinsic GTPase of the a  
subunit, causes deactivation and dissociation of the a  subunit from the effector. It then 
reassociates with the py subunit complex and returns to the 'inactive' state. The 
presence of a receptor-controlled GTPase activity and its function in the termination of 
an agonist stimulated response was first demonstrated for the p-adrenergic receptor in 
turkey erythrocytes (Cassel and Selinger 1975), where agonist occupation of these 
receptors caused a GTP dependent activation of adenylate cyclase and an increase in the 
high affinity GTPase activity. Agonist stimulated GTPase activity is indicative of 
receptor- G-protein coupling. Fusion mix was tested and found to stimulate GTPase 
activity in the membranes prepared from fusion-competent myobasts (fig. 4.3.2.1.).
GTPyS, a non-hydrolysable analog of GTP, stimulated total pH] inositol 
phosphate generation in electropermeabilised myoblasts (fig. 4.3.2.2.) and was 
synergistic with fusion mix in stimulating total pH] inositol phosphate generation in 
these cells (fig. 4.3.2.3) which suggests that they share a common mechanism i.e. G- 
protein activation, for promoting the activation of PI-PLC. GTPyS alone was also able 
to stimulate total pH] inositol phosphate generation in non-permeabilised cells and may 
achieve this either by acting at a P2-purinergic receptor or by entering 'leaky' cells to 
directly activate G-proteins. In order to establish whether this stimulation of total pH] 
inositol phosphate generation is due to activation of a purinergic receptor, these 
experiments should be repeated in the presence of a specific P2 receptor antagonist, for
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example, arylazido-aminopropionyl ATP (ANAPP3), a photo-affinity ligand which 
irreversibly blocks P2-purinergic receptors (Katsuragi and Furakawa, 1985).
4.7 .  Effects of cholera and pertussis toxin pretreatment.
Evidence for the involvement of G-proteins in the regulation of agonist 
stimulated PI-PLC activity has come from studies using cholera and pertussis toxins. 
Pertussis toxin catalyses the ADP-ribosylation of a cysteine residue that is positioned 4 
amino acids from the carboxy terminus of the a  subunit (Hurley et al., 1984; West et 
al., 1985). ADP-ribosylation at this site prevents the stimulation of G-protein subunit 
dissociation that normally occurs on agonist occupation of the receptor (Haga et al., 
1985). Agonists which mediate their effects through G-proteins, that are substrates for
%
pertussis-toxin-catalysed ADP-ribosylation, are therefore prevented from doing so by 
pretreatment with pertussis toxin. For example, pertussis toxin pretreatment inhibits 
the stimulation of inositol phosphate generation by fmet-leu-phe in mast cells (Ohta et 
al., 1985) and by platelet activating factor in macrophages (Huang et al., 1988).
Cholera toxin catalyses ADP-ribosylation of specific arginine residue in the a  
subunit of Gs (van Dop et al., 1984). This leads to a much reduced GTPase activity 
which maintains the a  subunit in the activated state (Cassel and Selinger, 1977). 
Cholera toxin pretreatment has been reported to inhibit receptor stimulated inositol 
phosphate generation in human pituitary clonal cells, and on this basis, it was 
suggested that the receptor-PI-PLC interaction was mediated by a novel cholera toxin 
sensitive G-protein (Lo and Hughes, 1987). Alternatively, the observed inhibition may 
be cyclic AMP mediated since cholera-toxin-catalysed ADP-ribosylation of Gs , would 
lead to permanent activation of adenylate cyclase and thus elevate intracellular levels of 
cyclic AMP. This has been demonstrated to be the case for cholera toxin inhibition of 
vasopressin stimulation of renal glomerulosa cells (Guillon et al., 1988) and L6  skeletal 
myoblasts (Gardner et al., 1989), where cholera toxin treatment led to a down 
regulation of the vasopressin receptors. This probably resulted from activation of the
cyclic AMP dependent protein kinase, protein kinase A, since this effect was mimicked
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by other agents which increase cyclic AMP levels. Thus cholera toxin mediated 
inhibition of agonist stimulated inositol phospholipid breakdown is not necessarily 
indicative of receptor-PI-PLC coupling via a cholera toxin sensitive G-protein. In 
many cells however, pretreatment with cholera or pertussis toxin does not modify 
agonist stimulated total pH] inositol phosphate generation. This suggests that, in these 
cells, the G-protein involved in receptor - PI-PLC coupling is not a substrate for either 
pertussis toxin or cholera toxin-catalysed ADP-ribosylation.
The receptor-mediated stimulation of myoblast fusion and inositol phospholipid 
breakdown by the agonist, fusion mix were examined for their sensitivity to pertussis 
and cholera toxins. Myoblasts were pretreated from 24 hours after initial plating to 
fusion-competence with pertussis toxin, cholera toxin or no addition (control) and their 
effect on fusion and fusion mix stimulated total pH] inositol phoshate generation 
determined. From figs. 4.3.3.1. and 4.3.3.2., it may be concluded that these events 
are pertussis and cholera toxin insensitive. - .
If these events are G-protein mediated, and involve a pertussis or cholera toxin 
sensitive substrate(s), then the lack of inhibition obtained with these toxins may be due 
to incomplete ADP-ribosylation of the available G-protein. This may be due to 
insufficient transport of the toxin across the cell membrane into the cytosol or 
alternatively, the cellular levels of NAD+ may be inadequate for complete ADP- 
ribosylation. This possibility was examined by pretreating myoblasts with no addition 
(control), pertussis toxin or cholera toxin from 34 hours after initial plating until fusion- 
competence. Membranes were then prepared from these cells and subsequently 
challenged with pertussis toxin or cholera toxin, in order to determine whether any of 
their toxin sensitive G-protein substrates were available for further ADP-ribosylation. 
Pretreatment of myoblasts with pertussis and cholera toxins resulted in the complete 
ADP-ribosylation of their available substrates, (fig. 4.3.3.3. and 4.3.3.4.). A cholera 
or pertussis toxin sensitive G-protein is therefore unlikely to be involved in fusion mix 
stimulated total pH] inositol phosphate generation and myoblast fusion. Thus, at this
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time, there is no convenient probe available with which to further identify the G-protein 
involved.
4.8.  Changes in the levels of myoblast G-proteins upon
differentiation. -
The main event in muscle differentiation is the fusion of monucleated myoblasts 
to form myotubes with concomitant synthesis of several muscle specific proteins.
These processes may be either causally related, or initiated simultaneously, but 
occuring independently. Fusion-negative mutants of the L6  and L8 rat myoblast cell 
lines have been obtained which are capable of producing some, but not all, muscle 
specific proteins (Devlin and Emerson, 1978). It would therefore appear that the 
synthesis of all the muscle specific proteins is not co-ordinated. However, there are 
subsets of muscle specific proteins, the synthesis of which is co-ordinately regulated 
during the differentiation of chick myoblasts (Schudt et al., 1975). Myoblast 
differentiation thus provides an experimental system in. which to examine co-ordinate 
protein synthesis.
Changes in the levels of myoblast G-proteins during differentiation have been
examined using the low Ca2+ culture system in which rapid synchronous fusion occurs
on addition of 1.4mM Ca2+ to fusion-competent myoblasts. Membranes were prepared
from proliferating, fusion-competent and non-fused myoblasts and from myotubes and
subjected to pertussis toxin and cholera toxin catalysed ADP-ribosylation. There was
an increase in the amounts of the cholera toxin and pertussis toxin substrates upon
myoblast differentiation (fig. 4.4.1.) which was dependent on extracellular Ca2+.
These increases in cholera toxin and pertussis toxin substrates may be regulated by
alterations in the intracellular levels of second messenger molecules since myoblast
fusion is a receptor mediated event that is apparently coupled to inositol phospholipid
breakdown (Wakelam and Pette, 1984). The hydrolysis of phosphatidylinositol 4,5
bisphosphate (Ptdlns 4,5 P2) by PI-PLC results in the generation of the second
messengers, inositol trisphosphate (IP3) and sn -1,2-diacylglycerol (sn -1,2-DAG).
IP3 causes a increase in the levels of intracellular Ca2+ by releasing Ca2+ from
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intracellular stores (Berridge and Irvine, 1984). Sn -1,2-DAG is a physiological 
acivator of protein kinase C (PKC) which is a Ca2+/phospholipid dependent serine 
threonine protein kinase Nishizuka, 1984). Following fusion, there is an increase in 
adenylate cyclase activity (Shainberg etal., 1971) and the levels of its product, the 
second messenger, cyclic AMP have been demonstrated to rise following fusion 
(Schutzle et al., 1984).
The effects of various pharmacological agents on the increases in cholera and 
pertussis toxin substrates were examined in an attempt to identify the second messenger 
signalling pathways involved. The role of PKC in this differentiation linked event, was 
investigated by the addition of TPA to fusion-competent myoblasts, in order to directly 
activate PKC and it was found to mimic the increases in cholera and pertussis toxin 
substrates which occured on differentiation (figs. 4.4.2. and 4.4.3.). In addition these 
increases were inhibited in the presence of the putative PKC inhibitor, polymyxin B 
(figs. 4.4.2. and 4.4.3.), which provides further support for PKC involvement. The 
increase in pertussis toxin substrates (fig. 4.4.2.), but not the cholera toxin substrate 
(fig. 4.4.3.), was mimicked by treatment of fusion-competent myoblasts with 
forskolin. This diterpene directly activates the catalytic unit of adenylate cyclase thus 
raising intracellular levels of cyclic AMP. Therefore synthesis of the pertussis toxin 
substrates appears to be stimulated by an increase in intracellular levels of cyclic AMP. 
These results suggest the involvement of PKC and adenylate cyclase activation in the 
changes in levels of G-proteins during myoblast differentiation.
Second messenger signalling systems have been demonstrated, in number of
reports, to play a role in muscle specific protein synthesis. Evidence for an
involvement of PKC in the synthesis of muscle specific proteins comes from
experiments using the phorbol ester, TPA, to stimulate PKC directly. Treatment of
myoblasts with TPA causes an increase in hexose transport which is due to increased
mRNA and protein synthesis of the saturable component of the hexose transport system
(Schimmel and Keldie, 1980). In addition, TPA has been demonstrated to stimulate
synthesis of plasminogen activator in chick myotubes (Miskin et al., 1978). The IP3
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mediated release of Ca2+ from intracellular stores will also effect biochemical events 
regulated by calmodulin (CaM) which is the intracellular Ca2+ receptor protein. CaM 
mediates many calcium-dependent processes in a variety of cell types (Cheung, 1980) 
but the physiological relevance of CaM-dependent interactions in relation to the 
synthesis of muscle specific protein synthesis remains to be determined. It has been 
implicated as a regulator of the intracellular levels of the second messenger cyclic AMP 
and may (i) increase cyclic AMP levels by stimulating adenylate cyclase, the enzyme 
present in the plasma membrane which converts ATP to cyclic AMP and (ii) cause a 
decrease in the levels of cyclic AMP by activation of the CaM dependent 
phosphodiesterase which degrades cyclic AMP to 5'-AMP. The rise in cyclic AMP 
which occurs following the onset of fusion has been implicated in the stimulation of the 
synthesis of a muscle specific protein, creatine kinase, since it precedes the appearance 
of this enzyme (Schutzle et al., 1984). Cyclic AMP may also be the second messenger 
involved in the calcitonin gene-related peptide (CGRP). stimulated synthesis of surface 
nicotinic acetylcholine receptor (AChR) in primary cultures of chick myotubes 
(Fontaine et al., 1986, New and Mudge, 1986) since CGRP has been shown to 
increase the levels of cyclic AMP in cultured myotubes, and to activate adenylate 
cyclase in chick muscle membranes (Laufer and Changeux, 1987). Additional evidence 
for cyclic AMP involvement comes from the demonstration that the increase in AChR 
was mimicked by cholera toxin, which persistently activates adenylate cyclase, thus 
elevating levels of cyclic AMP (Blosser and Appel, 1980). This is further supported by 
the demonstration that the cell permeant cyclic nucleotide derivative, dibutyryl cyclic 
AMP, elevates intracellular levels of cyclic AMP and increases the synthesis of AChR 
(Betz and Changeux 1979).
As discussed in chapter 3, protein kinase C activation is a key event in the 
process of myoblast fusion. A role for PKC in the increases in toxin sensitive G- 
proteins may be argued since i) direct activation of this enzyme by TPA mimicked these 
increases and ii) pretreatment of fusion-competent myoblasts with the putative PKC 
inhibitor polymyxin B resulted in inhibition. The generation of sn -1,2-DAG in the
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plasma membrane and consequent activation of PKC therefore represent critical 
biochemical steps in the mechanisms underlying i) the fusion event itself, which 
involves transient changes in membrane structure and cytoskeletal rearrangements (ii) in 
the regulation of associated muscle specific protein synthesis. Activation of PKC thus 
provides a mechanism by which myoblast fusion and protein synthesis may be co- 
ordinately regulated.
In summary, the results presented in this chapter demonstrate that myoblasts 
possess one cholera toxin substrate and 3 pertussis toxin substrates for ADP- 
ribosylation together with Gsa-, Gila-, Gi2a-, Gi3a- and G0a- immunoreactive
t » —
polypeptides. The role of G-proteins in myoblast^vas investigated and it may be 
mediated by a G-protein that is cholera and pertussis toxin insensitive.
The levels of the cholera and pertussis toxin substrates increase upon 
differentiation and these increases are mimicked by TPA. The increase in the pertussis 
toxin substrates but not the cholera toxin substrate was.also mimicked by forskolin. 
These results suggest that the increases in G-protein levels are second messenger 
mediated.
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Chapter 5
The developmental regulation of myoblast differentiation
Introduction
Myoblast differentiation in vitro requires the addition of supplements to a 
chemically defined medium (Konigsberg, 1963). These are, most commonly, heat- 
inactivated horse serum and chick embryo extract Such factor(s) may also be required 
for the differentiation of myoblasts in vivo, and of possible physiological relevance is 
the observation that chick embryo extract is essential for the fusion of chick embryonic 
myoblasts in primary culture (Wakelam and Pette, 1982). It apparently contains fusion 
stimulating factor(s) (FSF(s)), which are proposed to be neuronal in origin because 
chick embryonic brain and spinal cord extracts can substitute for the whole extract in 
promoting fusion (Oh, 1975; Wakelam, 1986). The differentiation of myoblasts in 
vivo is generally considered to be under neuronal control (Bonner and Adams, 1982); 
skeletal muscle is innervated by motor neurones derived from the spinal cord which 
exert a trophic influence on its morphological and biochemical properties. Such 
influence is proposed to be mediated by trophic substance(s) released ffom the nerve 
(Guth, 1968; Hoffmann et al., 1972; Oh et al., 1972). This proposal is supported by 
the observation that the neuropeptides, arginine vasopressin (AVP) and angiotensin II 
can stimulate fusion in the absence of chick embryo embryo extract (Wakelam and 
Pette, 1984 a,b).
In order to determine the nature of the factors) in spinal cord which stimulate
myoblast fusion, chick embryonic spinal cord extract was fractionated by gel filtration
chromatography and the ability of the fractions collected to stimulate fusion tested in a
bioassay using primary cultures of chick myoblasts prepared from 12-day-old chick
embryonic breast muscle. These cells were cultured in 'Ca2+-free' medium for 50
hours until fusion-competent, washed in 'Ca2+-free' medium to remove the chick
embryo extract and horse serum and plated into DMEM containing 1.4mM Ca2+.
Aliquots of the test fractions were added to fusion-competent myoblasts and their ability
to stimulate fusion i.e. to replace chick embryo extract determined. Several FSFs were
found to stimulate fusion including some of low molecular weight (<4kDa). The nature
of these low molecular weight factors was further investigated and an alternative
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method of assaying fusion was assessed to determine its suitability for rapid screening 
of possible FSF(s).
5.1. Characterisation of FSF(s) in spinal cord.
5.1.1. Fractionation by gel filtration chromatography.
Chick spinal cord extract (prepared as described in section 2.1.3.6) was 
fractionated by gel filtration chromatography on a column of Sephadex G100 (90 x 
1.6cm) using lOmM ammonium acetate (pH 4.0 with acetic acid) as the eluent buffer. 
1.5ml fractions were collected and elution was monitored by measuring the absorbance 
at 280nm.
This method allowed fractionation on the basis of molecular weight, with 
molecules eluted from the column in order of decreasing molecular size. Protein 
standards of known molecular weight were used to calibrate the column as described in 
section 2.4 which had a fractionation range of 4-150kDa. The fractions collected were 
freeze-dried to remove the eluent buffer and thus concentrate the sample, dissolved in
0.5ml ImM acetic acid and the fusion stimulating ability assessed by adding 75pil of 
each fraction to be tested to myoblasts in culture. Fusion was determined 20 hours later 
and a profile of fusion stimulating ability is shown in fig. 5.1.1.1., together with the 
protein concentration. The fusion stimulating ability is expressed in terms of fusion 
index. The fusion index of the ’non-fused1, control sample of myoblasts, which were 
cultured in DMEM in the absence of any fractions, was arbitrarily assigned a value of
1. The fusion index of each fraction was defined as
% fusion for myoblasts cultured in the presence of test fraction and DMEM 
% fusion for myoblasts cultured in the presence of DMEM only
There were four main regions of fusion stimulating ability in fractions 41-44, 61, 
71 and 110-128 which, by reference to the calibration curve, correspond to molecules 
of apparent molecular weights of >150 kDa, 37kDa, 19kDa and <4kDa.
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Figure 5.1.1.1.
Fractionation of chick embryonic spinal cord extract by 
gel filtration chromatography.
Chick embryonic spinal cord extract was applied to the 
Sephadex G100 gel filtration column (90 x 1.6cm) and eluted with 
lOmM ammonium acetate (pH 4.0 with acetic acid). The fractions
collected were tested for fusion stimulating ability ( -----) and
protein content ( ......).
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Figure 5.1.1.2.
The elution profile of [3H] AVP.
The sample of pH] AVP was applied to the Sephadex G100 
gel filtration column and eluted with lOmM ammonium acetate (pH 
4.0 with acetic acid). The fractions were collected and their
associated radioactivity determined ( ------). The profile of fusion
stimulating ability obtained for chick embryonic spinal cord is 
shown for comparison ( ......).
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The FSF(s) in fractions 41-44 elute in the same fractions as (3-amylase (200kDa) and 
alcohol dehydrogenase (150kDa) which correspond to the void volume of the column. 
The molecular weight of the factor(s) in fractions 110-128 is less than 4kDa since the 
elution volume is around that of the total column volume. This factor(s) elutes in a 
broad peak of activity. The elution profile of a tritiated neuropeptide, pH] AVP was 
determined for comparison and is shown in fig. 5.1.1.2., together with the profile of 
fusion stimulating ability obtained for chick embryonic spinal cord extract. pH] AVP 
also has a broad elution peak, from fractions 108- 124.
In view of the ability of the neuropeptides AVP and angiotensin II to stimulate 
fusion, attention was focused onto the 'low molecular weight1 fractions (less than 
4kDa). These were pooled, freeze-dried, dissolved into 1ml PBS and further 
characterised.
5.1.2. Biochemical tests performed on the pooled fractions.
Various biochemical tests were carried out on the 'low molecular weight' 
FSF(s). The sample was subjected to boiling, dialysis and to treatments with 
trichloroacetic acid (TCA) and diethyl ether. The results are shown in Table 5.1.2.1. 
and the data expressed in terms of fusion index calculated relative to the control level of 
fusion observed for the untreated pooled fractions which was arbitrarily assigned a 
value of 1. From this, the fusion stimulating ability of the factor(s) is stable to boiling 
and treatment with TCA and ether but lost upon dialysis.
The sensitivity of the FSF(s) to enzyme digestion was examined by treating 
aliquots (lOji.1) of the pooled fractions with trypsin, chymotrypsin, leucine 
aminopeptidase and carboxypeptidase Y. The results are shown in Table 5.1.2.2. and 
the data expressed in terms of fusion index calculated relative to the control level of 
fusion observed for the untreated pooled fractions. The percentage fusion obtained in 
the presence of lOjil untreated pooled fractions was arbitrarily assigned a fusion index 
of 1 and all results were calculated relative to this value.
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Table 5 .I.2 .I.
Biochemical properties of the 'low molecular weight' FSFs
Test Fusion index % inhibition 
relative to control
Boiling 0.98 6 .8
Dialysis 0.48 1 0 0
TCA 0.97 6 .8
Ether 0.95 11
Table 5.I.2.2.
Enzymic sensitivities of the 'low molecular weight' FSFs.
Enzyme treatment Fusion index % inhibition of fusion
• relative to the control
Control 0.96 8
Trypsin 0.5 100
Chy mo trypsin 0.99 2.7
Control 0.95 1
Leucine 0.94 12
aminopeptidase
Control 0.94 12
Carboxy- 0.94 12
peptidase Y
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Figure 5.1.2.3.
The effect of AVP and angiotensin II antagonists on the 
fusion stimulating ability of the 'low molecular weight ' 
F SF (s).
Myoblasts were cultured in 'Ca2+-ffee' medium until fusion- 
competence, washed and then plated into medium containing 1.4mM 
Ca2+ and the pooled 'low molecular weight' FSF(s), designated PF, 
in the presence and absence of the AVP and angiotensin II receptor 
antagonists. Fusion was determined 20 hours later.
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The neuropeptides AVP and angiotensin II can stimulate fusion and the factor(s) 
present in the pooled fractions was thus tested for sensitivity to the AVP receptor 
antagonist, [l-P-mercapto-p,p cyclopentamethylene propionic acid, 2  (O-methyl) 
tyrosine) arginine8 vasopressin (lOpM) and the angiotensin II receptor antagonist, 
saralasin (IOjiM). The results are shown in fig. 5.I.2.3. and are expressed in terms of 
fusion index. Fusion stimulating ability was not inhibited by these antagonists and is 
therefore unlikely to be either AVP or angiotensin n.
5.1.3. RP-HPLC profile of the low molecular weight fraction.
Low molecular weight fractions were prepared from extracts of brain, eye and 
spinal cord (50% (w/v) in 50mM NH4HCO3). These samples were centrifuged for 40 
hours at 100 ,0 0 0g, to remove nucleic acids and high molecular weight proteins, the 
supematents were collected and concentrated by freeze-drying to remove NH4CO3. 
They were then dissolved in 1ml NH4CO3 and cenfrifuged at 5000g through a lOkDa 
molecular weight cut-off membrane filter (Amicon). The filtrate obtained was 
collected, freeze-dried and dissolved into 100ml 0.1% trifluoroacetic acid (TFA) in 
deionised distilled water (buffer A): 0.1% TFA in propan-2-ol (buffer B), (90:10) and 
analysed by RP-HPLC using a Waters p. bondapack C18 column (4.6mm x 250mm, 
10|im pore size). A linear gradient of buffer A:buffer B from 90:10 to 10:90 over 80 
minutes was used to elute the sample. Elution was determined by monitoring the 
absorbance at 215nm and the elution profiles obtained for neuropeptide standards and 
the low molecular weight fractions are shown in fig. 5.1.3.1.
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Figure 5.1.3.1.
Reverse phase (RP) - HPLC profiles of 'low molecular 
weight' fractions prepared from brain, spinal cord and 
eye extracts.
The samples were analysed on a Waters \i bondapack C l8 
column equilibrated in 0.1% (v/v) TFA in double distilled H2O (A):
0.1% (v/v) TFA in propan-2-ol (B) (90:10). Samples were eluted 
using a linear gradient of A:B from 90:10 to 10:90 over 80 min with 
a flow rate of lml/min. Elution was monitored by continuous 
measurement of absorbance at 215nm (A215). The elution times of 
neuropeptide standards are shown for comparison
a) Arginine vasopressin
b) Neuromedin C
c) Angiotensin II
d) Bradykinin
e) Substance P
f) Somatostatin
g) Calcitonin Gene Related Peptide.
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5.2.1. Fusion assay.
The determination of fusion by counting cell nuclei to assess the development of 
multinucleated myotubes is time consuming and subjective and therefore not ideal for 
rapid screening of possible FSFs. An alternative method for assaying fusion was 
therefore investigated.
Fusion between myoblasts results in the formation of a myotube which, in 
addition to multinucleate morphology, has an increased cell volume relative to those of 
its individual myoblast components. The size distribution profile of the myoblast 
population should therefore change as a result of fusion. This provides an alternative 
criterion for fusion and is the basis of the fusion assay of Neff and Horwitz (1982) 
which used a Coulter® electronic particle counter to count myoblast populations on the 
basis of size. Samples of 'control' (non-fused) and ’fused1 myoblasts were prepared 
and analysed using this method with the modification that the Coulter® counter was 
interfaced to a Channelyser® multichannel analyser and that monolayer samples of 
myoblasts were used rather than in suspension. This equipment rapidly and 
reproducibly counted cell populations to generate histograms of cell number against cell 
size, thus providing a method to compare the size distributions o f’control’ and ’fused’ 
myoblast populations.
Myoblasts were plated in ’Ca2+-free’ medium and cultured as monolayers in 
35mm tissue culture dishes for 50 hours until fusion-competent At this time, cells 
were either maintained in ’Ca2+-free’ medium (’control’ sample) or cultured in the 
presence of 1.4mM Ca2+ and 5% (v/v) embryo extract to generate a sample of ’fused’ 
cells. The cells were analysed 16 hours later using the Coulter® counter. The samples 
were rinsed with 2 x 1ml PBS to remove non-attached cells and then removed from the 
dishes by trypsinisation for 10 seconds. Treatment with trypsin also served to disperse 
cells that were aggregated but not fused (Knudsen and Horwitz, 1977) and provided a 
collection of mononucleate and multinucleated cells that were suitable for Coulter® 
counter analysis (Neff and Horwitz, 1982). Trypsin treatment was terminated by the 
addition of (lmg/ml) soybean trypsin inhibitor. The samples were diluted 1ml in 10ml
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into the counting fluid 'Isoton®' (Coulter Inc.) and analysed. The size distribution 
profiles obtained for the ’control' and 'fused' cell samples are shown in fig. 5.2.1.1. 
and the data are expressed as cell number against cell diameter. The 'control' and 
'fused' samples exhibited different and heterogeneous size distribution profiles.
The Coulter® counter-Channelyser® collected data in a series of electronic 
'gates' or channels, each of which corresponds to a particular diameter, d, which 
ranged between 7.99pm and 15.36pm. The cell diameter measured by each channel (i) 
may be defined as dp The total number of cells analysed (R) is the sum of the number 
of cells in each channel (RO
15.36pm
i.e. R = X R i 
d=7.99pm
The relative frequency or % probability of possessing diameter d (Pi) is equal to
RixlOO
R
and
15.36pm
H  Pi = 100
d=7.99pm
The mean cell diameter, dav, can be calculated as
15.36pm
Pi dj = dav 
d=7.99pm
and
N
£ k  = Pn
d=7.99pm may also be determined by adding up the Pi
values
for each successive diameter up to Npm (dN). When Pn = 50,50% of the cells have'a 
diameter smaller than dpf. The 'control' and 'fused' cell populations can thus be 
compared in this respect
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Figure 5.2.1.1.
Size distribution profiles obtained using the Coulter 
counter® - Channelyser®
Representative profiles obtained for samples of 'control (non- 
fused)' ( ..... ) and 'fused' ( ------- ) myoblast populations.
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Figure 5.2.1.2.
Profiles of the size distribution of myoblast populations 
analysed using the Coulter counter® - Channelyser®
Representative profiles of 'control (non-fused)' ( ......) and
'fused' ( ------ ) myoblast populations, where % probability =
R; _ number of cells in channel i 
R total number of cell analysed
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Representative plots of % probability against cell diameter obtained for 'control' 
and 'fused' samples are shown in fig. 5.2.1.2. respectively. It may be seen that there 
was a change in the size distribution upon myoblast fusion with a net shift of the profile 
of the 'fused' sample to the right with respect to the 'control' sample. The dav of the 
'control' and 'fused' populations were calculated to be 11-64 ± 0-092(im and 12-227 ± 
0056|im respectively. The values of d corresponding to Pn -  50% were 11-64 ± 
0-186|im and 12-32 ± 0-26}im for the 'control' and 'fused' samples respectively (means 
of 3 separate experiments ± S.E.M.). These values are significantly different (p < 
0.01). The cells in the 'fused' population were therefore increased in size relative to the 
'control' population. This method is further discussed, in comparison with that of Neff 
and Horwitz (1982) in section 5.4.
Discussion
5.3. Investigation of FSF(s).
As discussed in the introduction, chick embryo extract contains FSF(s) which 
may be neuronal in origin. The differentiation of myoblasts is generally considered to 
be under neuronal control (Oh and Markelonis, 1980: Bonner and Adams, 1982), a 
conclusion which is supported by the demonstrations that chorioallantoic grafting of 
spinal cord tissue stimulates myoblast differentiation in vivo (Avery et al., 1956), co- 
culturing of spinal cord tissue explants and myoblasts accelerates myoblast growth and 
differentiation (Murray, 1965) and chick embryonic spinal cord extract can replace 
chick embryo extract in stimulating fusion (Oh, 1975; Wakelam 1986). Furthermore, 
the neuropeptides AVP and angiotensin II are also able to stimulate fusion. The 
possible nature of these FSF(s) was investigated by biochemical fractionation of an 
extract prepared from chick embryonic spinal cord.
This was achieved by gel filtration chromatography using a Sephadex G100
column (90cm x 1.6cm) which fractionates molecules on the basis of their molecular
weight with a fractionation range of 4kDa - 150kDa. The ability of the fractions
collected to stimulate fusion was assessed by means of a bioassay using myoblasts in
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primary culture. There were 4 main peaks of fusion stimulating ability (fig. 5.1.1.1.) 
corresponding to apparent molecular weights of >150kDa, 37kDa, 19kDa and >4kDa. 
The neuropeptides, AVP and angiotensin 13 are capable of stimulating fusion in the 
absence of chick embryo extract (molecular weights are 1.084kDa and 1.046kDa 
respectively). Attention was therefore focussed onto the fusion stimulating activity of 
>4kDa. Fractions containing these 'low molecular weight FSF(s)' were pooled and 
further analysed.
They were subjected to boiling, dialysis and treatment with TCA and ether.
From Table 5.2.1.1., the fusion stimulating activity was stable to both boiling and ether 
treatment. It was therefore heat stable and not lipid in nature. TCA treatment was 
without effect indicating that it may be a peptide, since peptides lack the complex 
secondary structure of polypeptides which would be destroyed by such treatment Its 
activity was however dialysable. The molecular weight of the factors) was therefore 
less than 3kDa since this is the size limit of the retention ability of the membrane.
Enzymic treatments performed on the factors) in the pooled fractions showed 
the fusion stimulating ability to be trypsin sensitive but it was unaffected by digestion 
with chymotrypsin, leucine aminopeptidase and carboxypeptidase Y. Tiypsin cleaves 
peptide bonds on the C terminal side of the amino acids, lysine and arginine. The 
factors) therefore probably contains a lysine or arginine residue and, from its apparent 
molecular weight, is probably a peptide. Chymotrypsin cleaves peptides and proteins 
at the C terminal side of tryptophan, tyrosine and phenylalanine, leucine and methionine 
residues with occasional cleavage at other sites. The activity may have been retained 
because there was no appropriate cleavage site for this enzyme. Alternatively, cleavage 
at one or more of these sites may occur, with the fragment(s) produced retaining 
activity.
Treatment with leucine aminopeptidase did not inhibit the fusion stimulating 
ability of the factor(s). This enzyme cleaves N terminal amino acids. Peptide bonds 
involving the secondary amino groups of proline are hydrolysed at a negligible rate, 
and thus proline effectively blocks the N terminus. It is possible either that the N
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terminal amino acid of the factors) was adjacent to a proline residue or, alternatively, 
the N terminus may be blocked by acetylation or cyclisation of N terminal glutamyl 
residues to pyrrolidonecarboxyl (pyroglutamyl). Another possibility is that the N 
terminal amino acid may have been cleaved, but was non-essential for fusion.
The fusion stimulating ability of the factor(s) was also insensitive to treatment 
with carboxypeptidase Y which cleaves the C terminal peptide bond. This could be due 
to C terminal cleavage of an amino acid residue that is non-essential for its activity. 
Alternatively, the C terminus may be blocked, for example by amidation thus 
preventing cleavage by this enzyme.
In previous experiments, chick embryonic brain extract was similarly 
fractionated by gel filtration using Sepahdex G100 (Caroline Evans, BSc Hons project) 
and the fractions collected tested for their ability to stimulate myoblast fusion using the 
bioassay described above. FSFs of apparent molecular weights of at least 150kDa, 
10.7kDa and less than 4kDa were found. The fractions containing the low molecular 
weight (less than 4kDa) factor(s) were pooled and further charaterised and in common 
with the low molecular weight factors) from spinal cord, the activity was dialysable 
but stable to boiling and treatments with TCA and ether. The factor(s) is probably also 
peptide in nature since its activity was lost on trypsin digestion. Its fusion stimulating 
ability was insensitive to treatment with chymotrypsin, leucine aminopeptidase and 
carboxypeptidase Y. Thus the 'low molecular weight FSFs' from brain and spinal cord 
share similar properties and enzyme sensitivities.
The evidence of Wakelam and Pette (1984a,b) that the neuropeptides, AVP and 
angiotensin II can replace embryo extract in stimulating fusion suggests a possible 
physiological role for these 'low molecular weight' factors. It is however unlikely that 
they are either of these peptides since their activity was not blocked in the presence of 
the AVP or angiotensin II antagonists (fig. 5.1.2.3.).
Skeletal muscle is innervated by motor neurones derived from the spinal cord
and possibly also receives innervation from sensory sympathetic and parasympathetic
ganglia. 'Developmental factor(s)' may be released from these nerves during
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embryonic development in vivo (Guth et a i, 1968; Hoffman et al., 1972; Oh et al., 
1972). In this regard, L6 rat muscle cells have been demonstrated to possess AVP 
receptors of the VI subtype which are coupled to inositol phospholipid breakdown. In 
addition, CGRP-I immunoreactivity has been detected in a subpopulation of 
motoneurones innervating the chick embryonic limb bud and the time course of the 
development of this immunoreactivity paralleled that of the formation of neuromuscular 
synapses (New and Mudge, 1986). CGRP is also able to increase synthesis of the 
nicotinic acetylcholine receptor (Fontaine et al., 1986; New and Mudge, 1986) and is 
therefore a candidate for a muscle trophic factor that is released from motoneurone 
terminals in vivo.
The RP-HPLC protocol described provides a means to separate the peptide 
components of the low molecular weight fractions (< lOkDa) prepared from chick 
embryonic brain, spinal cord and eye extracts. It is based on that of Moms et al.,. 
(1984) with the modification of trifluoroacetic acid (TFA) replacing acetic acid to allow 
sample elution to be followed by monitoring the absorbance of the carboxyl group of 
the peptide bond at 215nm, rather than the absorbance of aromatic amino acid residues 
at 280nm, which may not be present in all peptides. The carboxyl group of acetic acid 
interferes with absorbance measurement at 215nm, but TFA is suitable since its 
intrinsic absorbance at this wavelength is much lower due to the presence of the 
fluorine atoms. The presence of TFA in the eluent ensured complete protonation of the 
peptides which is required to prevent tailing of their elution profiles (Morris et ai,
1984). Peptides thus elute from the column as a function of their solubility in propan- 
2-ol. Using this method, it was possible to resolve mixtures of fig amounts of 
neuropeptides including for example, angiotensin n , AVP, CGRP and substance P 
(fig. 5.3.1.) and it was thus sensitive at the nanomole level of detection. This method 
is thus suitable for use as a step in a protocol for purification of possible FSF(s). In 
addition, the eluent was volatile so could be easily removed by freeze drying to generate 
samples suitable for bioassay. A limiting factor for purification is the amount of
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starting material available since chick embryos are comparatively small and thus only 
yield gram quantities of starting material.
The RP-HPLC profiles of brain spinal cord and eye extracts show that there are 
several peptide components, one of which co-eluted with CGRP. This may correspond 
to the CGRP I immunoreactive peptide which was found to exist in a subpopulation of 
motomeurones innervating the chick embryonic limb bud (New and Mudge, 1986). 
CGRP is however probably not a FSF in vivo since it was unable to increase total [3H] 
inositol phosphate generation in fusion-competent myoblasts (data not shown) and the 
CGRP receptor is coupled to the adenylate cyclase signalling system in myotubes 
(Laufer and Changeux, 1987) and muscle (Takamori and Yoshikawa, 1989). The 
ability of CGRP to stimualte the fusion of myoblasts in primary culture remains to be 
determined since myoblasts lose viability when cultured with this or other 
neuropeptides alone. The original experiments with AVP and angiotensin II were 
performed in the presence of a non-fusogenic batch of horse serum. However, all 
batches of horse serum used in this project were found to be fusogenic. Thus, such 
potential FSFD should be tested in a medium comprising additional ‘viability 
promoting’ components. Preliminary experiments in this direction using ovotransferrin 
were unsuccessful and further experimental work is therefore required to resolve this. 
Altenatively, a short term fusion assay to determine early fusion events (approximately 
30 minutes to 2 hours) could be developed to circumvent this problem.
5 . 4 .  The assessment of an alternative fusion assay.
The bioassay employed to determine fusion stimulating ability is based on the
counting of cell nuclei. This requires staining of the cells followed by visual scoring to
determine the number of nuclei present in the fused cells as a percentage of the total
number of nuclei in the sample. This method is time consuming and therefore not ideal
for rapid screening of FSFs. An alternative method for assaying fusion using a
Coulter® particle counter (Neff and Horwitz, 1982) was therefore investigated. This
method is based on the fact that myoblasts fuse to form myotubes whose cell volume is
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greater than any of their individual myoblast components. A Coulter® particle counter 
was employed since it is able to determine the number and size of particles in a 
conductive liquid. This is achieved by monitoring the electrical current between 2 
electrodes, on either side of a small aperture, through which the liquid flows. Each 
particle passing through the aperture is detected as a change in the resistance between 
the electrodes which generates an electrical impulse proportional to the particle size.
Neff and Horwitz (1982) have previously used a Coulter® counter to compare 'non­
fused1 and 'fused' populations of myoblasts. It was used to measure the number of 
cells above (and thus exclude those below) a certain threshold or size limit and cell 
counts were obtained for two such size limits. The lower size limit was chosen to 
accurately count all the cells in the population whilst the upper value corresponded to 
the largest difference in cell counts obtained. This upper value was determined 
empirically and the number of cells counted were calculated as the percentage of the 
number of cells counted at the lower threshold/size limit i.e. as a percentage of the total 
cell count. This percentage was found to increase upon fusion since the 'fused' cell 
population contained cells of larger volume than the 'non-fused' population, resulting 
in an increased cell count at the upper size limit relative to the total cell count 
Unfortunately this method gave variable results. The method was therefore modified 
by using the Coulter® counter coupled to a Channelyser® to obtain histograms of cell 
number against cell diameter and thus quantitatively analyse the size distribution 
profiles of samples of 'control' (unfused) and 'fused' myoblasts. The 'control' and 
'fused' populations are denoted in inverted commas since, as discussed in chapter 3, 
the percentage fusion in the control sample is never zero, due to the presence of 
preformed myotubes at the time of plating and the percentage fusion in the 'fused' 
sample is never 100%. This is due to presence of satellite cells in culture which do not 
fuse during embryonic development, but have the ability to do so in response to muscle 
injury, resulting in the repair of damaged muscle.
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If it is assumed that
(i) the cells in suspension are spherical, the cell volume (V) of each cell is equivalent
to
4k  r3 = V where r is the radius of the cell.
3
(ii) fusion between 2 or more myoblasts generates a cell whose volume (Vf) is the 
sum of their volumes prior to fusion. Considering for example, the simplest case of 
fusion between 2 myoblasts of volumes Vi and V2 and radii ri and r2 respectively, 
the volume of the fused cell of radius rf will be
Vf = Vi + V2
Substituting for V with 4n r3 gives the following equation:
3
47t rf3 = 4 t l i i3 + 4zlt23= 4k  (n 3 + r23)
3 3 3 3
which can be simplified to 
rf3 = ri3 + r23
therefore
rf = 3Vri3 + r23 
In general therefore, for fusion between n cells, where n > 3 
rf = 3Vri3 + r23  +rn3
The cell diameter d is equal to 2r, thus the diameter of the fused cell (df) is 
df = (3Vri3 + r23.....+rn3) x 2
The 'control' and 'fused' cell populations 
prepared from primary chick myoblast cultures were heterogenous in cell size and the 
size distribution profile of the 'fused' population was shifted to the right with respect to 
that of the 'control' sample (figs. 5.2.1.1. and 5.2.I.2.). The mean diameters, dav> of 
the 'control' and 'fused'
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samples, calculated as described in section 5.2.1., were 11-64 * 0-092jim and 12-227 ±
0 056pm and the values of d corresponding to Pn = 50% were 11-64 ± 0-186pm and 
12-32 ± 0-26pm for the 'control' and 'fused' populations respectively. This dav of
11-64 ± 0 092pm for the 'control' sample corresponds to the mean cell diameter, of
1 l-6pm, determined for mononucleated myoblasts using a micrometer (Neff and 
Horwitz, 1982). Thus the increase in the values of dav and d for Pn = 50 for the 
'fused' sample relative to those of the 'control' probably reflected the fusion of 
predominantly mononucleated myoblast to form larger multinucleated cells. This was 
characterised by a net loss of cells with a diameter below dav (11-64pm) and a gain of 
cells with a diameter greater than 1 l-64pm to result in a cell population of dav =
12-227pm. Using the above equation to calculate df, the dav value of the 'fused' 
sample corresponds, for example, to fusion between 2 myoblasts of diameter 9-7pm or 
between myoblasts of diameters 10-5pm and 8-75pm. This difference in size is 
relatively small despite the observation that the size distribution profile of the ‘fused’ 
sample was clearly shifted to the right with respect to the non-fiised, control sample. 
This was probably due to the fact that myoblasts in primary culture represent a cell 
population of heterogenous cell size. In this regard, the Coulter® counter- 
Channelyser® had the advantage over using a Coulter® counter alone since it allowed a 
quantitative rather than an empirical determination of the changes in cell size distribution 
which result from myoblast fusion and as such provides a method to analyse and 
directly compare samples. The calculations for dav and d corresponding to Pn values 
of, for example 50%, require the application of a series of mathematical formulae, 
which are the same for each sample and could thus be computerised to greatly facilitate 
the rapid analysis and comparison of samples. This method would thus be suitable for 
screening of possible FSFs especially if it could be used to determine fusion in short 
term assays (up to 6 hours). Further experiments are required to establish whether the 
method is sufficiently sensitive to detect early fusion events as well as long term i.e. 
multiple fusion events. Access to the Coulter® counter - Channelyser® was however 
only available for a short period of time which limited the number of experiments able
to be performed. Other possible approaches for a short term fusion assay include the 
the use of fluorescent molecules to monitor the development of membrane and/or 
cytoplasmic continuity which occurs upon myoblast fusion.
170
Chapter 6 
Final Discussion
Final discussion
The differentiation of chick embryonic skeletal myoblasts results in the formation 
of myotubes which are the precursors of muscle fibres. Myoblast_fusion represents a 
key stage in this process since it results in the formation of multinucleated myotubes 
and is associated with synthesis of muscle specific proteins required for mature cell 
function. The aim of this project has been to examine the biochemical events which 
regulate this process of terminal differentiation. The following section discusses the 
results obtained in the context of possible models for both myoblast fusion and its co­
ordination with the stimulation of muscle specific protein synthesis that is temporally 
associated with this event
6. 1 .  Possible models for myoblast fusion and associated muscle 
specific protein synthesis.
A possible scheme of the biochemical events underlying myoblast fusion is 
outlined in fig. 6.1.1. The fusion of myoblasts is a receptor mediated process which 
occurs upon agonist binding of a fusion stimulating factor(s) (FSF(s)) which are 
probably neuronal in origin. Several factors are capable of stimulating the fusion of 
myoblasts in primary culture, including ACh, PGEi (Entwistle et al., 1988) and factors 
in chick embryo spinal cord extract (see Chapter 5). Entwistle et a l , (1988) propose 
that there is more than one factor to ensure that fusion is achieved in vivo since this is a 
critical stage in muscle fibre development. Fusion stimulation is apparently coupled to 
PI-PLC hydrolysis of inositol phospholipids (Wakelam and Pette, 1984a,b).which
c
results in the loss of the hydrophiljd headgroup and the consequent generation of sn - 
1,2-DAG in the plasma membrane. This receptor - PI-PLC interaction in fusion- 
competent myoblasts may, in common with other signal transduction systems 
(Cockcroft and Gomperts, 1985), be G-protein mediated (section 4.3) by pertussis and 
cholera toxin insensitive G-protein designated Gf.
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Figure 6.1.1.
A model for myoblast fusion
A possible scheme of the biochemical events involved in agonist stimulation of 
the myoblast fusion following agonist stimulation by FSF(s) (see text in section 6.1.).
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The concentration of sn -1,2-DAG in fusion-competent myoblasts has been 
demonstrated to increase 2 -fold upon fusion stimulation, as determined using an assay 
specific for this stereoisomer of DAG (fig. 3.1.1.). This molecule.can potentially play 
a dual role in the process of fusion because it exhibits fusogenic properties in model 
membrane systems and is a physiological activator of the Ca2+/phospholipid protein 
kinase, PKC. DAG is a neutral hydrophobic molecule which tends to destabilise 
membrane bilayers by causing increased spreading of phospholipid headgroups (Das 
and Rand, 1986). This potentially leads to the formation of a non-bilayer, inverted 
hexagonal II (Hp) structure and subsequently to fusion of myoblasts via an inverted 
micellar fusion intermediate which allows mixing of membrane lipids at the point of 
contact (discussed in section 3.7).
The membrane destabilising effect of sn -1,2-DAG also results in the activation of 
PKC by allowing this enzyme to penetrate the plasma membrane. PKC is active when 
inserted in the membrane since this provides the appropriate lipid environment for 
activation. The role of PKC in myoblast fusion was investigated using compounds 
which modulate its activity and the results obtained suggest that its activation is 
required for fusion (section 3.2., 3.3. and 3.4.). Fusion mix stimulated myoblast 
fusion and total pH] inositol phosphate generation show different sensitivities to 
inhibition with TP A. Long or short term treatment of myoblasts with TP A results in 
the complete inhibition of fusion to control ’non-fused' levels (fig.3.2.1.1. and 3.4.3. 
respectively), but only partially inhibits total pH] inositol phosphate generation in 
response to fusion mix (fig. 3.5.3.2. and 3.5.3.1. respectively). A possible 
explanation for this may be that there is a threshold level of Ptdlns 4,5 P2 breakdown 
required for fusion, below which fusion is unable to occur. In this case, TPA could 
prevent fusion by inhibiting Ptdlns 4,5 P2 breakdown so that the required threshold 
level for fusion is not reached. Alternatively, there may be two or more isoforms of 
PKC present in fusion-competent myoblasts, one of which (PKC 1) regulates the 
breakdown of Ptdlns 4,5 P2 by negative control whilst another isoform (PKC 2) is 
involved in the fusion process itself. The role of PKC activation in fusion is unknown
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but it may stimulate Ca2+ entry by phosphorylation of the voltage dependent Ca2+ 
channel in the plasma membrane. Such a mechansim has been proposed for D600 
Sensitive, sensitive Ca2+ channels of myotubes (Navarro, 1987) and Aplysia neurones 
(De Reimer et al., 1985). *
In addition to sn -1,2-DAG, inositol phospholipids also provide a potential source 
of arachidonic acid which is the precursor for prostaglandin (PG) synthesis via the 
cyclo-oxygenase pathway. The demonstration that PGEi can stimulate myoblast fusion 
(Entwistle et a l , 1988; Farzeneh et a l , 1989) raises the possibility that prostaglandin(s) 
may act as agents to amplify and synchronise fusion in vitro (and possibly also 
in vivo) via an autocrine mechanism resulting from initial agonist stimulation of PI- 
PLC activity.
A possible scheme for the biochemical events involved in the apparent coupling of 
myoblast fusion with the synthesis of some muscle specific proteins is outlined in fig.
6.1.2. The levels of G-proteins that are cholera toxin and pertussis toxin substrates 
were found to increase following fusion. This increase in the amounts of G-proteins 
may reflect the enhanced synthesis of neurotransmitter receptors and the consequent 
responsiveness of myotubes to these receptor agonists. TPA, a direct activator of PKC 
was able to mimic these increases but they were prevented by pretreatment with the 
putative PKC inhibitor, polymyxin B. These results suggest that myoblast fusion and 
synthesis of these proteins may be co-ordinately regulated by the activation of PKC 2 
or another isozyme of PKC. This provides a potential mechanism for the coupling of 
fusion with the synthesis of some muscle specific proteins via PKC activation. 
Evidence for PKC involvement in the synthesis of other muscle specific proteins comes 
from the demonstations that treatment of myoblasts with TPA causes an increase in the 
saturable component of the hexose transport system (Schimmel and Keldie, 1980) and 
it stimulates the synthesis of plasminogen activator in chick myotubes (Miskin et al, 
1978).
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Figure 6.1.2.
A model for the co-ordination of myoblast fusion and the 
stimulation of the synthesis of some muscle specific proteins.
A possible scheme of the biochemical events involved in the process of FSF 
stimulated coupling of myoblast fusion with the differentiation linked increase in 
muscle specific protein synthesis (see text in section 6 .1.).
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Treatment of fusion-competent myoblasts with forskolin to activate adenylate 
cyclase and thus elevate intracellular levels of cyclic AMP also resulted in an increase in 
the levels of the pertussis toxin substrates (fig. 4.4.2.). Activation of adenylate cyclase 
thus provides an additional mechanism for stimulating the synthesis of muscle specific 
proteins and evidence to support this comes from the demonstration that cyclic AMP 
may also be the second messenger involved in the calcitonin gene-related peptide 
(CGRP) stimulation of both adenylate cyclase activity (Laufer and Changeux, 1987) 
and the synthesis of surface nicotinic acetylcholine receptors (AChR) in primary 
cultures of chick myotubes (Fontaine et al., 1986, New and Mudge, 1986). The rise in 
cyclic AMP which occurs following the onset of fusion has also been implicated in the 
stimulation of the synthesis of a muscle specific protein, creatine kinase, since it 
precedes the appearance of this enzyme (Schutzle et al., 1984). This stimulation of 
creatine kinase synthesis is sensitive to treatment with the cyclo-oxygenase inhibitor, 
indomethacin, which suggests that a prostaglandin (PG) can stimulate synthesis of this, 
and perhaps other muscle specific proteins in addition to its ability to stimulate fusion.
6.2. Future work
The exact nature of the role(s) of PKC in fusion and the stimulation of muscle 
specific protein synthesis remain to be determined. Given that there appears to be more 
than one isozyme of PKC involved, they may each lead to the phosphorylation of a 
different set of as yet undefined substrates. One possible target is a Ca2+ channel in the 
plasma membrane. The opening of such a channel would allow the entry of 
extracellular Ca2+ into fusion-competent myoblasts and thus fulfil a pre-requisite for 
fusion. As discussed in Chapter 3, this could be addressed using a fluorescent Ca2+ 
indicator, such as Quin 2 or Fura 2, to examine the effect of PKC modulators on 
extracellular Ca2+ influx. The different isoforms of PKC and the changes in their 
relative levels during differentiation could be determined by resolution of the isoforms 
by hydroxyapatite chromatography.
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The role of G-proteins in the event of fusion could be further investigated using 
an alternative to the non-hydrolysable GTP analog, GTPyS, as a means of direct 
activation. G-proteins can be directly activated by sodium fluoride (NaF) in the 
presence of Al3+ (Stemweis and Gilman, 1982) due to the [A1F4]* ion which interacts 
with the G protein in the GDP bound form. The combination of GDP and [AIF4]" 
effectively mimicks GTP to promote subunit dissociation and thus activate the G 
proteins. Its effects on total [3H] inositol phosphate generation and fusion could 
therefore be determined in order to gain further information about their role in fusion.
G-protein levels were found to increase upon differentiation. The increase in both 
the pertussis toxin and cholera toxin substrates was mimicked by TPA and inhibited by 
polymyxin B pretreatment (fig. 4.4.3. and 4.4.4), which suggests that these events are 
PKC dependent. The increase in the pertussis toxin substrates was also mimicked by 
forskolin, an agent which elevates intracellular levels of cyclic AMP, but this 
compound was without effect on the levels of the cholera toxin substrate. In the light 
of these results, it would be interesting to determine whether the increase in the cholera 
toxin substrate precedes that of the pertussis toxin substrates since it has been 
demonstrated TPA treatment increases in adenylate cyclase activity to raise the 
intracellular levels of cyclic AMP (Sulakhe et al., 1985). If this is the case, then up- 
regulation of the cholera toxin substrate, Gs, by activation of PKC could account for 
the elevation of intracellular cyclic AMP levels by increasing receptor-adenylate cyclase 
coupling. This could, in turn, provide a mechanism for subsequently increasing the 
levels of the pertussis toxin substrates. The effect of TPA on adenylate cyclase activity 
should thus be further investigated to determine whether (i) it is sensitive to treatment 
with inhibitors of protein synthesis such cycloheximide and (ii) its time course is 
consistent with increased synthesis of Gs.
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6.3. Physiological relevance
The study of myoblast differentiation may be of physiological importance to the 
repair of muscle following injury, a process which bears a strikingresemblance to the 
differentiation of embryonic myoblasts. Regenerating muscle cells arise from satellite 
cells, an effectively dormant population of myoblasts which become reactivated in 
response to muscle injury and reassume the characteristics of embryonic myoblasts. 
Satellite cells possess similar rates of proliferation and fusion in vitro to embryonic 
myoblasts and can fusewith embryonic myoblasts to form mosaic myotubes (Jones, 
1982. Thus a knowledge of the biochemical mechanisms underlying the regulation of 
myoblast differentiation could be of clinical use since it provides potential target sites 
for possible drugs to promote muscle repair.
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Appendices
Appendix 1
Composition of buffer and SDS-PAGE solutions 
1.1 Buffer compositions 
Earles' Salts (x20)
2.33M sodium chloride 
107mM potassium chloride 
33.2mM magnesium sulphate 
23.33mM sodium dihydrogen phosphate 
lOmM glucose
The pH of the buffer was adjusted to between 7.2 - 7.4 with 1M sodium hydroxide.
Hank's Buffered Saline 
1.26mM calcium chloride 
0.5mM magnesium chloride 
0.4mM magnesium sulphate 
5.37mM potassium chloride 
137mM sodium chloride 
4.2mM sodium hydrogen carbonate 
0.35mM sodium dihydrogen phosphate 
The pH of the buffer was between pH 7.2 - 7.4 when freshly made.
Phosphate Buffered Saline (PBS)
146mM sodium chloride 
5.36mM potassium chloride 
9.6mM disodium hydrogen phosphate 
1.46mM potassium dihydrogen phosphate 
The pH of the buffer was adjusted to pH 7.2 - 7.4 with 0.1M hydrochloric acid.
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Phosphate buffer pH 7.0 
30.5% v/v 0.2M disodium hydrogen phosphate 
19.5% v/v 0.2M sodium dihydrogen phosphate 
50% v/v distilled water
1.2. SDS- PAGE solutions.
Buffer 1
1.5MTris 
0.4% w/v SDS 
pH 8.8 with HC1
Buffer 2
0.5M Tris 
0.4% w/v SDS 
pH 6.8 with HC1
SDS-PAGE slab gels 16cm x 18cm
(i) Resolving gel (10% acrylamide/ 0.27% bisacrylamide)
6ml buffer 1
8 .2ml distilled water
8ml 30% w/v acrylamide/ 0.8% w/v bisacrylamide
1.6ml 50% v/v glycerol
8 |il N,N,N’N1-tetramethylenediamine (TEMED)
90JJ.110% w/v ammonium persulphate.
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(ii) Stacking gel (3% w/v acrylamide/ 0.08% w/v bisacrylamide) 
9.75ml distilled water 
3.75ml buffer 2
I.5ml 30% w/v acrylamide/ 0.8% w/v bisacrylamide 
8jilTEMED
150pl 10% w/v ammonium persulphate
SDS-PAGE slab gels 20cm x 20 cm
(i) Resolving gel (12.5% acrylamide/0.06% w/v bisacrylamide)
I I .6ml distilled water 
12mlbufferl
20ml 30% w/v acrylamide/0.15% bisacrylamide
4ml 50% v/v glycerol
60jil 10% w/v ammonium persulphate
4jil TEMED
(ii) Stacking gel (3% acrylamide/ 0.08 bisacrylamide)
14.6ml distilled water 
5.6ml buffer 2
2.3ml 30% w/v acrylamide/ 0.8% w/v bis acrylamide 
12pl TEMED
225pi 10% w/v ammonium persulphate
Laemmli buffer.
5M urea 
0.17M SDS 
0.38M dithiothreitol 
0.5M Tris/HCl
0.05% w/v bromophenol blue
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Appendix 2
Sources of chemicals
The following is a list of sources for the chemicals and cellculture materials 
used. The various drugs culture materials and biochemical compounds used in addition 
to standard laboratory reagents are listed below together with their sources. All 
solutions were prepared using glass distilled water unless otherwise stated.
Amersham International PLC. Amersham. Buckinghamshire. England.
[y_32p] Adenosine triphosphate (specific activity =3Ci/  mmol) 
myo pH] Inositol (specific activity = 22.8 Ci/ mmol)
[20 (npH] Phorbol 12,13 dibutyrate (specific activity =10-20Ci/ mmol) 
[methyl-3H] Thymidine (specific activity = 1 Ci/ mmol)
Avanti Polar Lipids. Pelham. Alabama 35124 USA.- .
Cardiolipin
BDH Chemical Company. Poole. England.
Acrylamide, ammonium formate, bisacrylamide, dimethylsulphoxide, EDTA 
(Ethylenediaminetetra-acetic acid), lithium chloride, orthophosphoric acid, 
potassium hydrogen phosphate, potassium dihydrogen phosphate, perchloric 
acid, sodium hydroxide, sodium carbonate, trichloroacetic acid and universal 
indicator.
Boehringer (UK1 Ltd.. Lewes. England.
Adenosine 5' triphosphate (ATP), adenosine 5'(P,y-imino) triphosphate 
(App(NH)p), guanosine 5* triphosphate (GTP), guanosine 5'-0-[3- 
thiotriphosphate] (GTPyS) Tris.
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Calbiochem.
Forskolin.
Cambridge Research Biochemicals. Cambridge. England 
All peptides.
Formachem (Research International) PLC.. Strathaven. Scotiand. 
Boric acid, D-glucose and sodium hydrogen carbonate.
FSA Laboratory Supplies. Loughborough. England.
HEPES (N-2-hydroxyethylpiperazine-N1-2-ethane sulphonic acid) Optiphase 
'HiSafe' 3 and Propanol-2-ol (HPLC grade).
Row Laboratories. Rickmansworth. England  ^ - .
0 .2 pm sterile filter units and chick embryo extract.
Gibco. Paisley. Scotland.
A ' M D f c  j P £ C I 4 l  / ^ e c - e J T
'Ca2+ free' Dulbeccos Modified Eagle's Medium and glutamine (lOOx).
Koch-Light Ltd. Suffolk. England.
Calcium chloride, magnesium sulphate, potassium chloride and sodium 
potassium tartrate.
Lipidex. Westfield. New Jersey 07090. USA.
sn -1,2-DAG kinase from Escherichia coli.
May and Baker. Dagenham. England.
Ammonium persulphate, copper (II) sulphate, formic acid, hydrochloric acid 
and sodium tetraborate.
Molecular Probes Inc. Oregon 97448 USA.
5-N-(octadecanoyl) aminofluorescein.
National Diagnostics. Avlesburv. England.
Ecoscint.
NEN Research Products, Stevenage England.
[adenylate-32P] Nicotinamide adenine dinucleotide (NAD) 
di(triethylammonium) salt (specific activity lOOOCi/mmol)
Pierce and Warriner. London, England.
Micropor (Spectrapor 3) dialysis tubing.
Porton Products. Porton Down. England.
Pertussis toxin.
Riedel-DettaenAg Seelze-Hannover. Germany.
Magnesium chloride and sodium dihydrogen carbonate.
Ross Poultry. Aberdeenshire. Scotland.
Fertilised pathogen free chicken eggs.
Schleicher and Schuell. D-3354 Dassel. West Germany. 
Nitrocellulose
Scottish Antibody Production Unit. Scotland.
Donkey anti-rabbit IgG coupled to horse radish peroxidase.
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Whatman Limited. Maidstone. England.
0.45jim millipore filters.
All other chemicals were obtained from the Sigma Chemical Company, Poole, 
England.
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